WO2011115998A2 - Modulators of hec1 activity and methods therefor - Google Patents

Modulators of hec1 activity and methods therefor Download PDF

Info

Publication number
WO2011115998A2
WO2011115998A2 PCT/US2011/028532 US2011028532W WO2011115998A2 WO 2011115998 A2 WO2011115998 A2 WO 2011115998A2 US 2011028532 W US2011028532 W US 2011028532W WO 2011115998 A2 WO2011115998 A2 WO 2011115998A2
Authority
WO
WIPO (PCT)
Prior art keywords
mmol
mhz
yield
ethanone
nmr
Prior art date
Application number
PCT/US2011/028532
Other languages
French (fr)
Other versions
WO2011115998A3 (en
Inventor
Johnson Lau
Jiann-Jyh Huang
Original Assignee
Taivex Therapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NZ602121A priority Critical patent/NZ602121A/en
Priority to ES11756862.6T priority patent/ES2557465T3/en
Priority to KR1020127027026A priority patent/KR101609856B1/en
Priority to CN201180024772.3A priority patent/CN103038231B/en
Priority to SG2012064762A priority patent/SG183853A1/en
Priority to RU2012144022/04A priority patent/RU2576036C2/en
Priority to JP2013500159A priority patent/JP5825535B2/en
Priority to MX2015015934A priority patent/MX346395B/en
Application filed by Taivex Therapeutics Inc. filed Critical Taivex Therapeutics Inc.
Priority to BR112012023355A priority patent/BR112012023355A2/en
Priority to MX2012010664A priority patent/MX2012010664A/en
Priority to MYPI2012003984A priority patent/MY192693A/en
Priority to EP11756862.6A priority patent/EP2547676B1/en
Priority to AU2011227398A priority patent/AU2011227398C1/en
Priority to CA2793311A priority patent/CA2793311C/en
Publication of WO2011115998A2 publication Critical patent/WO2011115998A2/en
Publication of WO2011115998A3 publication Critical patent/WO2011115998A3/en
Priority to HK13103078.4A priority patent/HK1176055A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the spindle apparatus can be targeted with spindle poisons (e.g., taxanes, vinca alkaloids, etc.) with relatively high activity, but many spindle poisons are unacceptable for pharmaceutical intervention as such poisons are often non-specific.
  • spindle poisons e.g., taxanes, vinca alkaloids, etc.
  • components for spindle and kinetochore regulation or mitotic checkpoint control may be selected that have been shown to be functionally associated with cancer.
  • Hec1 is a critical component in spindle checkpoint signaling that is highly expressed in cancer and helps assure correct segregation of chromosomes during cell division.
  • Hec1 interacts with various other kinetochore components including Nuf2, Spc 24, Spc25, and Zwint-1, as well as with mitotic kinases Nek2 and Aurora B.
  • Overexpression of Hec1 is common among a large variety of cancers and cancer cell lines, and can often serve as a prognostic marker in primary breast cancer and other cancers.
  • RNAi has been used to reduce Hec1 expression and shown considerable promise, at least in an animal model.
  • siRNA with high specificity to the tumor is often problematic.
  • various small molecule inhibitors have been developed that interfere with the Nek2/Hec1 interaction.
  • Nek2 is a regulatory component of Hec1 in mitosis
  • abrogation of the Hec1/Nek2 function was expected to result in chromosome mis-segregation and cell death.
  • Several promising compounds have been reported (see J. Med. Chem., 2009, 52 (6), pp 1757–1767, Cancer Res. 2008 Oct 15;68(20):8393-9) that had significant cell killing activity and directly targeted the Hec1/Nek2 pathway.
  • This and all other extrinsic materials discussed herein are incorporated by reference in their entirety. Where a definition or use of a term in an incorporated reference is inconsistent or contrary to the definition of that term provided herein, the definition of that term provided herein applies and the definition of that term in the reference does not apply.
  • R 1 , R 2 , R 3 , R 4 , and R 5 are described as further below. Further especially preferred compounds will have a structure according to Formulae II and III (with respective radicals also described in more detail below).
  • contemplated compounds are inhibitors of Hec1, and/or may be characterized as disrupting Hec1/Nek2 interaction. Consequently, the compounds presented herein are particularly suitable for use as therapeutic agents that disrupt the mitotic pathway. Therefore, and viewed from yet another perspective, especially contemplated compositions include pharmaceutical compositions that comprise one or more of contemplated compounds at a concentration effective to disrupt Hec1/Nek2 binding in a patient when the composition is administered to the patient.
  • a method of disrupting Nek2/Hec1 interaction is contemplated and will include a step of contacting a Nek2/Hec1 complex with one or more compounds presented herein in an amount that is effective to disrupt Nek2/Hec1 binding. While all manners of contacting are generally contemplated, it is typically preferred that the step of contacting the Nek2/Hec1 complex is performed in vivo in a mammal, and that the step of contacting may also be performed in combination with an agent that interferes with microtubule formation or degradation.
  • Figures 1A and 1B are tables illustrating the cytotoxic effect of selected compounds on tumor cells (1A) and normal cells (1B).
  • Figures 2A-2D are photographs of western blots depicting disruption of Hec1/Nek2 interaction (2A, 2B), Nek2 degradation (2C), and Nek2 instability (2D) caused by selected compounds.
  • Figure 3 is a table illustrating percentage of mitotic cells affected by contemplated compounds.
  • Figure 4 is a table illustrating high specificity of contemplated compounds with respect to protein kinases.
  • Figures 5A and 5B are graphs depicting in vivo effect of selected compounds on tumor volume in nude mice.
  • Contemplated Compounds [0017] The inventors have discovered that certain compounds according to Formula I can be prepared and have advantageous properties as moieties that interfere with Hec1. Particularly preferred compounds will include those according to Formula I
  • R 2 , R 3 , and R 4 are independently hydrogen, C 1 –C 6 alkyl, halogen, or OR a ; and R 5 is alkyl, phenylalkyl, heteroarylalkyl, phenyalkenyl, heteroarylalkenyl, phenyl, heteroaryl, heterocycloalkyl, or heterocycloalkenyl; wherein each of R 1 , R 2 , R 3 , R 4 , R 5 , R a , and R b are independently optionally substituted.
  • R 1 and R 2 are methyl and where R 3 is hydrogen, R 5 is not thiazolyl, N-methylimidazolyl, pyrazinyl, pyridinyl, morpholinyl, phenyl, or dimethoxyphenyl;
  • R 1 , R 2 , and R 3 are methyl, R 5 is not thiazolyl, N-methylimidazolyl, pyrazinyl, pyridinyl, morpholinyl, phenyl, methoxyphenyl, dihydroxyphenyl, hydroxymethoxyphenyl, trifluoromethylphenyl, or dimethoxyphenyl; and
  • R 1 and R 2 are methyl and where R 3 is hydroxyl or methoxy, R 5 is not phenyl.
  • R 1 is alkoxy, SR a , OR a , or ,–S(O) 2 R a , that R a is alkyl or optionally substituted aryl, that R 2 , R 3 , and R 4 are independently hydrogen or C 1 –C 6 alkyl, and that R 5 is optionally substituted heteroaryl.
  • R 1 is alkoxy, SR a , OR a , or ,–S(O) 2 R a , where R a is alkyl or an optionally substituted aryl, where R 2 and R 3 are C 1 –C 6 alkyl, and where R 5 is optionally substituted (e.g., halogenated) pyridinyl.
  • R 1 is OR a , wherein R a is optionally substituted aryl, R 2 and R 3 are C 1 –C 6 alkyl, and R 5 is an optionally substituted pyridinyl.
  • Y is CH 2 , CHR a , CR a R b , O, NH, NR a , S, SO, or SO 2 ;
  • R 1 , R 2 , and R 3 are independently H, alkyl, alkoxy, or halogen; n is 0, 1, or 2; and in which A is an optionally substituted aryl or an optionally substituted heteroaryl, and most preferably a compound as shown below
  • each of X and X is independently optionally substituted, and wherein R c and R d are independently R a .
  • Y is O, S, or SO 2
  • A is an optionally substituted pyridinyl.
  • X 1 and X 2 in such compounds will be independently H, alkyl, and alkoxy, and n is 0 or 1. With respect to remaining radicals, the same considerations as provided for Formula I apply.
  • alkenyl refers to an alkyl having at least one double bond. Where more than one double bond is present, it is contemplated that the double bonds may be conjugated or un-conjugated.
  • alkynyl refers to an alkyl having at least one triple bond. Contemplated alkynyls may further include another triple bond or double bond, which may or may not be conjugated with the first triple bond.
  • alkoxy refers to an O-alkyl group, wherein the "alkyl” is defined as provided above.
  • a "cycloalkyl” as used herein refers to a non-aromatic monovalent monocyclic or polycyclic radical having from 3 to 14 carbon atoms, each of which may be saturated or unsaturated, and may be un-substituted or substituted by one or more suitable substituents as defined herein, and to which may be fused one or more aryl groups, heteroaryl groups, cycloalkyl groups, or heterocycloalkyl groups which themselves may be un-substituted or substituted by one or more substituents.
  • cycloalkyl groups include cyclopropyl, cycloheptyl, cyclooctyl, cyclodecyl, cyclobutyl, adamantyl, norpinanyl, decalinyl, norbornyl, cyclohexyl, and cyclopentyl.
  • heterocycloalkyl refers to a non-aromatic monovalent monocyclic or polycyclic radical having 1-5 heteroatoms selected from nitrogen, oxygen, and sulfur, and may be unsubstituted or substituted by one or more suitable substituents as defined herein, and to which may be fused one or more aryl groups, heteroaryl groups, cycloalkyl groups, or heterocycloalkyl groups which themselves may be un-substituted or substituted by one or more substituents.
  • heterocycloalkyl groups include oxiranyl, pyrrolidinyl, piperidyl, tetrahydropyran, and morpholinyl.
  • An "aryl” (Ar) as used herein refers to an aromatic monocyclic or polycyclic radical comprising generally between 5 and 18 carbon ring members, which may be un-substituted or substituted by one or more suitable substituents as defined herein, and to which may be fused one or more cycloalkyl groups, heterocycloalkyl groups, or heteroaryl groups, which themselves may be un-substituted or substituted by one or more suitable substituents.
  • the term "aryl group” includes a benzyl group (Bzl).
  • heteroaryl refers to an aromatic monocyclic or polycyclic radical comprising generally between 4 and 18 ring members, including 1-5 heteroatoms selected from nitrogen, oxygen, and sulfur, which may be un-substituted or substituted by one or more suitable substituents as defined below, and to which may be fused one or more cycloalkyl groups, heterocycloalkyl groups, or aryl groups, which themselves may be unsubstituted or substituted by one or more suitable substituents.
  • Examples include thienyl, furanyl, thiazolyl, triazolyl, imidazolyl, isoxazolyl, oxadiazolyl, tetrazolyl, pyridyl, pyrrolyl, thiadiazolyl, oxadiazolyl, oxathiadiazolyl, thiatriazolyl, pyrimidinyl, isoquinolinyl, quinolinyl, napthyridinyl, phthalimidyl, benzimidazolyl, and benzoxazolyl.
  • heterocycle or “heterocyclic” as used herein refers to aromatic and non-aromatic heterocyclic groups, typically with 4 to 10 atoms forming a ring, and containing one or more heteroatoms (typically O, S, or N).
  • Non-aromatic heterocyclic groups include groups having only 4 atoms in their ring system, but aromatic heterocyclic groups typically have at least 5 atoms in their ring system.
  • non-aromatic heterocyclic groups include pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidino, morpholino, thiomorpholino, thioxanyl, piperazinyl, azetidinyl, oxetanyl, thietanyl,
  • 1,2,3,6-tetrahydropyridinyl 2-pyrrolinyl,3-pyrrolinyl, indolinyl,2H-pyranyl,4H-pyranyl, dioxanyl, 1 ,3-dioxolanyl, pyrazolinyl, dithianyl, dithiolanyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl, pyrazolidinyl, imidazolinyl, imidazolidinyl,3-azabicyclo[3.i.0]hexanyl,
  • aromatic heterocyclic groups are pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, is benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, quin
  • Contemplated 4-10 membered heterocycles may be C-attached or N-attached (where appropriate).
  • a group derived from pyrrole may be pyrrol-i-yl (N-attached) or pyrrol-3-yl (C-attached).
  • substituted refers to a replacement or modification of an atom (radical) or chemical group (e.g., NH 2 , or OH) in a molecule with a functional group to produce a substituted molecule
  • functional groups include nucleophilic groups (e.g., -NH 2 , -OH, -SH, -NC, etc.), electrophilic groups (e.g., C(O)OR, C(O)OH, etc.), polar groups (e.g., -OH), non-polar groups (e.g., aryl, alkyl, alkenyl, alkynyl, etc.), ionic groups (e.g., -NH +
  • halogens e.g., -F, -Cl
  • the replaced radical is a hydrogen radical
  • the functional group is a hydroxyl group
  • the H-atom is substituted by an OH group to form a substituted alkyl.
  • the modified group is the amino group
  • the functional group is an alkyl group
  • the amino group is alkylated to form an N-substituted amino acid.
  • suitable substituents include halogen (chloro, iodo, bromo, or fluoro);
  • C 1-6 -alkyl C 1-6 -alkenyl; C 1-6 -alkynyl, hydroxyl, C 1-6 alkoxyl; amino; nitro; thiol; thioether; imine; cyano; amido; phosphonato; phosphine; carboxyl; carbonyl; aminocarbonyl; thiocarbonyl;
  • sulfonyl sulfonamine
  • sulfonamide ketone
  • aldehyde ester
  • substituents contemplated herein may further optionally be substituted by one or more substituents noted above.
  • substituents include hydroxyl groups, halogens, oxo groups, alkyl groups (and especially lower alkyl), acyl groups, sulfonyl groups, mercapto groups, alkylthio groups, alkyloxyl groups, cycloalkyl groups, heterocycloalkyl groups, aryl groups, heteroaryl groups, carboxyl groups, amino groups, alkylamino groups, dialkylamino groups, carbamoyl groups, aryloxyl groups, heteroaryloxyl groups, arylthio groups, heteroarylthio groups.
  • the compounds according to the inventive subject matter may comprise one or more asymmetric centers, and may therefore exist in different enantiomeric forms, and all enantiomeric forms of contemplated compounds are specifically contemplated herein. Similarly, where contemplated compounds exhibit optical activity and/or have stereoisomers, all optical activities and/or isomeric forms are contemplated herein. Similarly, where double bonds distinguish a Z-form from an E-form (or cis- from trans-), both isomers are contemplated. Moreover, it is noted that the compounds according to the inventive subject matter may also be isotopically-labeled.
  • Contemplated compounds may be prepared as pharmaceutically acceptable salt(s), which especially include salts of acidic or basic groups which may be present in the contemplated compounds.
  • contemplated compounds may form a wide variety of salts with various inorganic and organic acids.
  • Suitable acids will provide pharmacologically acceptable anions, including chloride, bromide, iodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, acid citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, and pamoate,
  • [1,1’-methylene-bis-(2-hydroxy-3-naphthoate)] anions may form base salts with various pharmacologically acceptable cations, and especially suitable cations include alkali metal or alkaline earth metal ions (e.g., sodium and potassium cations).
  • suitable cations include alkali metal or alkaline earth metal ions (e.g., sodium and potassium cations).
  • the compounds presented herein may be prepared as prodrugs, and all known manners and types of prodrugs are considered suitable for use herein, so long as such prodrug will increase the concentration of the drug (or metabolite of the prodrug) at a target organ, target cell, and/or Hec1.
  • contemplated compounds have a free amino, amido, hydroxy, thio, or carboxylic group
  • such groups can be employed to covalently and releasably bind a moiety that converts the drug into a prodrug.
  • prodrugs particularly include those in which contemplated compounds form an ester, amide, or disulfide bond with another cleavable moiety.
  • Such moieties may assist in organ or cell-specific delivery of the drug and therefore particularly include receptor ligands and their analogs, antibody fragments or other high-affinity ligands (K d ⁇ 10 6 M).
  • a carboxyl group can be derived to form an amide or alkyl ester, which may include an ether, amine-, and/or carboxylic acid group.
  • Free hydroxyl groups may be derived using hemisuccinates, phosphate esters, dimethylaminoacetates, and phosphoryloxymethyloxy- carbonyls, as outlined in D.
  • acyloxymethyl and (acyloxy)ethylethers wherein the acyl group may be an alkyl ester (option- ally substituted), or where the acyl group is an amino acid ester are also contemplated (prodrugs of this type are described in R. P. Robinson et al., J. Medicinal Chemistry (1996) 39:p.10).
  • the compounds according to the inventive subject matter may also be active as a metabolite (of a prodrug or non-prodrug form) and that all of such metabolites are especially contemplated herein.
  • suitable metabolites include hydroxylated forms, oxidized forms, glucuronidated forms, sulfated forms, etc. Moreover, it is also noted that the metabolites may be more active that the originally administered form.
  • Contemplated Compositions and Formulations [0041] Based on the activity of the compounds as Hec1 modulators, the inventors contemplate that the compounds and compositions according to the inventive subject matter may be employed for prophylaxis and/or treatment of various diseases associated with Hec1 dysfunction and/or overexpression, and in fact for all diseases that positively respond to administration of contemplated compounds.
  • disfunction of Hec1 refers to any abnormality in Hec1, especially as it relates to its association with Nek2 function and spindle checkpoint signaling. Such abnormalities may be due to one or more of a mutation (e.g., increasing or reducing affinity to a binding partner), temporary or permanent overexpression (e.g., activated by inappropriate or mutated promoter), irreversible or tighter binding of an activator, inappropriate activation by non-physiological molecule, etc.
  • a mutation e.g., increasing or reducing affinity to a binding partner
  • temporary or permanent overexpression e.g., activated by inappropriate or mutated promoter
  • irreversible or tighter binding of an activator e.g., inappropriate activation by non-physiological molecule, etc.
  • neoplastic diseases include neoplastic diseases, and especially cancerous neoplastic diseases (e.g., breast cancer, squamous cell cancer, bladder cancer, gastric cancer, pancreatic cancer, head cancer, neck cancer, oesophageal cancer, prostate cancer, colorectal cancer, lung cancer, renal cancer, gynecological cancer, or thyroid cancer).
  • cancerous neoplastic diseases include benign hyperplasia of the skin (e.g., psoriasis) or prostate (e.g., benign prostatic hypertrophy (BPH).
  • compositions that include the compounds presented herein and it is generally contemplated that the compounds according to the inventive subject matter may be formulated into pharmaceutical compositions that have a therapeutically effective amount of contemplated compounds (or pharmaceutically acceptable salt, hydrate, or prodrug thereof), and a pharmaceutically acceptable carrier.
  • Activity, toxicity, and other pharmacological and pharmacodynamic parameters can be established for the compounds presented herein using numerous known protocols.
  • cytotoxicity can be established via MTS assay in various cell lines, while disruption of Hec1- Nek2 interaction can be monitored via co-immunoprecipitation or a yeast two-hybrid system.
  • Cell cycle analysis can be performed by monitoring various stage populations (e.g., sub-G1, G0/G1, S, etc.), and metaphase chromosomal misalignment quantitation can be performed using
  • contemplated compounds are formulated with one or more non-toxic pharmaceutically acceptable carriers, preferably formulated for oral administration in solid or liquid form, or for parenteral injection.
  • pharmaceutical compositions according to the inventive subject matter may be administered to humans and other animals using various routes, including orally, rectally, parenterally, intraperitoneally, vaginally, or topically.
  • suitable pharmaceutical compositions for injection preferably comprise pharmaceutically acceptable sterile aqueous or nonaqueous solutions, dispersions, emulsions, or suspensions, as well as sterile powders for reconstitution into sterile injectable solutions or dispersions prior to use.
  • aqueous and nonaqueous carriers examples include water, ethanol, polyols (e.g., glycerol, propylene glycol, polyethylene glycol, etc.), and suitable mixtures thereof, oils, and injectable organic esters (e.g., ethyl oleate).
  • polyols e.g., glycerol, propylene glycol, polyethylene glycol, etc.
  • suitable mixtures thereof e.g., oils, and injectable organic esters (e.g., ethyl oleate).
  • Contemplated compositions may also contain various inactive ingredients, including preservatives, wetting agents, emulsifying agents, and/or dispersing agents. Sterility may be ensured by inclusion of antibacterial and/or antifungal agents (e.g., paraben, phenol sorbic acid, chlorobutanol, etc.). Where appropriate, osmotically active agents may be included (e.g., sugars, sodium chloride, etc.). [0046] Alternatively, contemplated compositions may be formulated into solid dosage forms for oral administration, and may therefore be capsules, tablets, pills, powders, and granules.
  • preservatives e.g., paraben, phenol sorbic acid, chlorobutanol, etc.
  • osmotically active agents may be included (e.g., sugars, sodium chloride, etc.).
  • contemplated compositions may be formulated into solid dosage forms for oral administration, and may therefore be capsules, tablets, pills, powders, and gran
  • contemplated compound are mixed with at least one of a pharmaceutically acceptable excipient or carrier (e.g., sodium citrate or dicalcium phosphate), a filler or extender (e.g., starch, lactose, sucrose, glucose, mannitol, or silicic acid), a binder (e.g., carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, etc.), a humectant (e.g., glycerol), a disintegrating agent (e.g., agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, or sodium carbonate), a solution retarding agent (e.g., paraffin), an absorption accelerator (e.g., quaternary ammonium compound), a wetting agents (e.g., cetyl alcohol and glycerol monostearate), and absorbents (e.g.
  • Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
  • the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art.
  • Contemplated compositions may further be formulated to release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes.
  • Contemplated compounds may also be in micro-encapsulated form, if appropriate, with one or more of the above-mentioned excipients.
  • Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs.
  • liquid dosage forms may contain inert diluents commonly used in the art (e.g., water, or other solvent, solubilizing agents), emulsifiers (e.g., ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethyl formamide), oils (and in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
  • inert diluents commonly used in the art
  • emulsifiers e.g., ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl be
  • the oral compositions may also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
  • adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
  • Compounds according to the inventive subject matter can also be administered in form of liposomes, which may be unilamellar, oligolamellar, or polylamellar.
  • Contemplated compositions in liposome form may further contain stabilizers, preservatives, excipients, etc.
  • Preferred lipids for liposome formation include phospholipids and the phosphatidyl cholines (lecithins), both natural and synthetic. Methods to form liposomes are known in the art.
  • contemplated compounds in pharmaceutical compositions may be varied so as to obtain an amount of contemplated compound(s) that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration.
  • the selected dosage level will depend upon various factors, including the activity of the particular compound, the route of administration, the severity of the condition being treated, and the condition and prior medical history of the patient being treated.
  • contemplated formulations especially include those suitable for oral administration, parenteral administration, for administration as cream, or as eye-drops or other liquid topical formulation.
  • chemotherapeutic inhibitors exhibited synergistic effect with selected chemotherapeutic inhibitors.
  • compounds including Taxol, vincristine, and vinblastine showed synergistic effect, and are also expected to have synergistic effect with respect to tubulin formation or polymerization inhibitors, as well as pretubulin inhibitors.
  • suitable chemotherapeutic inhibitors especially include one or more drugs that interfere with microtubule formation or degradation. Therefore, any drugs that affect cell division and any anti-metabolites are deemed useful in combination with the Hec1 inhibitors contemplated herein.
  • contemplated pharmaceutical compositions may also include additional pharmaceutically active compounds, and especially contemplated additional pharmaceutically active compounds include antineoplastic agents, which may act on DNA replication, cell cycle, cell metabolism, angiogenesis, or induce apoptosis.
  • additional pharmaceutically active compounds include immunologically active agents (e.g., anti-inflammatory agents,
  • immunosuppressants steroids, interferons (alpha, beta, or gamma) and fragments thereof, and those molecules that selectively increase or suppress Th1 and/or Th2 cytokine expression).
  • suitable active agents include antibacterial and antiviral agents, drugs that stimulate or modify metabolism, neurologically active drugs, and/or analgesic drugs.
  • additional pharmaceutically active compounds may be included in the same pharmaceutical composition, or may be administered separately, and a person of ordinary skill in the art will readily determine schedule and route of suitable co-administration of the additional pharmaceutically active compounds.
  • Contemplated 4-aryl-2-amidothiazole compounds can be prepared by numerous synthetic routes, and the following is provided to give exemplary guidance only. While the below scheme can be used to prepare most of the compounds presented herein, other compounds may require minor modifications top the general scheme that will be readily apparent to the skilled artisan.
  • Aromatic compounds of structure A including substituted benzene, pyridine, or other heterocyclic compound (5-, 6-, or 7-membered) are reacted with acetyl chloride in the presence of AlCl 3 to afford acetylated arenes B. Bromination of B give -Br-acetylated arenes C, which are allowed to react with thiourea to generate aminothiazoles D with an aryl substituent at the C-4 position. The so prepared aminothiazoles then react with different acids give the final 4-aryl-2-amidothiazoles E. [0055] Acetylation of Ar 1 :
  • Suitable bromination agents include Br 2 , HBr, NBS, TBABr 3 , CuBr 2 , etc. in various solvents, including ether, THF, halogenated hydrocarbons, ester, etc.
  • Suitable coupling agents include CDI, EDC, CDC, etc.
  • X is typically CI or Br; base is typically Et 3 N, Me 3 N, DIPEA, K 2 C0 3 , Na 2 CO 3 , DMAP, etc.
  • 4-Aryl-2-amidothiazoles can be prepared as follows:
  • coupling may also be performed as follows:
  • N-(4-(2-bromoacetyl)-3,5-dimethylphenyl)acetamide (7.34 g, 25.8 mmol) and thiourea (1.97 g, 25.9 mmol) in 95% EtOH (36.9 mL) was heated at reflux for 120 min. The solution was concentrated and added with water (100 mL) and saturated aqueous Na 2 CO 3 (5.0 mL). The resultant precipitate was filtered and recrystallized in toluene (50 mL).
  • l-(2,4,6-triisopropylphenyl)ethanone (10.0 g, 65.3 mmol) in acetonitrile (81 mL) was added tetrabutylammoniumtribromide (TBABr 3 , 19.6 g, 40.6 mmol).
  • TBABr 3 tetrabutylammoniumtribromide
  • the reaction was stirred at room temperature for 3.0 h.
  • the solution was concentrated under reduced pressure, added with water, and extracted with ethyl acetate.
  • the organic layer was washed with brine, dried over anhydrous MgS0 4 (s), and concentrated under reduced pressure to give
  • l-(4-isopropoxy-2,6-dimethylphenyl)ethanone (4.3 g, 20.9 mmol) in acetonitrile (41.7 mL) was added tetrabutylammoniumtribromide (TBABr 3 , 11.1 g, 22.9 mmol).
  • TBABr 3 tetrabutylammoniumtribromide
  • the reaction was heated at 100 C for 120 min under N 2 .
  • the solution was cooled to room temperature and filtered through a small pad of Celite.
  • the cake was washed with ethyl acetate (50 mL) and combined filtrate was concentrated under reduced pressure.
  • the residue was purified by flash column chromatography on silica gel to give
  • N-(4-(4-(4-(4-methoxyphenoxy)-2,6-dimethylphenyl)tMazol-2-yl)-2-mtroisonicotinamide (0.20 g, 0.40 mmol) and Pd/C (0.15 g, 10% w/w) in ethanol (10 mL) was stirred under H 2 overnight.
  • N-(4-Mesitylthiazol-2-yl)-2-(4-methylpiperazin-l-yl)isonicotinamide A mixture of 2-chloro-N-(4-mesitylthiazol-2-yl)isonicotinamide (300.0 mg, 0.8 mmol, 1.0 equiv) and
  • N-(4-Mesitylthiazol-2-yl)-2-(piperidin-l-yl)isonicotinamide A mixture of 2-chloro-N-(4-mesitylthiazol-2-yl)isonicotinamide (200 mg, 0.60 mmol, 1.0 equiv) and piperidine (0.70 mL, 6.7 mmol, 12 equiv) in methylpyrrolidone (6.0 mL) was stirred at 150 ⁇ C for 16 h. The mixture was poured into icy H 2 O (10.0 mL) and the resultant solids were filtered.
  • N-(4-(4-iodo-2,6-dimethylphenyl)thiazol-2-yl)isonicotinamide (435 mg, 1.0 mmol) and tetrakistriphenylphosphine palladium (57.8 mg, 0.10 mmol) in THF (5.0 mL).
  • the reaction mixture was heated at reflux for 16 h under N 2 and then poured into saturated aqueous NaHC0 3 .
  • the mixture was extracted with ethyl acetate, washed with brine, dried MgS0 4 , and concentrated under reduced pressure.
  • N-(4-(4-(4-Methoxybenzyl)-2,6-dimethylphenyl)thiazol-2-yl)isonicotinamide A THF solution of 4-methoxylbenzylzinc(II) bromide (4.0 mL, 2.0 mmol) was added to a degassed solution of N-(4-(4-iodo-2,6-dimethylphenyl)thiazol-2-yl)isonicotinamide (435 mg, 1.0 mmol) and tetrakistriphenylphosphine palladium (57.8 mg, 0.10 mmol) in THF (5.0 mL).
  • Cytotoxicity and Antiproliferative Activity Cells from established cell lines ⁇ e.g. from cell lines like MDA-MB-231 , MDA-MB-468, Hela, and K562) were cultured in 10% FBS (Hylcone) in DMEM medium (Sigma, D5523). Cells were grown at 37°C in a humidified atmosphere with 5% C0 2 and 95% air. Cells were seeded in 96 well tissue culture plates.
  • Compound treatment started after overnight incubation of cells (TO).
  • TO overnight incubation of cells
  • Compound was prepared in an eight point 3x dilution from 10, M to 4.6 nM.
  • Compound was added to the plate in triplicate wells, and the plates were then incubated for 96 hours.
  • DMSO compounds diluents
  • Cell viability was then determined by MTS assay using CellTiter 96® AQueous non-radioactive cell proliferation assay system (Promega).
  • a plate reader (Molecular Devices, Vmax) was used to read the optical densities, and the results were used to deduce concentration-response curves.
  • the IC50 values refer to the concentration that causes 50% growth inhibition.
  • the GI50 values growth inhibitory activity were determined to emphasize on the correction for the cell count at time zero; thus, the % inhibition of test drug were: [1- (T - T0)/(C - T0)] x 100; and these value were used to plot the concentration-response curves, and then analyzed with linear regression software (GraphPad Prism 5).
  • WI-38 is human normal lung fibroblast cell line
  • RPTEC is renal proximal tubule epithelial cells
  • HuVec is human umbilical vein endothelial cells
  • HAoSMC Human aortic smooth muscle cells.
  • FIG. 2A and 2B depicts an exemplary result of such experiment where it is readily apparent that selected compounds tested significantly disrupted Hec1/Nek2 interaction.
  • Figure 2C shows typical results of the Nek2 reduction upon incubation of K562 cells for 24 hrs with 1mcM of tested compounds, and
  • Figure 2D depicts results demonstrating protein instability of Nek2 over time after treatment of K562 cells exposed to selected compounds at 1 mcM final concentration.
  • Selected compounds induce aberrant mitosis: Cells were grown on cover slips and gently washed with PEMG buffer [80 mM piperazine-N,N -bis(2-ethanesulfonic acid) (PIPES), pH 6.8, 5 mM EGTA, 1 mM MgCl 2 , and 4 M glycerol] or phosphate-buffered saline(PBS). Cells were then fixed with 100% methanol at–20°C or 4% paraformaldehyde in PEMG or PBS buffer and permeabilized with 0.4% Triton-X 100.
  • PEMG buffer 80 mM piperazine-N,N -bis(2-ethanesulfonic acid) (PIPES), pH 6.8, 5 mM EGTA, 1 mM MgCl 2 , and 4 M glycerol
  • PBS phosphate-buffered saline
  • NGS normal goat serum
  • Primary antibodies were conjugated with Alexa 488 or 594 (Invitrogen, Carlsbad, CA).
  • Alexa 488 or 594 Alexa 488 or 594
  • 4 ,6-Diamidino-2-phenylindole (DAPI) staining was applied and cells were mounted on cover slides with Prolong gold anti-fade reagent (Invitrogen). Images were captured with a Nikon H550L microscope equipped with digital cameras and SPOT digital imaging software (version 4, Diagnostic Instruments, Inc).
  • Figure 3 is a table depicting the effect of selected compounds on mitosis. More specifically, the results are expressed as percentages of chromosome misalignment in mitotic cells over 48 hrs. As can be taken, the tested compounds substantially affected mitosis in a large number of cells.
  • Selected compounds are highly selective kinase inhibitors: Inhibition of kinase activity by test compound was measured by quantifying the amount of [ 33 P] incorporation of substrate in the present of test compound.
  • the standard kinase assays were initiated with MgATP, in the presence of test compound (diluted in final concentration of 4% DMSO) or DMSO control, stopped by the addition of 3 % phosphoric acid and harvested onto a filter plate using a unifilter harvester (PerkinElmer, Boston, MA, U.S.A.) and counted using TopCount.
  • each test compound was evaluated at two concentrations (10mM and 1mM) in duplication.
  • the results were the average of duplicate measurements and expressed as percentage inhibition (compound treatment versus DMSO control).
  • the available kinase assays are as followed: VEGFR2, PDGFR- , FGFR1, Flt3, c-Met, CHK1, CHK2, Cdk1/Cyclin B, Aurora A, Aurora B, B-Raf, B-Raf (V600E), C-Raf, and mTOR.
  • the ATP concentration used in most of the kinase assay is at or below the Km for ATP for each enzyme.
  • Bioavailability Selected compounds were administered to rats per os or via injection following well known procedures. For example, compound 82 was injected i.v. at a concentration of 2 mg/kg in a formulation containing 5 % DMSO, 10 % Cremophor, and 85% WFI.
  • Selected compounds are effective in mouse xenograft model: The procedure was adapted from a previous published protocol (Small molecule targeting the Hec1Nek2 mitotic pathway suppresses tumor cell growth in culture and in animal. Cancer Res. 2008 Oct 15;68(20):8393-9). More specifically, female BALB/c nude (nu/nu) mice (5–8 weeks) were purchased from Lasco (Taiwan). The animals were maintained under specific pathogen-free conditions, and food and water were supplied ad libitum. Housing and all procedures involving animals were performed according to protocols approved by the IACUC in DCB.
  • mice were treated (i.v., QD/21 cycles or p.o., QD/28 cycles in total) with vehicle A (5% DMSO, 10% Cremophor, 85% H 2 O), or candidate compounds formulated in vehicle A (7.5-150 mg/kg body weight).
  • vehicle A 5% DMSO, 10% Cremophor, 85% H 2 O
  • candidate compounds formulated in vehicle A 7.5-150 mg/kg body weight.
  • Perpendicular diameter measurement of each tumor were made with digital calipers and the volume of the tumor calculated using formula (Lx W x W)/2, in which L and W represent the length and the width, respectively.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compounds, compositions, and methods for modulation of Hecl/Nek2 interaction are provided. Especially preferred, compounds disrupt Nck2/Hecl binding and are therefore useful as chemotherapeutic agent for neoplastic diseases.

Description

MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR [0001] This application claims priority to our copending US provisional application with the serial number 61/314798, which was filed March 17, 2010. Field of the Invention [0002] The field of the invention is various compounds, compositions, and methods related to modulation of activity of HECl , particularly as it related to inhibition of tumor cell propagation. Background [0003] While mechanisms associated with mitotic regulation are conceptually an attractive target in attempts to reduce tumor cell growth, compounds with high specific activity and selectivity and desirable pharmacological profile have been elusive. For example, the spindle apparatus can be targeted with spindle poisons (e.g., taxanes, vinca alkaloids, etc.) with relatively high activity, but many spindle poisons are unacceptable for pharmaceutical intervention as such poisons are often non-specific. [0004] To improve specificity of treatment, components for spindle and kinetochore regulation or mitotic checkpoint control may be selected that have been shown to be functionally associated with cancer. For example, Hec1 is a critical component in spindle checkpoint signaling that is highly expressed in cancer and helps assure correct segregation of chromosomes during cell division. Hec1 interacts with various other kinetochore components including Nuf2, Spc 24, Spc25, and Zwint-1, as well as with mitotic kinases Nek2 and Aurora B. Overexpression of Hec1 is common among a large variety of cancers and cancer cell lines, and can often serve as a prognostic marker in primary breast cancer and other cancers. Based on the apparent importance of Hec1 in tumor cell growth, RNAi has been used to reduce Hec1 expression and shown considerable promise, at least in an animal model. However, in vivo delivery of siRNA with high specificity to the tumor is often problematic. [0005] More recently, various small molecule inhibitors have been developed that interfere with the Nek2/Hec1 interaction. Since Nek2 is a regulatory component of Hec1 in mitosis, abrogation of the Hec1/Nek2 function was expected to result in chromosome mis-segregation and cell death. Several promising compounds have been reported (see J. Med. Chem., 2009, 52 (6), pp 1757–1767, Cancer Res. 2008 Oct 15;68(20):8393-9) that had significant cell killing activity and directly targeted the Hec1/Nek2 pathway. This and all other extrinsic materials discussed herein are incorporated by reference in their entirety. Where a definition or use of a term in an incorporated reference is inconsistent or contrary to the definition of that term provided herein, the definition of that term provided herein applies and the definition of that term in the reference does not apply. However, while the observed activity was in at least some cases promising, problems associated with solubility, toxicity, and relatively high half-maximal inhibitory concentrations nevertheless remained. [0006] Thus, there is still a need for improved compounds, compositions, and methods for Hec1 inhibition, particularly as it relates to use of such compounds in the treatment of cancer. Summary of The Invention [0007] The inventive subject matter is drawn to various compounds, compositions, and methods for Hec1 inhibition. More particularly, contemplated compounds will include those according to Formula I
rmu a [0008] where R1, R2, R3, R4, and R
Figure imgf000003_0001
5 are described as further below. Further especially preferred compounds will have a structure according to Formulae II and III (with respective radicals also described in more detail below).
Figure imgf000003_0002
[0009] In one aspect of the inventive subject matter, contemplated compounds are inhibitors of Hec1, and/or may be characterized as disrupting Hec1/Nek2 interaction. Consequently, the compounds presented herein are particularly suitable for use as therapeutic agents that disrupt the mitotic pathway. Therefore, and viewed from yet another perspective, especially contemplated compositions include pharmaceutical compositions that comprise one or more of contemplated compounds at a concentration effective to disrupt Hec1/Nek2 binding in a patient when the composition is administered to the patient. [0010] Thus, in another aspect of the inventive subject matter, a method of disrupting Nek2/Hec1 interaction is contemplated and will include a step of contacting a Nek2/Hec1 complex with one or more compounds presented herein in an amount that is effective to disrupt Nek2/Hec1 binding. While all manners of contacting are generally contemplated, it is typically preferred that the step of contacting the Nek2/Hec1 complex is performed in vivo in a mammal, and that the step of contacting may also be performed in combination with an agent that interferes with microtubule formation or degradation. [0011] Various objects, features, aspects and advantages of the inventive subject matter will become more apparent from the following detailed description of preferred embodiments, along with the accompanying drawing figures in which like numerals represent like components. Brief Description of the Drawing [0012] Figures 1A and 1B are tables illustrating the cytotoxic effect of selected compounds on tumor cells (1A) and normal cells (1B). [0013] Figures 2A-2D are photographs of western blots depicting disruption of Hec1/Nek2 interaction (2A, 2B), Nek2 degradation (2C), and Nek2 instability (2D) caused by selected compounds. [0014] Figure 3 is a table illustrating percentage of mitotic cells affected by contemplated compounds. [0015] Figure 4 is a table illustrating high specificity of contemplated compounds with respect to protein kinases. [0016] Figures 5A and 5B are graphs depicting in vivo effect of selected compounds on tumor volume in nude mice. Detailed Description Contemplated Compounds [0017] The inventors have discovered that certain compounds according to Formula I can be prepared and have advantageous properties as moieties that interfere with Hec1. Particularly preferred compounds will include those according to Formula I
Figure imgf000005_0001
ormu a [0018] In especially preferred aspects, R1 is hydrogen, alkyl, alkenyl, alkynyl, alkoxy, aryl, halogen, nitro, cyano, cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, ORa, SRa, NRaRb,–S(O)2Ra,–S(O)2NRaRb,–C(O)Ra,–C(O)NRaRb,–NRaC(O)Rb,–NRaS(O)2Rb,–N=CRaRb, or–NRaC(O)NHRb; Ra and Rb are independently hydrogen, alkyl, alkenyl, alkynyl, aryl, aryloxy, alkoxy, hydroxy, heteroaryl, cycloalkyl, heterocycloalkyl, cycloalkenyl, or heterocycloalkenyl, or Ra and Rb, together with a nitrogen atom to which they are bonded, are heteroaryl,
heterocycloalkyl, or heterocycloalkenyl; R2, R3, and R4 are independently hydrogen, C1–C6 alkyl, halogen, or ORa; and R5 is alkyl, phenylalkyl, heteroarylalkyl, phenyalkenyl, heteroarylalkenyl, phenyl, heteroaryl, heterocycloalkyl, or heterocycloalkenyl; wherein each of R1, R2, R3, R4, R5, Ra, and Rb are independently optionally substituted. Less preferred compounds include those where (I) R1 and R2 are methyl and where R3 is hydrogen, R5 is not thiazolyl, N-methylimidazolyl, pyrazinyl, pyridinyl, morpholinyl, phenyl, or dimethoxyphenyl; (II) where R1, R2, and R3 are methyl, R5 is not thiazolyl, N-methylimidazolyl, pyrazinyl, pyridinyl, morpholinyl, phenyl, methoxyphenyl, dihydroxyphenyl, hydroxymethoxyphenyl, trifluoromethylphenyl, or dimethoxyphenyl; and (III) where R1 and R2 are methyl and where R3 is hydroxyl or methoxy, R5 is not phenyl. [0019] It is particularly preferred that R1 is alkoxy, SRa, ORa, or ,–S(O)2Ra, that Ra is alkyl or optionally substituted aryl, that R2, R3, and R4 are independently hydrogen or C1–C6 alkyl, and that R5 is optionally substituted heteroaryl. Even more preferred compounds among those are compounds where R1 is alkoxy, SRa, ORa, or ,–S(O)2Ra, where Ra is alkyl or an optionally substituted aryl, where R2 and R3 are C1–C6 alkyl, and where R5 is optionally substituted (e.g., halogenated) pyridinyl. Most preferably, R1 is ORa, wherein Ra is optionally substituted aryl, R2 and R3 are C1–C6 alkyl, and R5 is an optionally substituted pyridinyl. [0020] Consequently, and viewed from a different perspective, compounds are also preferred that have a structure according to Formula II
Figure imgf000006_0001
ormu a [0021] in which wherein X1 and X2 are independently H, alkyl, alkenyl, alkynyl, halogen, nitro, cyano, cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, ORa, NRaRb,–S(O)2Ra, –S(O)2NRaRb,–C(O)Ra,–C(O)NRaRb,–NRaC(O)Rb,–NRaS(O)2Rb,–N=CRaRb, or
–NRaC(O)NHRb; Y is CH2, CHRa, CRaRb, O, NH, NRa, S, SO, or SO2; R1, R2, and R3 are independently H, alkyl, alkoxy, or halogen; n is 0, 1, or 2; and in which A is an optionally substituted aryl or an optionally substituted heteroaryl, and most preferably a compound as shown below
[0022] where
Figure imgf000006_0002
in each of X and X is independently optionally substituted, and wherein Rc and Rd are independently Ra. Among such compounds, it is further preferred that Y is O, S, or SO2, and/or that A is an optionally substituted pyridinyl. Most typically, X1 and X2 in such compounds will be independently H, alkyl, and alkoxy, and n is 0 or 1. With respect to remaining radicals, the same considerations as provided for Formula I apply. [0023] Still further preferred compounds have a structure according to Formula III u a [0024] in which wherein X
Figure imgf000007_0001
1, X2, and X are independently H, alkyl, alkenyl, alkynyl, halogen, nitro, cyano, cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, ORa, NRaRb, –S(O)2Ra,–S(O)2NRaRb,–C(O)Ra,–C(O)NRaRb,–NRaC(O)Rb,–NRaS(O)2Rb,–N=CRaRb, or –NRaC(O)NHRb; Y is CH2, CHRa, CRaRb, O, NH, NRa, S, SO, or SO2; R1, R2, and R3 are independently H, alkyl, alkoxy, or halogen; n is 0, 1, or 2; wherein each of X1 and X2 is independently optionally substituted; wherein Rc and Rd is independently Ra, and in which A and Het are independently and preferably an aromatic and optionally substituted aryl or heteroaryl. Among other suitable choices, it is typically preferred that
and that
Figure imgf000007_0002
.
Figure imgf000008_0001
[0025] Wit respect to remanng ra cas, te same cons eratons as note or ormula I apply. Especially preferred compounds according to Formula II will include those in which A is an optionally substituted pyridinyl, and/or that Y is O, S, or SO2. [0026] In view of the above and further experimental data (see below), particularly preferred compounds will have a structure as shown below
Figure imgf000008_0002
[0027] T
Figure imgf000009_0001
y u y , w y ht, cyclic, or branched. The term "alkenyl", refers to an alkyl having at least one double bond. Where more than one double bond is present, it is contemplated that the double bonds may be conjugated or un-conjugated. The term "alkynyl", as used herein refers to an alkyl having at least one triple bond. Contemplated alkynyls may further include another triple bond or double bond, which may or may not be conjugated with the first triple bond. The term "alkoxy", as used herein, refers to an O-alkyl group, wherein the "alkyl" is defined as provided above. [0028] A "cycloalkyl" as used herein refers to a non-aromatic monovalent monocyclic or polycyclic radical having from 3 to 14 carbon atoms, each of which may be saturated or unsaturated, and may be un-substituted or substituted by one or more suitable substituents as defined herein, and to which may be fused one or more aryl groups, heteroaryl groups, cycloalkyl groups, or heterocycloalkyl groups which themselves may be un-substituted or substituted by one or more substituents. Examples of cycloalkyl groups include cyclopropyl, cycloheptyl, cyclooctyl, cyclodecyl, cyclobutyl, adamantyl, norpinanyl, decalinyl, norbornyl, cyclohexyl, and cyclopentyl. [0029] A "heterocycloalkyl" as used herein refers to a non-aromatic monovalent monocyclic or polycyclic radical having 1-5 heteroatoms selected from nitrogen, oxygen, and sulfur, and may be unsubstituted or substituted by one or more suitable substituents as defined herein, and to which may be fused one or more aryl groups, heteroaryl groups, cycloalkyl groups, or heterocycloalkyl groups which themselves may be un-substituted or substituted by one or more substituents.
Examples of heterocycloalkyl groups include oxiranyl, pyrrolidinyl, piperidyl, tetrahydropyran, and morpholinyl. [0030] An "aryl" (Ar) as used herein refers to an aromatic monocyclic or polycyclic radical comprising generally between 5 and 18 carbon ring members, which may be un-substituted or substituted by one or more suitable substituents as defined herein, and to which may be fused one or more cycloalkyl groups, heterocycloalkyl groups, or heteroaryl groups, which themselves may be un-substituted or substituted by one or more suitable substituents. Thus, the term "aryl group" includes a benzyl group (Bzl). Examples include phenyl, biphenyl, 1,2,3,4-tetrahydronaphthyl, naphthyl, anthryl, and phenanthryl. [0031] A "heteroaryl" as used herein refers to an aromatic monocyclic or polycyclic radical comprising generally between 4 and 18 ring members, including 1-5 heteroatoms selected from nitrogen, oxygen, and sulfur, which may be un-substituted or substituted by one or more suitable substituents as defined below, and to which may be fused one or more cycloalkyl groups, heterocycloalkyl groups, or aryl groups, which themselves may be unsubstituted or substituted by one or more suitable substituents. Examples include thienyl, furanyl, thiazolyl, triazolyl, imidazolyl, isoxazolyl, oxadiazolyl, tetrazolyl, pyridyl, pyrrolyl, thiadiazolyl, oxadiazolyl, oxathiadiazolyl, thiatriazolyl, pyrimidinyl, isoquinolinyl, quinolinyl, napthyridinyl, phthalimidyl, benzimidazolyl, and benzoxazolyl. [0032] The term "heterocycle" or "heterocyclic" as used herein refers to aromatic and non-aromatic heterocyclic groups, typically with 4 to 10 atoms forming a ring, and containing one or more heteroatoms (typically O, S, or N). Non-aromatic heterocyclic groups include groups having only 4 atoms in their ring system, but aromatic heterocyclic groups typically have at least 5 atoms in their ring system. Examples of non-aromatic heterocyclic groups include pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidino, morpholino, thiomorpholino, thioxanyl, piperazinyl, azetidinyl, oxetanyl, thietanyl,
homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl,
1,2,3,6-tetrahydropyridinyl,2-pyrrolinyl,3-pyrrolinyl, indolinyl,2H-pyranyl,4H-pyranyl, dioxanyl, 1 ,3-dioxolanyl, pyrazolinyl, dithianyl, dithiolanyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl, pyrazolidinyl, imidazolinyl, imidazolidinyl,3-azabicyclo[3.i.0]hexanyl,
3H-indolyl, and quinolizinyl. [0033] Examples of aromatic heterocyclic groups are pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, is benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, quinazolinyl, benzothiazolyl, benzoxazolyl, quinoxalinyl, naphthyridinyl, and furopyridinyl. Contemplated 4-10 membered heterocycles may be C-attached or N-attached (where appropriate). For instance, a group derived from pyrrole may be pyrrol-i-yl (N-attached) or pyrrol-3-yl (C-attached). [0034] As still further used herein, the term "substituted" as used herein refers to a replacement or modification of an atom (radical) or chemical group (e.g., NH2, or OH) in a molecule with a functional group to produce a substituted molecule, and particularly contemplated functional groups include nucleophilic groups (e.g., -NH2, -OH, -SH, -NC, etc.), electrophilic groups (e.g., C(O)OR, C(O)OH, etc.), polar groups (e.g., -OH), non-polar groups (e.g., aryl, alkyl, alkenyl, alkynyl, etc.), ionic groups (e.g., -NH +
3 ), and halogens (e.g., -F, -Cl), and all chemically reasonable combinations thereof. For example, where the molecule is an alkyl, the replaced radical is a hydrogen radical, and the functional group is a hydroxyl group, the H-atom is substituted by an OH group to form a substituted alkyl. In another example, where the molecule is an amino acid, the modified group is the amino group, and the functional group is an alkyl group, the amino group is alkylated to form an N-substituted amino acid. [0035] For example, suitable substituents include halogen (chloro, iodo, bromo, or fluoro);
C1-6-alkyl; C1-6-alkenyl; C1-6-alkynyl, hydroxyl, C1-6 alkoxyl; amino; nitro; thiol; thioether; imine; cyano; amido; phosphonato; phosphine; carboxyl; carbonyl; aminocarbonyl; thiocarbonyl;
sulfonyl; sulfonamine; sulfonamide; ketone; aldehyde; ester; oxygen (=O); haloalkyl (e.g., trifluoromethyl); carbocyclic cycloalkyl, which may be monocyclic or fused or non-fused polycyclic (e.g., cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl), or a heterocycloalkyl, which may be monocyclic or fused or non-fused polycyclic (e.g., pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, or thiazinyl); carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic aryl (e.g., phenyl, naphthyl, pyrrolyl, indolyl, furanyl, thiophenyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, tetrazolyl, pyrazolyl, pyridinyl, quinolinyl, isoquinolinyl, acridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, benzimidazolyl, benzothiophenyl, or benzofuranyl); amino (primary, secondary, or tertiary); nitro; thiol; thioether, O-lower alkyl; O-aryl, aryl; aryl-lower alkyl; CO2CH3; CONH2; OCH2CONH2; NH2; SO2NH2; OCHF2; CF3; OCF3; etc. It should be further noted that all substituents contemplated herein may further optionally be substituted by one or more substituents noted above. Especially preferred substituents include hydroxyl groups, halogens, oxo groups, alkyl groups (and especially lower alkyl), acyl groups, sulfonyl groups, mercapto groups, alkylthio groups, alkyloxyl groups, cycloalkyl groups, heterocycloalkyl groups, aryl groups, heteroaryl groups, carboxyl groups, amino groups, alkylamino groups, dialkylamino groups, carbamoyl groups, aryloxyl groups, heteroaryloxyl groups, arylthio groups, heteroarylthio groups. [0036] Moreover, it should be appreciated that the compounds according to the inventive subject matter may comprise one or more asymmetric centers, and may therefore exist in different enantiomeric forms, and all enantiomeric forms of contemplated compounds are specifically contemplated herein. Similarly, where contemplated compounds exhibit optical activity and/or have stereoisomers, all optical activities and/or isomeric forms are contemplated herein. Similarly, where double bonds distinguish a Z-form from an E-form (or cis- from trans-), both isomers are contemplated. Moreover, it is noted that the compounds according to the inventive subject matter may also be isotopically-labeled. Examples of suitable isotopes 2H, 3H, 13C, 14C, 15N, 18O 17O, 18F, or 36Cl. Certain isotopically-labeled compounds of the inventive subject matter, for example those into which 14C or 3H is incorporated, may be useful in drug and/or substrate tissue distribution assays. On the other hand, substitution with non-radioactive isotopes (e.g., 2H or 13C) can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements and, hence, may be preferred in some circumstances. [0037] Contemplated compounds may be prepared as pharmaceutically acceptable salt(s), which especially include salts of acidic or basic groups which may be present in the contemplated compounds. For example, where contemplated compounds are basic in nature it should be noted that such compounds may form a wide variety of salts with various inorganic and organic acids. Suitable acids will provide pharmacologically acceptable anions, including chloride, bromide, iodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, acid citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, and pamoate
[1,1’-methylene-bis-(2-hydroxy-3-naphthoate)] anions. Similarly, where contemplated compounds are acidic in nature, it should be noted that such compounds may form base salts with various pharmacologically acceptable cations, and especially suitable cations include alkali metal or alkaline earth metal ions (e.g., sodium and potassium cations). [0038] In still further contemplated aspects, the compounds presented herein may be prepared as prodrugs, and all known manners and types of prodrugs are considered suitable for use herein, so long as such prodrug will increase the concentration of the drug (or metabolite of the prodrug) at a target organ, target cell, and/or Hec1. For example, where contemplated compounds have a free amino, amido, hydroxy, thio, or carboxylic group, it is contemplated that such groups can be employed to covalently and releasably bind a moiety that converts the drug into a prodrug.
Therefore, prodrugs particularly include those in which contemplated compounds form an ester, amide, or disulfide bond with another cleavable moiety. Such moieties may assist in organ or cell-specific delivery of the drug and therefore particularly include receptor ligands and their analogs, antibody fragments or other high-affinity ligands (Kd<106M). [0039] For instance, a carboxyl group can be derived to form an amide or alkyl ester, which may include an ether, amine-, and/or carboxylic acid group. Free hydroxyl groups may be derived using hemisuccinates, phosphate esters, dimethylaminoacetates, and phosphoryloxymethyloxy- carbonyls, as outlined in D. Fleisher, R. Bong, B. H. Stewart, Advanced Drug Delivery 40 Reviews (1996) 19, 115. Carbamate prodrugs of hydroxyl and amino groups are also included, as are carbonate prodrugs and sulfate esters of hydroxyl groups. Deriving hydroxyl groups as
(acyloxy)methyl and (acyloxy)ethylethers, wherein the acyl group may be an alkyl ester (option- ally substituted), or where the acyl group is an amino acid ester are also contemplated (prodrugs of this type are described in R. P. Robinson et al., J. Medicinal Chemistry (1996) 39:p.10). [0040] In still further contemplated aspects, it should be appreciated that the compounds according to the inventive subject matter may also be active as a metabolite (of a prodrug or non-prodrug form) and that all of such metabolites are especially contemplated herein. For example, suitable metabolites include hydroxylated forms, oxidized forms, glucuronidated forms, sulfated forms, etc. Moreover, it is also noted that the metabolites may be more active that the originally administered form. Contemplated Compositions and Formulations [0041] Based on the activity of the compounds as Hec1 modulators, the inventors contemplate that the compounds and compositions according to the inventive subject matter may be employed for prophylaxis and/or treatment of various diseases associated with Hec1 dysfunction and/or overexpression, and in fact for all diseases that positively respond to administration of contemplated compounds. The term "dysfunction of Hec1" as used herein refers to any abnormality in Hec1, especially as it relates to its association with Nek2 function and spindle checkpoint signaling. Such abnormalities may be due to one or more of a mutation (e.g., increasing or reducing affinity to a binding partner), temporary or permanent overexpression (e.g., activated by inappropriate or mutated promoter), irreversible or tighter binding of an activator, inappropriate activation by non-physiological molecule, etc. Consequently, particularly contemplated diseases include neoplastic diseases, and especially cancerous neoplastic diseases (e.g., breast cancer, squamous cell cancer, bladder cancer, gastric cancer, pancreatic cancer, head cancer, neck cancer, oesophageal cancer, prostate cancer, colorectal cancer, lung cancer, renal cancer, gynecological cancer, or thyroid cancer). Non cancerous neoplastic diseases include benign hyperplasia of the skin (e.g., psoriasis) or prostate (e.g., benign prostatic hypertrophy (BPH). [0042] Therefore, the inventor also contemplates numerous pharmaceutical compositions that include the compounds presented herein and it is generally contemplated that the compounds according to the inventive subject matter may be formulated into pharmaceutical compositions that have a therapeutically effective amount of contemplated compounds (or pharmaceutically acceptable salt, hydrate, or prodrug thereof), and a pharmaceutically acceptable carrier. [0043] Activity, toxicity, and other pharmacological and pharmacodynamic parameters can be established for the compounds presented herein using numerous known protocols. Similarly, cytotoxicity can be established via MTS assay in various cell lines, while disruption of Hec1- Nek2 interaction can be monitored via co-immunoprecipitation or a yeast two-hybrid system. Cell cycle analysis can be performed by monitoring various stage populations (e.g., sub-G1, G0/G1, S, etc.), and metaphase chromosomal misalignment quantitation can be performed using
immunofluorescence methods well known in the art. In vivo activity can be established using various animal models, and especially xenograft models. Exemplary results are provided in the attached table and normalized data. Consequently, the inventors contemplate a pharmaceutical composition that includes a pharmaceutically acceptable carrier and contemplated compounds herein wherein the compounds are present in a concentration effective to disrupt Hec1/Nek2 binding in a patient when the composition is administered to the patient. The inventors have also discovered that numerous compounds according to the inventive subject matter were bioavailable upon oral administration and could be detected in serum over prolonged periods after oral administration or intravenous (i.v.), administration (see below). [0044] Most preferably, contemplated compounds are formulated with one or more non-toxic pharmaceutically acceptable carriers, preferably formulated for oral administration in solid or liquid form, or for parenteral injection. Thus, it should be appreciated that pharmaceutical compositions according to the inventive subject matter may be administered to humans and other animals using various routes, including orally, rectally, parenterally, intraperitoneally, vaginally, or topically. [0045] For example, suitable pharmaceutical compositions for injection preferably comprise pharmaceutically acceptable sterile aqueous or nonaqueous solutions, dispersions, emulsions, or suspensions, as well as sterile powders for reconstitution into sterile injectable solutions or dispersions prior to use. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents, or vehicles include water, ethanol, polyols (e.g., glycerol, propylene glycol, polyethylene glycol, etc.), and suitable mixtures thereof, oils, and injectable organic esters (e.g., ethyl oleate).
Contemplated compositions may also contain various inactive ingredients, including preservatives, wetting agents, emulsifying agents, and/or dispersing agents. Sterility may be ensured by inclusion of antibacterial and/or antifungal agents (e.g., paraben, phenol sorbic acid, chlorobutanol, etc.). Where appropriate, osmotically active agents may be included (e.g., sugars, sodium chloride, etc.). [0046] Alternatively, contemplated compositions may be formulated into solid dosage forms for oral administration, and may therefore be capsules, tablets, pills, powders, and granules. In preferred solid dosage forms, contemplated compound are mixed with at least one of a pharmaceutically acceptable excipient or carrier (e.g., sodium citrate or dicalcium phosphate), a filler or extender (e.g., starch, lactose, sucrose, glucose, mannitol, or silicic acid), a binder (e.g., carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, etc.), a humectant (e.g., glycerol), a disintegrating agent (e.g., agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, or sodium carbonate), a solution retarding agent (e.g., paraffin), an absorption accelerator (e.g., quaternary ammonium compound), a wetting agents (e.g., cetyl alcohol and glycerol monostearate), and absorbents (e.g., kaolin, or bentonite clay), and a lubricant (e.g., talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate). [0047] Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. Contemplated compositions may further be formulated to release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes. Contemplated compounds may also be in micro-encapsulated form, if appropriate, with one or more of the above-mentioned excipients. [0048] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, liquid dosage forms may contain inert diluents commonly used in the art (e.g., water, or other solvent, solubilizing agents), emulsifiers (e.g., ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethyl formamide), oils (and in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions may also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents. [0049] Compounds according to the inventive subject matter can also be administered in form of liposomes, which may be unilamellar, oligolamellar, or polylamellar. Contemplated compositions in liposome form may further contain stabilizers, preservatives, excipients, etc. Preferred lipids for liposome formation include phospholipids and the phosphatidyl cholines (lecithins), both natural and synthetic. Methods to form liposomes are known in the art. See, for example, Prescott, Ed., Methods in Cell Biology, Volume XIV, Academic Press, New York, N.Y. (1976), p. 33 et seq. [0050] Actual dosage levels of contemplated compounds in pharmaceutical compositions according to the inventive subject matter may be varied so as to obtain an amount of contemplated compound(s) that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration. Thus, the selected dosage level will depend upon various factors, including the activity of the particular compound, the route of administration, the severity of the condition being treated, and the condition and prior medical history of the patient being treated. However, it is within the skill of the art to start doses of the compound at levels lower than required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved. Generally, dosage levels of about 0.01 mg to about 500 mg, more preferably of about 0.5 mg to about 50 mg of contemplated compound per kilogram of body weight per day are administered orally to a mammalian patient. If desired, the effective daily dose may be divided into multiple doses for purposes of administration, e.g., two to four separate doses per day. Therefore, contemplated formulations especially include those suitable for oral administration, parenteral administration, for administration as cream, or as eye-drops or other liquid topical formulation. [0051] Furthermore, preliminary data showed that various Hec1 inhibitors, exhibited synergistic effect with selected chemotherapeutic inhibitors. Among other chemotherapeutic inhibitors, compounds including Taxol, vincristine, and vinblastine showed synergistic effect, and are also expected to have synergistic effect with respect to tubulin formation or polymerization inhibitors, as well as pretubulin inhibitors. Thus, suitable chemotherapeutic inhibitors especially include one or more drugs that interfere with microtubule formation or degradation. Therefore, any drugs that affect cell division and any anti-metabolites are deemed useful in combination with the Hec1 inhibitors contemplated herein. In contrast, anthracyclines (e.g., doxorubicin) were shown only to have at most additive effect and no synergistic effect with Hec1 inhibitors. [0052] It should still further be appreciated that contemplated pharmaceutical compositions may also include additional pharmaceutically active compounds, and especially contemplated additional pharmaceutically active compounds include antineoplastic agents, which may act on DNA replication, cell cycle, cell metabolism, angiogenesis, or induce apoptosis. Further suitable active agents include immunologically active agents (e.g., anti-inflammatory agents,
immunosuppressants, steroids, interferons (alpha, beta, or gamma) and fragments thereof, and those molecules that selectively increase or suppress Th1 and/or Th2 cytokine expression). Still other suitable active agents include antibacterial and antiviral agents, drugs that stimulate or modify metabolism, neurologically active drugs, and/or analgesic drugs. Of course, it should be recognized that additional pharmaceutically active compounds may be included in the same pharmaceutical composition, or may be administered separately, and a person of ordinary skill in the art will readily determine schedule and route of suitable co-administration of the additional pharmaceutically active compounds. Examples/Experiments Exemplary Synthesis of 4-Aryl-2-amidothiazoles [0053] Contemplated 4-aryl-2-amidothiazole compounds can be prepared by numerous synthetic routes, and the following is provided to give exemplary guidance only. While the below scheme can be used to prepare most of the compounds presented herein, other compounds may require minor modifications top the general scheme that will be readily apparent to the skilled artisan.
[005 s E.
Figure imgf000017_0001
Aromatic compounds of structure A, including substituted benzene, pyridine, or other heterocyclic compound (5-, 6-, or 7-membered) are reacted with acetyl chloride in the presence of AlCl3 to afford acetylated arenes B. Bromination of B give -Br-acetylated arenes C, which are allowed to react with thiourea to generate aminothiazoles D with an aryl substituent at the C-4 position. The so prepared aminothiazoles then react with different acids give the final 4-aryl-2-amidothiazoles E. [0055] Acetylation of Ar1:
Figure imgf000017_0002
[0056] The acetylation of Ar1 can be achieved by use of different reagents as shown in the above Scheme.
[0057] Bromination of Acetyl Ar1:
Figure imgf000018_0003
[0058] Suitable bromination agents include Br2, HBr, NBS, TBABr3, CuBr2, etc. in various solvents, including ether, THF, halogenated hydrocarbons, ester, etc.
[0059] Amidation of Aminothiazoles:
Figure imgf000018_0004
[0060] Suitable coupling agents include CDI, EDC, CDC, etc.
Figure imgf000018_0001
[0061] X is typically CI or Br; base is typically Et3N, Me3N, DIPEA, K2C03, Na2CO3, DMAP, etc. Alternatively, 4-Aryl-2-amidothiazoles can be prepared as follows:
Figure imgf000018_0002
[0062] Alternatively, coupling may also be performed as follows:
Figure imgf000018_0005
[0063] To a solution of 4-arylthiazol-2-amine (1.0 equiv) in CH2Cl2 was added triethylamine (3.0 equiv) or DMAP (3.0 equiv) followed by aryloxy chloride (1.5 equiv) or aryloxychloride hydrochloride (1.5 equiv). The reaction mixture was stirred at room temperature overnight. The solution was concentrated under reduced pressure and added with hot water. The resultant precipitate was filtered, and dried under vacuum to give the corresponding
4-aryl-2-amidothiazoles. For specific examples of synthesis, see below.
Synthesis of Exemplary Aminothiazoles and the Related Intermediates
Figure imgf000019_0001
[0064] 2-Bromo-l-mesitylethanone. To a solution of 1-mesitylethanone (1.02 g, 6.27 mmol) in EtOAc (50 mL) was added copper(II) bromide (CuBr2, 2.85 g, 12.8 mmol). The reaction mixture was heated at reflux for 90 min. The solution was allowed to cool down, and the resultant solids were filtered off and washed with EtOAc. The filtrate was concentrated under reduced pressure to give crude 2-bromo- 1-mesitylethanone (1.67 g) as yellow oil: 1H NMR (500 MHz, CDCl3)□6.87 (2 H, s), 4.27 (2 H, s), 2.31 (3 H, s), 2.22 (6 H, s).
Figure imgf000019_0002
[0065] 4-Mesitylthiazol-2-amine.2-Bromo-l-mesitylethanone (2.43 g, 10.1 mmol) and thiourea (0.810 g, 10.6 mmol) were dissolved in 95% ethanol (20 mL). The reaction mixture was heated at reflux for 2.0 h. The solution was concentrated under reduced pressure, and the residue was recrystallized from 2-propanol to give the desired 4-mesitylthiazol-2-amine (2.36 g) as white solids: 1H NMR (500 MHz, CD3OD)□7.00 (2 H, s), 6.67 (1 H, s), 2.31(3 H, s), 2.19 (6 H, s).
Figure imgf000019_0003
[0066] 4-(/7-Tolyl)thiazol-2-amine. A mixture of 2-bromo- l-(p-tolyl)ethanone (5.00 g, 23.5 mmol) and thiourea (1.97 g, 25.9 mmol) in 95% EtOH (33.5 mL) was heated at reflux for 60 min. The solution was concentrated and added with water (50 mL) and saturated aqueous Na2CO3 (1.0 mL). The resultant precipitate was filtered and washed with hot water. The solids were filtered and dried under vacuum to give 4-(p-tolyl)thiazol-2-amine (4.40 g) as white solids in 99% yield: 1H NMR (500 MHz, CDCl3)□7.66 (d, J= 8.0 Hz, 2 H), 7.18 (d, J= 7.5 Hz, 2 H), 6.66 (s, 1 H), 5.25 (bs, 2 H), 2.36 (s, 6 H).
Figure imgf000020_0001
[0067] 5-Methyl-4-(p-tolyl)thiazol-2-amine. A mixture of 2-bromo-l-(p-tolyl)propan-l-one (6.88 g, 30.3 mmol) and thiourea (2.54 g, 33.4 mmol) in 95% EtOH (43 mL) was heated at reflux for 60 min. The solution was concentrated and added with water (100 mL) and saturated aqueous Na2CO3 (5.0 mL). The resultant precipitate was filtered and recrystallized in toluene. The solids were filtered and dried under vacuum to give 5-methyl-4-(p-tolyl)thiazol-2-amine (6.10 g) as white solids in 99% yield: 1H NMR (500 MHz, CDCl3)□7.40 (d, J= 8.0 Hz, 2 H), 7.23 (d, J= 8.0 Hz, 2 H), 3.18 (bs, 2 H), 2.37 (s, 3 H), 2.35 (s, 3 H).
Figure imgf000020_0002
[0068] 2-Bromo-l-(4-methoxy-2,6-dimethylphenyl)ethanone. To a solution of
1- (4-methoxy-2,6-dimethylphenyl)ethanone (5.7 g, 32 mmol) in acetonitrile (64 mL) was added tetrabulylammoniumtribromide (TBABr3, 15.4 g, 32.0 mmol). The reaction was stirred at room temperature for 80 min. The solution was concentrated under reduced pressure, added with water, and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous MgS04(s), and concentrated under reduced pressure to give
2- bromo-l-(4-methoxy-2,6-dimethylphenyl)ethanone (9.14 g), which was used directly for the next step without further purification.
Figure imgf000020_0003
[0069] 4-(4-Methoxy-2,6-dimethylphenyl)thiazol-2-amine. A mixture of
2-bromo-l-(4-methoxy-2,6-dimethylphenyl)ethanone (8.65 g, 33.6 mmol) and thiourea (2.56 g, 33.6 mmol) in 95% EtOH (48 mL) was heated at reflux for 60 min. The solution was concentrated and added with water (50 mL) and saturated aqueous Na2CO3 (5.0 mL). The resultant precipitate was filtered and recrystallized in toluene (50 mL). The solids were filtered and dried under vacuum to give 4-(4-methoxy-2,6-dimethylphenyl)thiazol-2-amine (5.9 g) as white solids in 66% yield: 1H NMR (500 MHz, CDCl3)□6.61 (s, 2 H), 6.27(s, 1 H), 4.91 (bs, 2 H), 3.79 (s, 3 H), 2.15 (s, 6 H).
Figure imgf000021_0001
[0070] 2-Bromo-l-(2,4,6-trimethylpyridin-3-yl)ethanone hydrobromide. To a solution of
1- (2,4,6-trimethylpyridin-3-yl)ethanone (5.0 g, 30.6 mmol) in 33% HBr in acetic acid solution (10.2 mL) was added bromine (1.57 ml, 30.6 mmol) in acetic acid (10.2 mL) dropwisely. The reaction was stirred at 70 C for 2.0 h. The solution was cooled to room temperature and washed with ether. The residue was dried under reduced pressure to give
2- bromo-l-(2,4,6-trimethylpyridin-3-yl)ethanone hydrobromide, which was used directly for the next step without further purification.
Figure imgf000021_0002
[0071] 4-(2,4,6-Trimethylpyridin-3-yl)thiazol-2-amine. A mixture of
2-bromo-l-(2,4,6-trimethylpyridin-3-yl)ethanone hydrobromide (9.00 g, 27.9 mmol) and thiourea (2.12 g, 27.9 mmol) in 95% EtOH (39.8 mL) was heated at reflux for 120 min. The solution was concentrated and added with water (50 mL) and saturated aqueous Na2CO3 (5.0 mL). The resultant precipitate was filtered and recrystallized in toluene. The solids were filtered and dried under vacuum to give 4-(2,4,6-trimethylpyridin-3-yl)thiazol-2-arnine (3.80 g) as yellow solids in 62% yield: 1HNMR (500 MHz, CDCl3)□6.87 (s, 1 H), 6.31 (s, 1 H), 5.07 (bs, 2 H), 2.49 (s, 3 H), 2.38 (s, 3 H), 2.14 (s, 3 H).
Figure imgf000021_0003
[0072] 2-Bromo-l-(4-ethoxy-2,6-dimethylphenyl)ethanone. To a solution of
1- (4-ethoxy-2,6-dimethylphenyl)ethanone (4.00 g, 20.8 mmol) in acetonitrile (41.6 mL) was added tetrabutylammoniumtribromide (TBABr3, 10.0 g, 20.8 mmol). The reaction was stirred at room temperature overnight. The solution was concentrated under reduced pressure, added with water, and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous MgS04(s), and concentrated under reduced pressure to give
2- bromo-l-(4-ethoxy-2,6-dimethylphenyl)ethanone (6.40 g), which was used directly for the next step without further purification.
Figure imgf000022_0001
[0073] 4-(4-Ethoxy-2,6-dimethylphenyl)thiazol-2-amine. A mixture of
2-bromo-l-(4-ethoxy-2,6-dimethylphenyl)ethanone (6.35 g, 23.4 mmol) and thiourea (1.78 g, 23.4 mmol) in 95% EtOH (33.5 mL) was heated at reflux for 60 min. The solution was concentrated and added with water (50 mL) and saturated aqueous Na2CO3 (5.0 mL). The resultant precipitate was filtered and recrystallized in toluene (30 mL). The solids were filtered and dried under vacuum to give 4-(4-ethoxy-2,6-dimethylphenyl)thiazol-2-amine (4.18 g) as white solids in 72% yield: 1H NMR (500 MHz, DMSO-d6)□6.84 (s, 2 H), 6.60 (s, 2 H), 6.27(s, 1 H), 3.99 (q, J= 6.5 Hz, 2 H), 2.06 (s, 6 H), 1.31 (t, J = 6.95 Hz, 3 H).
Figure imgf000022_0002
[0074] 4-Acetyl-3,5-dimethylphenyl trifluoromethanesulfonate. A solution of
l-(4-hydroxy-2,6-dimethylphenyl)ethanone (3.30 g, 20.1 mmol), triethylamine (4,07 g, 40.2 mmol) in anhydrous CH2Cl2 (20.1 mL) was cooled to 0 C, and then added with
trifluoromethanesulfonic anhydride (4.0 mL, 24 mmol) dropwisely. After the addition was completed, the reaction mixture was warmed to room temperature and stirred for 1.0 h. The solution was added with water and extracted with ethyl acetate (60 mL). The organic layer was separated, dried over MgSO^s), concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel to give 4-acetyl-3,5-dimethylphenyl trifluoromethanesulfonate (5.0 g) as yellow oil in 85% yield.
Figure imgf000022_0003
[0075] l-(3,5-Dimethyl-[l,l'-biphenyl]-4-yl)ethanone. To a solution of
4-acetyl-3,5-dimethylphenyl trifluoromethanesulfonate (1.00 g, 3.38 mmol), KF (0.65 g, 11 mmol), and phenylboronic acid (0.49 g, 4.0 mmol) in THF (4.0 mL) was added
tricyclohexylphosphine (11.4 mg, 0.04 mmol) and Pd(OAc)2 (7.6 mg, 0.03 mmol). The reaction mixture was stirred at room temperature for 5.0 h under N2. The reaction mixture was filtered through a small pad of Celite, and the cake was washed with ethyl acetate (40 niL). The filtrate was concentrated under reduced pressure, and the residue was purified by flash chromatography on silica gel to give l-(3,5-dimethyl-[l,l'-biphenyl]-4-yl)ethanone (0.68 g) in 90% yield: 1HNMR (500 MHz, CDCl3)□7.56 (d, J= 8.0 Hz, 2 H), 7.44 (t, J= 7.0 Hz, 2 H), 7.35 (m, 1 H), 7.25 (s, 2 H), 2.52 (s, 3 H), 2.33 (s, 6 H).
Figure imgf000023_0001
[0076] 2-Bromo-l-(3,5-dimethyl-[l,l'-biphenyl]-4-yl)ethanon. To a solution of
1- (3,5-dimethyl-[l,l'-biphenyl]-4-yl)ethanone (1.89 g, 8.43 mmol) in acetonitrile (16.9 mL) was added tetrabutylammoniumtribromide (TBABr3, 4.07 g, 8.43 mmol). The reaction was stirred at room temperature overnight. The solution was concentrated under reduced pressure, added with water, and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous MgS04(s), and concentrated under reduced pressure to give
2- bromo-l-(3,5-dimethyl-[l,l'-biphenyl]-4-yl)ethanone (3.2 g), which was used directly for the next step without further purification.
Figure imgf000023_0002
[0077] 4-(3,5-Dimethyl-[l,l'-biphenyl]-4-yl)thiazol-2-amine. A mixture of
2-bromo-l-(3,5-dimethyl-[l,l'-biphenyl]-4-yl)ethanone (2.56 g, 8.44 mmol) and thiourea (0.64 g, 8.44 mmol) in 95% EtOH (12.1 mL) was heated at reflux for 60 min. The solution was concentrated and added with water (50 mL) and saturated aqueous Na2CO3 (1.0 mL). The resultant precipitate was filtered and recrystallized in toluene (10 mL). The solids were filtered and dried under vacuum to give 4-(3,5-dimethyl-[l, r-biphenyl]-4-yl)thiazol-2-amine (0.66 g) as yellow solids in 28% yield: 1H NMR (500 MHz, CDCl3)□7.60 (d, J = 1 Hz, 2 H), 7.43 (t, J = 7.5 Hz, 1 H), 7.32 (m, 1 H), 7.25 (s, 2 H), 6.34 (s, 1 H), 5.03 (bs, 2 H), 2.24 (s, 6 H).
Figure imgf000023_0003
[0078] l-(4-Chloro-2,6-dimethylphenyl)ethanone. Anhydrous copper(II) chloride (98.9 g, 0.74 mol) was mixed with tert-buty\ nitrite (94.8 g, 0.83 mol) in acetonitrile (1.02 L). The solution was cooled to 0 C and slowly added with l-(4-amino-2,6-dimethylphenyl)ethanone (100 g, 0.61 mol) in a period of 5.0 min. After the addition was completed, the reaction mixture was warmed to room temperature, and was poured into an aqueous hydrochloric acid solution (20%, 1.0 L). The solution was extracted with EtOAc (800 mL), and the organic layer was separated, washed with H2O (1.0 L), dried over MgSO4 (s), and concentrated under reduced pressure. The liquid was distilled to give 1 -(4-chloro-2,6-dimethylphenyl)ethanone (85.0 g) as yellow oil in 76% yield: 1H NMR (500 MHz, CDCl3)□7.02 (s, 2 H), 2.45 (s, 3 H), 2.22 (s, 6 H).
Figure imgf000024_0001
[0079] 2-Bromo-l-(4-chloro-2,6-dimethylphenyl)ethanone. To a solution of
1- (4-chloro-2,6-dimethylphenyl)ethanone (5.0 g, 27 mmol) in acetonitrile (54.8 mL) was added tetrabutylammoniumtribromide (TBABr3, 13.2 g, 27.4 mmol). The reaction was stirred at room temperature overnight. The solution was concentrated under reduced pressure, added with water, and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous MgSO4(s), and concentrated under reduced pressure to give
2- bromo-l-(4-chloro-2,6-dimethylphenyl)ethanone (7.2 g), which was used directly for the next step without further purification,
Figure imgf000024_0002
[0080] 4-(4-Chloro-2,6-dimethylphenyl)thiazol-2-amine. A mixture of
2-bromo-l-(4-chloro-2,6-dimethylphenyl)ethanone (6.54 g, 25.0 mmol) and thiourea (1.90 g, 25.0 mmol) in 95% EtOH (35.7 mL) was heated at reflux for 60 min. The solution was concentrated and added with water (50 mL) followed by saturated aqueous Na2CO3 (4.0 mL). The resultant precipitate was filtered and recrystallized in toluene (30 mL). The solids were filtered and dried under vacuum to give 4-(4-chloro-2,6-dimethylphenyl)thiazol-2-amine (4.30 g) as white solids in 72% yield: 1H NMR (500 MHz, DMSO-d6)□7.16 (s, 2 H), 6.43 (s, 1 H), 2.10 (s, 6 H).
Figure imgf000025_0001
[0081] N-(4-(2-Bromoacetyl)-3,5-dimethylphenyl)acetamide. To a solution of
N-(4-acetyl-3,5-dimethylphenyl)acetamide (5.00 g, 24.4 mmol) in acetonitrile (48.7 mL) was added tetrabutylammoniumtribromide (ΤΒΑΒr3, 11.7 g, 24.4 mmol). The reaction was stirred at room temperature overnight. The solution was concentrated under reduced pressure, added with water, and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous MgS04(s), and concentrated under reduced pressure to give
N-(4-(2-bromoacetyl)-3,5-dimethylphenyl)acetamide (7.00 g), which was used directly for the next step without further purification.
Figure imgf000025_0002
[0082] N-(4-(2-aminothiazol-4-yl)-3,5-dimethylphenyl)acetamide. A mixture of
N-(4-(2-bromoacetyl)-3,5-dimethylphenyl)acetamide (7.34 g, 25.8 mmol) and thiourea (1.97 g, 25.9 mmol) in 95% EtOH (36.9 mL) was heated at reflux for 120 min. The solution was concentrated and added with water (100 mL) and saturated aqueous Na2CO3 (5.0 mL). The resultant precipitate was filtered and recrystallized in toluene (50 mL). The solids were filtered and dried under vacuum to give N-(4-(2-aminothiazol-4-yl)-3,5-dimethylphenyl)acetamide (5.83 g) as yellow solids in 86% yield: 1H NMR (500 MHz, DMSO-d6)□9.80 (s, 1 H), 7.26 (s, 2 H), 6.90 (bs, 2 H), 6.30 (s, 1 H), 2.06 (s, 6 H), 2.02 (s, 3 H).
Figure imgf000025_0003
[0083] 2-Bromo-l-(2,4,6-triisopropylphenyl)ethanone. To a solution of
l-(2,4,6-triisopropylphenyl)ethanone (10.0 g, 65.3 mmol) in acetonitrile (81 mL) was added tetrabutylammoniumtribromide (TBABr3, 19.6 g, 40.6 mmol). The reaction was stirred at room temperature for 3.0 h. The solution was concentrated under reduced pressure, added with water, and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous MgS04(s), and concentrated under reduced pressure to give
2-bromo-l-(2,4,6-triisopropylphenyl)ethanone (13.2 g), which was used directly for the next step without further purification.
Figure imgf000026_0001
[0084] 4-(2,4,6-Triisopropylphenyl)thiazol-2-amine. A mixture of
2-bromo-l-(2,4,6-triisopropylphenyl)ethanone (13.9 g, 42.7 mmol) and thiourea (3.24 g, 42.6 mmol) in 95% EtOH (60.9 mL) was heated at reflux overnight. The solution was concentrated and added with water (100 mL), saturated aqueous Na2CO3 (10 mL), and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous MgS04(s), and concentrated under reduced pressure, which was purified by column chromatography on silica gel (33% EtOAc in hexanes as eluant) to give 4-(2,4,6-triisopropylphenyl)thiazol-2-amine (3.28 g) as white solids in 25% yield: 1H NMR (500 MHz, CDCl3)□7.03 (s, 2 H), 6.22 (s, 1 H), 4.75 (bs, 2 H), 2.89 (m, 1 H), 2.68 (m, 2 H), 1.27-1.14 (m, 18 H).
Figure imgf000026_0002
[0085] l-(2,6-Dimethyl-4-phenoxyphenyl)ethanone. To a solution of
l-(4-chloro-2,6-dimethylphenyl)ethanone (4.50 g, 24,6 mmol), K3P04 (10.5 g, 49.3 mmol), and phenol (2.78 g, 29.5 mmol) in toluene (49.3 mL) was added 2-(di-tert-butylphosphino)biphenyl (221 mg, 0.74 mmol) and Pd(OAc)2 (233 mg, 1.04 mmol). The reaction was heated at 100 EC for 2.0 h under N2. The solution was cooled to room temperature and filtered through a small pad of Celite. The cake was washed with ethyl acetate (50 mL) and the combined filtrate was concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel to give 1 -(2,6-dimethyl-4-phenoxyphenyl)ethanone as a yellow oil in 68% yield: 1H NMR (500 MHz, CDCl3)□7.35 (t, J= 8.0 Hz, 2 H), 7.12 (t, J= 7.5 Hz ,1 H), 7.00 (d, J= 7.5 Hz, 2 H), 6.65 (s, 2 H), 2.48 (s, 3 H), 2.22 (s, 6 H).
Figure imgf000027_0001
[0086] 2-Bromo-l-(2,6-dimethyl-4-phenoxyphenyl)ethanone. To a solution of
1- (2,6-dimethyl-4-phenoxyphenyl)ethanone (3.60 g, 15.0 mmol) in acetonitrile (30 mL) was added tetrabutylammoniumtribromide (TBABr3, 7.95 g, 15.0 mmol). The reaction was stirred at room temperature overnight. The solution was concentrated under reduced pressure, added with water, and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous MgS04(s), and concentrated under reduced pressure to give
2- bromo-l-(2,6-dimethyl-4-phenoxyphenyl)ethanone (4.8 g), which was used directly for the next step without further purification.
Figure imgf000027_0002
[0087] 4-(2,6-Dimethyl-4-phenoxyphenyl)thiazol-2-amine. A mixture of
2-bromo-l-(2,6-dimethyl-4-phenoxyphenyl)ethanone (5.18 g, 16.2 mmol) and thiourea (1.24 g, 16.3 mmol) in 95% EtOH (23.2 mL) was heated at reflux for 60 min. The solution was concentrated and added with water (50 mL) and saturated aqueous Na2CO3 (5.0 mL). The resultant precipitate was filtered and recrystallized in toluene (30 mL). The solids were filtered and dried under vacuum to give 4-(2,6-dimethyl-4-phenoxyphenyl)thiazol-2 -amine (2.84 g) as yellow solids in 59% yield: 1H NMR (500 MHz, CDCl3)□7.33 (t, J= 7.5 Hz, 2 H), 7.26 (t, J= 7.5 Hz ,1 H), 7.10 (d, J= 7.3, 2 H), 6.72 (s, 2 H), 6.30 (s, 1 H), 5.18 (bs, 2 H), 2.14 (s, 6 H).
Figure imgf000027_0003
[0088] 2-Bromo-l-(4-isopropoxy-2,6-dimethylphenyl)ethanone. To a solution of
l-(4-isopropoxy-2,6-dimethylphenyl)ethanone (4.3 g, 20.9 mmol) in acetonitrile (41.7 mL) was added tetrabutylammoniumtribromide (TBABr3, 11.1 g, 22.9 mmol). The reaction was stirred at room temperature overnight. The solution was concentrated under reduced pressure, added with water, and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous MgS04(s), and concentrated under reduced pressure to give 2-bromo-l-(4-isopropoxy-2,6-dimethylphenyl)ethanone (5.9 g), which was used directly for the next step without further purification.
Figure imgf000028_0001
[0089] 4-(4-Isopropoxy-2,6-dimethylphenyl)thiazol-2-amine. A mixture of
2-bromo-l-(4-isopropoxy-2,6-dimethylphenyl)ethanone (5.18 g, 18.2 mmol) and thiourea (1.38 g, 18.2 mmol) in 95% EtOH (26 mL) was heated at reflux for 60 min. The solution was concentrated and added with water (50 mL) and saturated aqueous Na2CO3 (5.0 mL). The resultant precipitate was filtered and recrystallized in toluene (30 mL). The solids were filtered and dried under vacuum to give 4-(4-isopropoxy-2,6-dimethylphenyl)thiazol-2-amine (3.44 g) as yellow solids in 72.2% yield: 1HNMR (500 MHz, CDCl3)□6.60 (s, 2 H), 6.26 (s, 1 H), 4.97 (bs, 2 H), 4.54 (m, 1 H), 2.13 (s, 6 H), 1.32 (d, J = 6.1 Hz, 6 H).
Figure imgf000028_0002
[0090] 2-Bromo-l-(4-(cyclopentyloxy)-2,6-dimethylphenyl)ethanone. To a solution of
1- (4-(cyclopentyloxy)-2,6-dimethylphenyl)ethanone (4.60 g, 1 .8 mmol) in acetonitrile (39.6 mL) was added tetrabutylammoniumtribromide (TBABr3, 10.5 g, 21.8 mmol). The reaction was stirred at room temperature overnight. The solution was concentrated under reduced pressure, added with water, and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous MgS04(s), and concentrated under reduced pressure to give
2- bromo-l-(4-(cyclopentyloxy)-2,6-dimethylphenyl)ethanone (6.2 g), which was used directly for the next step without further purification.
Figure imgf000028_0003
[0091] 4-(4-(Cyclopentyloxy)-2,6-dimethylphenyl)thiazol-2-amine. A mixture of
2-bromo-l-(4-(cyclopentyloxy)-2,6-dimethylphenyl)ethanone (6.16 g, 19.8 mmol) and thiourea (1.51 g, 19.8 mmol) in 95% EtOH (28.3 mL) was heated at reflux for 90 min. The solution was concentrated and added with water (50 mL) and saturated aqueous Na2CO3 (5.0 mL). The resultant precipitate was filtered and recrystallized in toluene (30 mL). The solids were filtered and dried under vacuum to give 4-(4-(cyclopentyloxy)-2,6-dimethylphenyl)thiazol-2-amine (4.2 g) as white solids in 73.7% yield: 1H NMR (500 MHz, CDCl3)□6.58 (s, 2 H), 6.24(s, 1 H), 4.75 (m, 1 H), 2.13 (s, 6 H), 1.88-1.78 (m, 6 H), 1.62-1.59 (m, 2 H).
Figure imgf000029_0001
[0092] l-(4-(4-Methoxyphenoxy)-2,6-dimethylphenyl)ethanone. To a solution of
1- (4-chloro-2,6-dimethylphenyl)ethanone (10.0 g, 54.8 mmol), K3P04 (23.2 g, 110 mmol) 4-methoxyphenol (8.16 g, 65.7 mmol) in toluene (78.2 mL), was added
2- di-tert-Bu1ylphosphino-2',4',6'-triisopropylbiphenyl (349 mg, 0.82 mmol), Pd(OAc)2 (259 mg, 1.15 mmol). The reaction was heated at 100L for 5.0 h under N2. The solution was cooled to room temperature and filtered through a small pad of Celite. The cake was washed with ethyl acetate ( 0 mL) and combined filtrate was concentrated under reduced pressure. The residue was recrystallized in MeOH to give l-(4-(4-methoxyphenoxy)-2,6-dimethylphenyl)ethanone (11.1 g) as white solids in 75.0%: 1H NMR (500 MHz, CDCI3)□6.96 (m, 2 H), 6.88 (m, 2 H), 6.57 (s, 2 H), 3.81 (s, 3 H), 2.46 (s, 3 H), 2.20 (s, 6 H).
Figure imgf000029_0002
[0093] 2-Bromo-l-(4-(4-methoxyphenoxy)-2,6-dimethylphenyl)ethanone. To a solution of
1- (4-(4-methoxyphenoxy)-2,6-dimethylphenyl)ethanone (3.80 g, 14.1 mmol) in acetonitrile (28.1 mL) was added tetrabutylammoniumtribromide (TBABr3, 7.46 g, 15.5 mmol). The reaction was stirred at room temperature overnight. The solution was concentrated under reduced pressure, added with water, and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous MgS04(s), and concentrated under reduced pressure to give
2- bromo-l-(4-(4-methoxyphenoxy)-2,6-dimethylphenyl)ethanone (5.25 g), which was used directly for the next step without further purification.
Figure imgf000029_0003
[0094] 4-(4-(4-Methoxyphenoxy)-2,6-dimethylphenyl)thiazol-2-amine. A mixture of
2-bromo-l-(4-(4-methoxyphenoxy)-2,6-dimethylphenyl)ethanone (4.90 g, 14.0 mmol) and thiourea (1.07 g, 14.1 mmol) in 95% EtOH (20.0 mL) was heated at reflux for 100 min. The solution was concentrated and added with water ( 100 mL) and saturated aqueous Na2CO3 (5.0 mL) . The resultant precipitate was filtered and recrystallized in toluene. The solids were filtered and dried under vacuum to give 4-(4-(4-methoxyphenoxy)-2,6-dimethylphenyl)thiazo 1-2 -amine (3.10 g) as yellow solids in 68% yield: 1H NMR (500 MHz, CDCl3)□6.98 (m, 2 H), 6.88 (m, 2 H), 6.64 (s, 2 H), 6.27 (s, 1 H), 5.40 (bs, 2 H), 3.81 (s, 3 H), 2.13 (s, 6 H).
Figure imgf000030_0001
[0095] l-(4-(4-Fluorophenoxy)-2,6-dimethylphenyl)ethanone. To a solution of
1- (4-chloro-2,6-dimethylphenyl)ethanone (4.50 g, 24.6 mmol), K3P04 (10.5 g, 49.3 mmol), 4-fluorophenol (3.31 g, 29.5 mmol) in toluene (49.3 mL), was added
2- di-tert-butylphosphino-2',4',6'-triisopropylbiphenyl (314 mg, 0.74 mmol), Pd(OAc)2 (233 mg, 1.04 mmol). The reaction was heated at 100 LC overnight under N2. The solution was cooled to room temperature and filtered through a small pad of Celite. The cake was washed with ethyl acetate (100 mL), and combined filtrate was concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel to give
1 -(4-(4-Fluorophenoxy)-2,6-dimethylphenyl)ethanone (4.40 g) as yellow oil in 68% yield: 1H NMR (500 MHz, CDCl3)□7.03 (m, 2 H), 6.98 (m, 2 H), 6.60 (s, 2 H), 2.47 (s, 3 H), 2.22 (s, 6 H).
Figure imgf000030_0002
[0096] 2-Bromo-l-(4-(4-fluorophenoxy)-2,6-dimethylphenyl)ethanone. To a solution of l-(4-(4-fluorophenoxy)-2,6-dimethylphenyl)ethanone (4.40 g, 17.0 mmol) in acetonitrile (34,1 mL) was added tetrabutylammoniumtribromide (TBABr3, 9.04 g, 18.8 mmol). The reaction was stirred at room temperature overnight. The solution was concentrated under reduced pressure, added with water, and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous MgS04(s), and concentrated under reduced pressure to give 2-bromo-l-(4-(4-fluorophenoxy)-2,6-dimethylphenyl)ethanone (5.8 g), which was used directly for the next step without further purification.
Figure imgf000031_0001
[0097] 4-(4-(4-Fluorophenoxy)-2,6-dimethylphenyl)thiazol-2-amine. A mixture of
2-bromo-l-(4-(4-fluorophenoxy)-2,6-dimethylphenyl)ethanone (5.74 g, 17.0 mmol) and thiourea (1.30 g, 17.1 mmol) in 95% EtOH (24.3 mL) was heated at reflux for 60 min. The solution was concentrated and added with water (100 mL) and saturated aqueous Na2CO3 (5.0 mL). The resultant precipitate was filtered and recrystallized in toluene. The solids were filtered and dried under vacuum to give 4-(4-(4-fluorophenoxy)-2,6-dimethylphenyl)thiazol-2-amine (4.50 g) as yellow solids in 84% yield: 1H NMR (500 MHz, CDCl3)□7.05-6.97 (m, 4 H), 6.66 (s, 2 H), 6.28 (s, 1 H), 5.95 (bs, 2 H), 2.14 (s, 6 H).
Figure imgf000031_0002
[0098] 2-Bromo-l-(4-isobutoxy-2,6-dimethylpheny])ethanone. To a solution of
l-(4-isobutoxy-2,6-dimethylphenyl)ethanone (4.3 g, 19.5 mmol) in acetonitrile (39 mL) was added tetrabutylammoniumtribromide (TBABr3, 9.41 g, 19.5 mmol). The reaction was stirred at room temperature overnight. The solution was concentrated under reduced pressure, added with water, and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous MgS04(s), and concentrated under reduced pressure to give
1 -(4-isobutoxy-2,6-dimethylphenyl)ethanone (6.1 g), which was used directly for the next step without further purification.
Figure imgf000031_0003
[0099] 4-(4-Isobutoxy-2,6-dimethylphenyl)thiazol-2-amine. A mixture of
2-bromo-l-(4-isobutoxy-2,6-dimethylphenyl)ethanone (5.84 g, 19.5 mmol) and thiourea (1.49 g, 19.6 mmol) in 95% EtOH (28 mL) was heated at reflux for 60 min. The solution was concentrated and added with water (50 mL) and saturated aqueous Na2CO3 (5.0 mL). The resultant precipitate was filtered and recrystallized in toluene (30 mL). The solids were filtered and dried under vacuum to give 4-(4-isobutoxy-2,6-dimethylphenyl)thiazol-2-amine (4.4 g) as white solids in 82% yield: 1H NMR (500 MHz, CDCl3)□6.61 (s, 2 H), 6.24 (s, 1 H), 3.70 (d, J= 6.5 Hz, 2 H), 2.15 (s, 6 H), 2.07 (m, 1 H), 1.01 (d, J= 6.7 Hz, 6 H).
Figure imgf000032_0001
[00100] l-(4-(Benzo[d][l,3]dioxol-5-yloxy)-2,6-dimethylphenyl)ethanone. To a solution of 1 -(4-chloro-2,6-dimethylphenyl)ethanone (5.0 g, 27.4 mmol), K3PO4 (11.6 g, 54.7 mmol), sesamol (4.54 g, 32.9 mmol) in toluene (54.8 mL), was added
2-di-tert-butylphosphino-2',4',6'-triisopropylbiphenyl (349 mg, 0.82 mmol), Pd(OAc)2 (259 mg, 1.15 mmol) . The reaction was heated at 100 LC overnight under N2. The solution was cooled to room temperature and filtered through a small pad of Celite. The cake was washed with ethyl acetate (50 mL) and combined filtrate was concentrated under reduced pressure. The residue was recrystallized in MeOH to give l-(4-(benzo[d][l,3]dioxol-5-yloxy)-2,6-dimethylphenyl)ethanone (4.80 g) as white solids in 62% yield: 1H NMR (500 MHz, CDCl3)□6.77 (d, J= 8.5 Hz, 1 H), 6.59 (s, 2 H), 6.56 (s, 1 H), 6.48 (m, 1 H), 5.98 (s, 2 H), 2.46 (s, 3 H), 2.21 (s, 6 H).
Figure imgf000032_0002
[00101] l-(4-(Benzo[d][l,3]dioxol-5-yloxy)-2,6-dimethylphenyl)-2-bromoethanone. To a solution of l-(4-(benzo[d][l,3]dioxol-5-yloxy)-2,6-dimethylphenyl)ethanone (4,80 g, 16.9 mmol) in acetonitrile (33.8 mL) was added tetrabutylammoniumtribromide (TBABr3, 8.14 g, 16.9 mmol). The reaction was stirred at room temperature overnight. The solution was concentrated under reduced pressure, added with water, and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous MgS04(s), and concentrated under reduced pressure to give l-(4-(benzo[d][l,3]dioxol-5-yloxy)-2,6-dimethylphenyl)-2-bromoethanone (6.70 g), which was used directly for the next step without further purification.
Figure imgf000032_0003
[00102] 4-(4-(Benzo [d] [1,3] dioxol-5-yloxy)-2,6-dimethylphenyl)thiazol-2-amine. A mixture of l-(4-(benzo[d][l,3]dioxol-5-yloxy)-2,6-dimethylphenyl)-2-bromoethanone (6.13 g, 16.9 mmol) and thiourea (1.29 g, 16.9 mmol) in 95% EtOH (24.1 mL) was heated at reflux for 90 min. The solution was concentrated and added with water ( 100 mL) and saturated aqueous Na2CO3 (5.0 mL) . The resultant precipitate was filtered and recrystallized in toluene. The solids were filtered and dried under vacuum to give
4-(4-(benzo[d][l,3]dioxol-5-yloxy)-2,6-dimethylphenyl)thiazol-2-amine (5.50 g) as yellow solids in 96% yield: 1H NMR (500 MHz, CDCl3)□6.75 (d, J= 8.5 Hz, 1 H), 6.66 (s, 2 H), 6.58 (m, 1 H), 6.49 (m, 1 H), 6.28 (s, 1 H), 5.98 (s, 2 H), 5.05 (bs, 2 H), 2.13 (s, 6 H).
Figure imgf000033_0001
[00103] l-(4-(3,5-Dimethylphenoxy)-2,6-dimethylphenyl)ethanone. To a solution of
1- (4-chloro-2,6-dimethylphenyl)ethanone (5.0 g, 27.4 mmol), K3P04 (11.6 g, 54.7 mmol), 3,5-dimethylphenol (4.01 g, 32.8 mmol) in toluene (54.8 mL), was added
2- di-tert-butylphosphino-2',4',6'-triisopropylbiphenyl (349 mg, 0.82 mmol), Pd(OAc)2 (259 mg, 1.15 mmol). The reaction was heated at 100 overnight under N2. The solution was cooled to room temperature and filtered through a small pad of Celite. The cake was washed with ethyl acetate (50 mL) and combined filtrate was concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel to give
l-(4-(3,5-dimethylphenoxy)-2,6-dimethylphenyl)ethanone (6.3 g) as yellow solids in 86% yield: 1H NMR (500 MHz, CDCl3)□6.76 (s, 1 H), 6.63 (s, 2 H), 6.62 (s, 2 H), 2.48 (s, 3 H), 2.29 (s, 6 H), 2.22 (s, 6 H).
Figure imgf000033_0002
[00104] 2-Bromo-l-(4-(3,5-dimethylphenoxy)-2,6-dimethylphenyl)ethanone. To a solution of l-(4-(3,5-dimethylphenoxy)-2,6-dimethylphenyl)ethanone (6.30 g, 23.5 mmol) in acetonitrile (47.0 mL) was added tefrabutylammoniumtribromide (TBABr3, 11.9 g, 24.7 mmol). The reaction was stirred at room temperature overnight. The solution was concentrated under reduced pressure, added with water, and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous MgSO^s), and concentrated under reduced pressure to give
2-bromo-l-(4-(3,5-dimethylphenoxy)-2,6-dimethylphenyl)ethanone (8.3 g), which was used directly for the next step without further purification.
Figure imgf000034_0001
[00105] 4-(4-(3,5-Dimethylphenoxy)-2,6-dimethylphenyl)thiazol-2-amine. A mixture of 2-bromo-l-(4-(3,5-dimethylphenoxy)-2,6-dimethylphenyl)ethanone (8.15 g, 23.5 mmol) and thiourea (1.79 g, 23.5 mmol) in 95% EtOH (33.5 mL) was heated at reflux for 120 min. The solution was concentrated and added with water ( 100 mL) and saturated aqueous Na2CO3 (5.0 mL) . The resultant precipitate was filtered and recrystallized in toluene. The solids were filtered and dried under vacuum to give 4-(4-(3,5-dimethylphenoxy)-2,6-dimethylphenyl)thiazol-2-amine (4.50 g) as yellow solids in 59% yield: 1H NMR (500 MHz, CDCl3)□6.76 (s, 1 H), 6.68 (s, 2 H), 6.64 (s, 2 H), 6.26 (s, 1 H), 2.29 (s, 6 H), 2.16 (s, 6 H).
Figure imgf000034_0002
[00106] l-(4-(3-Methoxyphenoxy)-2,6-dimethylphenyl)ethanone. To a solution of l-(4-chloro-2,6-dimethylphenyl)ethanone (5.00 g, 27.4 mmol), K3P04 (11.6 g, 54.7 mmol), 3-methoxyphenol (4.08 g, 32.9 mmol) in toluene (54.8 mL) was added
2-di-tert-butylphosphino-2',4',6'-triisopropylbiphenyl (349 mg, 0.82 mmol), Pd(OAc)2 (259 mg, 1.15 mmol). The reaction was heated at 100 LC overnight under N2. The solution was cooled to room temperature and filtered through a small pad of Celite. The cake was washed with ethyl acetate (50 mL) and combined filtrate was concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel to give
l-(4-(3-methoxyphenoxy)-2,6-dimethylphenyl)ethanone (5.4 g) as yellow oil in 73% yield: 1H NMR (500 MHz, CDClj)□7.24 (m, 1 H), 6.68-6.66 (m, 3 H), 6.57-6.56 (m, 2 H), 3.79 (s, 3 H), 2.48 (s, 3 H), 2.22 (s, 6 H).
Figure imgf000035_0001
[00107] 2-Bromo-l-(4-(3-methoxyphenoxy)-2,6-dimethylpheny])ethanone. To a solution of
1- (4-(3-methoxyphenoxy)-2,6-dimethylphenyl)ethanone (5.40 g, 20.0 mmol) in acetonitrile (40.0 mL) was added tetrabutylammoniumtribromide (TBABr3, 10.1 g, 21.0 mmol). The reaction was stirred at room temperature overnight. The solution was concentrated under reduced pressure, added with water, and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous MgS04(s), and concentrated under reduced pressure to give
2- bromo-l-(4-(3-methoxyphenoxy)-2,6-dimethylphenyl)ethanone (7.00 g), which was used directly for the next step without further purification.
Figure imgf000035_0002
[00108] 4-(4-(3-Methoxyphenoxy)-2,6-dimethy]phenyl)thiazol-2-amine. A mixture of 2-bromo-l-(4-(3-methoxyphenoxy)-2,6-dimethylphenyl)ethanone (6.98 g, 20.0 mmol) and thiourea (1.52 g, 20.0 mmol) in 95% EtOH (28.5 mL) was heated at reflux for 5.0 h. The solution was concentrated and added with water (50 mL) and saturated aqueous Na2CO3 (1.0 mL), and extracted with ethyl acetate (100 ml). The organic layer was washed with brine, dried over anhydrous MgS04(s), and concentrated under reduced pressure to give
4-(4-(3-methoxyphenoxy)-2,6-dimethylphenyl)thiazol-2 -amine (4.30 g) as deep-brown oil, which was used directly for the next step without further purification.
Figure imgf000035_0003
[00109] l-(2,6-Dimethyl-4-(4-(trifluoromethyl)phenoxy)phenyl)ethanone. To a solution of l-chloro-4-(trifluoromethyl)benzene (6.60 g, 36.6 mmol), K3P04 (12.9 g, 60.9 mmol), l-(4-hydroxy-2,6-dimethylphenyl)ethanone (5.00 g, 30.5 mmol) in toluene (60.9 mL) was added 2-di-tert-burylphosphino-2',4',6'-triisopropylbiphenyl (388 mg, 0.91 mmol) and Pd(OAc)2 (288 mg, 1.28 mmol). The reaction was heated at 100 C for 120 min under N2. The solution was cooled to room temperature and filtered through a small pad of Celite. The cake was washed with ethyl acetate (50 mL) and combined filtrate was concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel to give
l-(2,6-dimethyl-4-(4-(trifluoromethyl)phenoxy)phenyl)ethanone (1.8 g) as yellow oil in 19% yield: 1H NMR (500 MHz, CDCl3)□7.58 (d, J= 8.5 Hz, 2 H), 7.04 (d, J= 8.5 Hz, 2 H), 6.70 (s, 2 H), 2.50 (s, 3 H), 2.25 (s, 6 H)..
Figure imgf000036_0001
[00110] 2-Bromo-l-(2,6-dimethyl-4-(4-(trifluoromethyl)phenoxy)phenyl)ethanone. To a solution of 1 -(2,6-dimethyl-4-(4-(rrifluoromethyl)phenoxy)phenyl)ethanone ( 1.80 g, 5.84 mmol) in acetonitrile (11.7 mL) was added tetrabutylammoniumtribromide (TBABr3, 2.82 g, 5.84 mmol). The reaction was stirred at room temperature overnight. The solution was concentrated under reduced pressure, added with water, and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous MgSO4(s), and concentrated under reduced pressure to give 2-bromo-l-(2,6-dimethyl-4-(4-(trifluoromethyl)phenoxy)phenyl)ethanone (2.16 g), which was used directly for the next step without further purification.
Figure imgf000036_0002
[00111] 4-(2,6-Dimethyl-4-(4-(trifluoromethyl)phenoxy)phenyl)thiazol-2-amine. A mixture of 2-bromo-l-(2,6-dimethyl-4-(4-(trifluoromethyl)phenoxy)phenyl)ethanone (2,20 g, 5.68 mmol) and thiourea (0.43 g, 5.68 mmol) in 95% EtOH (8.1 mL) was heated at reflux for 60 min. The solution was concentrated and added with water (50 mL) and saturated aqueous Na2CO3 (1.0 mL). The resultant precipitate was filtered and recrystallized in toluene. The solids were filtered and dried under vacuum to give
4-(2,6-dimethyl-4-(4-(trifluoromethyl)phenoxy)phenyl)thiazol-2-amine (1.30 g) as yellow solids in 63% yield: 1H NMR (500 MHz, CDCl3)□7.56 (d, J= 8.5 Hz, 2 H), 7.05 (d, J= 8.5 Hz, 2 H), 6.76 (s, 2 H), 6.32 (s, 1 H), 5.03 (s, 2 H), 2.17 (s, 6 H).
Figure imgf000037_0001
[00112] l-(4-(4-Ethylphenoxy)-2,6-dimethylphenyl)ethanone. To a solution of
1- (4-chloro-2,6-dimethylphenyl)ethanone (5.0 g, 27.4 mmol), K3PO4 (11.6 g, 54.7 mmol), 4-ethylphenol (4.01 g, 32.8 mmol) in toluene (54.8 mL) was added
2- di-tert-butylphosphino-2',4',6'-triisopropylbiphenyl (349 mg, 0.82 mmol) and Pd(OAc)2 (259 mg, 1.15 mmol). The reaction was heated at 100 LC overnight under N2. The solution was cooled to room temperature and filtered through a small pad of Celite. The cake was washed with ethyl acetate (50 mL) and combined filtrate was concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel to give
l-(4-(4-ethylphenoxy)-2,6-dimethylphenyl)ethanone (6.0 g) as yellow oil in 82% yield: LH NMR (500 MHz, CDCI3)□7.17 (d, J= 8.5 Hz, 2 H), 6.93 (d, J= 8.5 Hz, 2 H), 6.63 (s, 2 H), 2.64 (q, J= 7.5 Hz, 2 H), 2.47 (s, 3 H), 2.21 (s, 6 H), 1.25 (t, J= 7.5 Hz, 3 H).
Figure imgf000037_0002
[00113] 2-Bromo-l-(4-(4-ethylphenoxy)-2,6-dimethylphenyl)ethanone. To a solution of
1- (4-(4-ethylphenoxy)-2,6-dimethylphenyl)ethanone (6.00 g, 22.4 mmol) in acetonitrile (44.7 mL) was added tetrabutylammoniumtribromide (ΤΒΑΒr3, 10.8 g, 22.4 mmol). The reaction was stirred at room temperature overnight. The solution was concentrated under reduced pressure, added with water, and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous MgS04(s), and concentrated under reduced pressure to give
2- bromo-l-(4-(4-ethylphenoxy)-2,6-dimethylphenyl)ethanone (8.2 g), which was used directly for the next step without further purification.
Figure imgf000037_0003
[00114] 4-(4-(4-Ethylphenoxy)-2,6-dimethylphenyl)thiazol-2-amine. A mixture of
2-bromo-l-(4-(4-ethylphenoxy)-2,6-dimethylphenyl)ethanone (7.70 g, 22.2 mmol) and thiourea (1.69 g, 22.2 mmol) in 95% EtOH (31.7 mL) was heated at reflux for 180 min. The solution was concentrated and added with water (100 mL) and saturated aqueous Na2CO3 (5.0 mL). The resultant precipitate was filtered and recrystallized in toluene. The solids were filtered and dried under vacuum to give 4-(4-(4-ethylphenoxy)-2,6-dimethylphenyl)thiazol-2-amine (6.30 g) as yellow solids in 88% yield: 1H NMR iSOO MHz, C3Clj) 07.18 (d, J= 7.5 Hz, 2 H), 6.95 (d, J= 8.5, 2 H), 6.71 (s, 2 H), 6.29 (s, 1 H), 5.45 (bs, 2 H), 2.64 (q, J= 7.5 Hz, 2 H), 2.14 (s, 6 H), 1.25 (t, J= 8.0 Hz, 3 H).
Figure imgf000038_0001
[00115] 2-Bromo-l-(3,5-difluoro-4-methoxyphenyl)ethanone. To a CH3CN solution (56 mL) containing l-(3,5-difluoro-4-methoxyphenyl)ethanone (5.0 g, 26.9 mmol, 1.0 equiv) was added TBABr3 (12.95 g, 26.9 mmol, 1.0 equiv). The reaction mixture was stirred at room temperature for 16 h. The solution was concentrated under reduced pressure, and the residue was re-dissolved in EtOAc (50 mL). The solution was washed with saturated aqueous NaHC03 (30 mL), dried over MgS04, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (2.0% EtOAc in hexanes as eluant) to provide
2-bromo-l-(3,5-difluoro-4-methoxyphenyl)ethanone (5.05 g, 19.0 mmol) as white solids in 71% yield: 1H NMR (DMSO-d6, 500 MHz)□7.76-7.81 (m, 2 H), 4.91 (s, 2 H), 4.07 (s, 3 H).
Figure imgf000038_0002
[00116] 4-(3,5-Difluoro-4-methoxyphenyl)thiazol-2-amine. A reaction mixture containing 2-bromo-l-(3,5-difluoro-4-methoxyphenyl)ethanone (2.0 g, 7.5 mmol, 1.0 equiv) and thiourea (0.57 g, 7.5 mmol, 1.0 equiv) in EtOH (20.0 mL) was heated at reflux for 3.0 h. The residue was basified with saturated aqueous NaHCO3 (20 mL) and extracted with EtOAc (3□ 30 mL). The organic layer was separated, dried over MgS04(s), and concentrated under reduced pressure. The resultant solids were washed with hexanes to give
4-(3,5-difluoro-4-methoxyphenyl)thiazol-2-amine (1.54 g, 6.4 mmol) as white solids in 84% yield: 1H NMR (DMSO-d6, 500 MHz)□7.49-7.54 (m, 2 H), 7.12-7.14 (m, 3 H), 3.92 (s, 3 H); ESI-MS: m/z 243.0 (M + H)+.
Figure imgf000039_0001
[00117] l-(2,6-Difluoro-4-methoxyphenyl)ethanone. A mixture of aluminium chloride (10.0 g, 69.4 mmol, 5.0 equiv) and acetyl chloride (2.0 niL, 28 mmol, 2.0 equiv) in CH2Cl2 (50.0 mL) was stirred at 0 LC for 30 min. The reaction mixture was slowly added with
1 ,3-difluoro-5-methoxy-benzene (2.0 g, 13.9 mmol, 1.0 equiv) in CH2Cl2 (10.0 mL), and the resultant solution was stirred at room temperature for additional 2.0 h. The solution was basified with saturated aqueous NaHC03 (20 mL) to pH 8-9. The organic layer was separated, dried over MgS04(s), and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (1 % EtOAc in hexanes as eluant) at give
l-(2,6-difluoro-4-methoxyphenyl)ethanone (1.5 g, 8.1 mmol) as yellow oil in 58% yield: NMR (CDCl3, 500 MHz)□6.46-6.48 (m, 2 H), 3.83 (s, 3 H), 2.56 (s, 3 H); ESI-MS: m/z 187.0 (M + H)+.
Figure imgf000039_0002
[00118] 2-Bromo-l-(2,5-difluoro-4-methoxyphenyl)ethanone. A CH3CN solution (20 mL) containing 1 -(2,6-difluoro-4-methoxyphenyl)ethanone (1.5 g, 8.1 mmol, 1.0 equiv) was added with TBABr3 (3.88 g, 8.1 mmol, 1.0 equiv). The reaction mixture was stirred at room temperature for 16 h. The solution was concentrated under reduced pressure, and the residue was re-dissolved in EtOAc (50 mL). The solution was washed with saturated aqueous NaHC03 (30 mL), dried over MgS04, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (2.0% EtOAc in hexanes as eluant) to provide
2-bromo-l-(2,5-difluoro-4-methoxyphenyl)ethanone (5.05 g, 19.1 mmol) as yellow oil in 84% yield: 1H NMR (CDCl3, 500 MHz)□6.50-6.52 (m, 2 H), 4.34 (s, 2 H), 3.85 (s, 3 H).
Figure imgf000039_0003
[00119] 4-(2,6-Difluoro-4-methoxyphenyl)thiazol-2-amine. A reaction mixture containing 2-bromo-l-(2,5-difluoro-4-methoxyphenyl)ethanone (1.5 g, 5.7 mmol, 1.0 equiv) and thiourea (430.8 mg, 5.7 mmol, 1.0 equiv) in EtOH (15.0 mL) was heated at reflux for 6.0 h. The residue was basified with saturated aqueous NaHC03 (20 mL) and extracted with EtOAc (3□ 30 mL). The organic layer was separated, dried over MgS04(s), and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (3.0% EtOAc in hexanes as eluant) to provide 4-(2,6-difluoro-4-methoxy-phenyl)-thiazol-2-amine (928.6 mg, 3.8 mmol) as white solids in 68% yield: 1HNMR (CDCl3, 500 MHz)□6.68 (s, 1 H), 6.50-6.52 (m, 2 H), 5.07 (brs, 2 H), 3.81 (s, 3 H); ESI-MS: m/z 243.7 (M + H)+.
Figure imgf000040_0001
[00120] l-(4-(2-Hydroxypropoxy)-2,6-dimethylphenyl)ethanone. A pressure glass vessel charged with l-(4-hydroxy-2,6-dimethylphenyl)ethanone (500 mg, 3.1 mmol, 1.0 equiv) and 2-methyloxirane (0,22 mL, 3.1 mmol, 1.0 equiv) in 50% aqueous NaOH solution (5,0 niL) was stirred at 140 C for 4.0 h. The mixture was diluted with H2O (20 mL) and extracted with EtOAc.
The organic layer was collected, dried over MgSO^s), and concentrated under reduced pressure.
The residue was purified by column chromatography on silica gel (30% EtOAc in hexanes as eluant) to provide l-(4-(2-hydroxypropoxy)-2,6-dimethylphenyl)ethanone (445.9 mg, 2.1 mmol) as yellow oil in 66% yield: 1H NMR (CDCl3, 500 MHz)□6.57 (s, 2 H), 4.10-4.20 (brs, 1 H),
3.90-3.93 (m, 2 H), 3.75-3.79 (m, 1 H), 2.45 (s, 3 H), 2.23 (s, 6 H), 1.25-1.28 (m, 3 H); ESI-MS: m/z 223.4 (M + H)+.
Figure imgf000040_0002
[00121] 2-Bromo-l-(4-(2-hydroxypropoxy)-2,6-dimethylphenyl)ethanone. To a CH3CN solution (6.0 mL) containing l-(4-(2-hydroxypropoxy)-2,6-dimethylphenyl)ethanone (445.9 mg, 2.0 mmol, 1.0 equiv) was added TBABr3 (967.3 mg, 2.0 mmol, 1.0 equiv). The reaction mixture was stirred at room temperature for 16 h. The solvent was concentrated under reduced pressure, and the residue was re-dissolved in EtOAc (50mL). The solution was washed with saturated aqueous NaHC03 (30mL), dried over MgS04, and concentrated under reduced pressure.
2-Bromo-l-(4-(2-hydroxypropoxy)-2,6-dimethylphenyl)ethanone (547.8 mg, 1.8 mmol) was obtained as brown oil in 91% yield: 1H NMR (CDCl3, 500 MHz)□6.60 (s, 2 H), 4.25 (s, 2 H), 4.10-4.20 (brs, 1 H), 3.91-3.94 (m, 2 H), 3.79-3.80 (s, 1 H), 2.24 (s, 6 H), 1.27-1.29 (m, 3 H).
Figure imgf000041_0001
[00122] l-(4-(2-Aminothiazol-4-yl)-3,5-dimethylphenoxy)propan-2-ol. A reaction mixture containing 2-bromo-l-(2,5-difluoro-4-methoxyphenyl)etlianone (547.8 mg, 1.8 mmol, 1.0 equiv) and thiourea (138.5 mg, 1.8 mmol, 1.0 equiv) in EtOH (3.0 mL) was heated at reflux for 16 h. The solution was concentrated under reduced pressure, and the residue was re-dissolved in EtOAc (30 mL). The solution was washed with saturated aqueous NaHC03 (30 mL), dried over MgS04, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (30% EtOAc in hexanes as eluant) to provide
l-(4-(2-aminothiazol-4-yl)-3,5-dimethylphenoxy)propan-2-ol (332.5 mg, 1.2 mmol) as yellow oil in 66% yield: 1H NMR (CDCl3, 500 MHz)□6.62 (s, 2 H), 6.26 (s, 1 H), 4.95 (brs, 2 H), 4.10-4.20 (brs, 1 H), 3.91-3.94(m, 2 H), 3.75-3.79 (m, 1 H), 2.15 (s, 6 H), 1.26-1.28 (m, 3 H); ESI-MS: m/z 279.7 (M + H)+.
Figure imgf000041_0002
[00123] l-(4-(2,3-Dihydroxypropoxy)-2,6-dimethylphenyl)ethanone. A pressure glass vessel charged with l-(4-hydroxy-2,6-dimethylphenyl)ethanone (2.00 g, 12.2 mmol, 1.0 equiv) and 3-chloropropane-l,2-diol (1.02 mL, 12.2 mmol, 1.0 equiv) in 50% aqueous NaOH solution (20.0 mL) was heated at 140 EC for 16 h. The mixture was diluted with H20 (20 mL) and extracted with EtOAc. The organic layer was collected, dried over MgS04(s), and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (30% EtOAc in hexanes as eluant) to provide l-(4-(2,3-dihydroxypropoxy)-2,6-dimethylphenyl)ethanone (1.66 g, 7.0 mmol) as yellow oil in 57% yield: 1H NMR (CDCl3, 500 MHz)□6.57 (s, 2 H), 4.10-4.11 (m, 1 H), 4.08^1.09 (m, 2 H), 4.01^1.02 (m, 1 H), 3.74-3.75 (m, 1 H), 2.58-2.59 (brs, 1 H), 2.45 (s, 3 H), 2.23 (s, 6 H), 2.05-2.10 (brs, 1 H); ESI-MS: m/z 239.9 (M + H)+.
Figure imgf000041_0003
[00124] 2-Bromo-l-(4-(2,3-dihydroxypropoxy)-2,6-dimethylphenyl)ethanone. To a
CH3CN solution (10.0 mL) containing l-(4-(2,3-dihydroxypropoxy)-2,6-dimethylphenyl)etlianone (1.0 g, 4.2 mmol, 1.0 equiv) was added TBABr3 (2.04 g, 4.2 mmol, 1.0 equiv). The reaction mixture was stirred at room temperature for 16 h. The solution was concentrated under reduced pressure, and the residue was re-dissolved in EtOAc (50 mL). The solution was washed with saturated aqueous NaHC03 (30 mL), dried over MgS04, and concentrated under reduced pressure. 2-Bromo-l-(4-(2,3-dihydroxypropoxy)-2,6-dimethylphenyl)ethanone (741.9 mg, 2.3 mmol) was obtained as yellow solids in 56% yield: 1H NMR (CDCl3, 500 MHz)□6.60 (s, 2 H), 4.25 (s, 2 H), 4.10-4.11 (m, 1 H), 4.03^1.04 (m, 2 H), 3.82-3.85 (m, 1 H), 3.75-3.76 (m, 1 H), 2.24 (s, 6 H).
Figure imgf000042_0001
[00125] 3-(4-(2-Aminothiazol-4-yl)-3,5-dimethylphenoxy)propane-l,2-diol. A reaction mixture containing 2-bromo-l-(4-(2,3-dihydroxypropoxy)-2,6-dimethylphenyl)ethanone (741.9 mg, 2.3 mmol, 1.0 equiv) and thiourea (178.1 mg, 2.3 mmol, 1.0 equiv) in EtOH (10.0 mL) was heated at reflux for 16 h. The solution was concentrated under reduced pressure, and the residue was re-dissolved in EtOAc (30 mL). The solution was washed with saturated aqueous NaHC03 (30 mL), dried over MgS04, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (30.0% EtOAc in hexanes as eluant) to provide
3-(4-(2-aminothiazol-4-yl)-3,5-dimethylphenoxy)propane-l,2-diol (694.1 mg, 2.4 mmol) as yellow solids in >99% yield: 1H NMR (CDCl3, 500 MHz)□6.76 (s, 2 H), 5.31-5.32 (m, 1 H), 3.99-4.00 (m, 1 H), 3.79-3.87 (m, 1H), 3.78-3.79 (m, 1 H), 3.43-3.44 (m, 2 H), 3.37 (brs, 2 H), 2.15 (s, 6 H); ESI-MS: m/z 295.6 (M + H)+.
Figure imgf000042_0002
[00126] l-(4-(2-Methoxyethoxy)-2,6-dimethylphenyl)ethanone. A pressure glass vessel charged with l-(4-hydroxy-2,6-dimethylphenyl)ethanone (500 mg, 3.1 mmol, 1.0 equiv) and 1 -chloro-2-methoxyethane (0.28 mL, 3.1 mmol, 1.0 equiv) in 50% aqueous NaOH solution (5.0 mL) was heated at 140 C for 16 h. The residue was diluted with H20 (20 mL) and extracted with EtOAc (3□ 30 mL). The organic layer was separated, dried with MgS04, and concentrated under reduced pressure to give l-(4-(2-methoxyethoxy)-2,6-dimethylphenyl)ethanone (430.9 mg, 1.9 mmol) as yellow oil in 64% yield: 1H NMR (CDCl3, 500 MHz)□6.58 (s, 2 H), 4.09^1.10 (m, 2 H), 3.72-3.74 (m, 2 H), 3.44 (s, 3 H), 2.45 (s, 3 H), 2.23 (s, 6 H); ESI-MS: m/z 223.6 (M + H)+.
Figure imgf000043_0001
[00127] 2-Bromo-l-(4-(2-methoxyethoxy)-2,6-dimethylphenyl)ethanone. To a CH3CN solution (6.0 mL) containing l-(4-(2-methoxyethoxy)-2,6-dimethylphenyl)ethanone (400 mg, 1.8 mmol, 1.0 equiv) was added TBABr¾ (867.7 mg, 1.8 mmol, 1.0 equiv). The reaction mixture was stirred at room temperature for 16 h. The solution was concentrated under reduced pressure, and the residue was re-dissolved in EtOAc (50 mL). The solution was washed with saturated aqueous NaHC03 (30 mL), dried over MgS04(s), and concentrated under reduced pressure.
2-Bromo-l-(4-(2-methoxyethoxy)-2,6-dimethylphenyl)ethanone (322.9 mg, 1.1 mmol) was obtained as yellow solids in 60% yield: 1H NMR (CDCl3, 500 MHz)□6.61 (s, 2 H), 4.25 (s, 2 H), 4.09-4.11 (m, 2 H), 3.73-3.75 (m, 2 H), 3.45 (s, 3 H), 2.24 (s, 6 H).
Figure imgf000043_0002
[00128] 4-(4-(2-Methoxyethoxy)-2,6-dimethylphenyl)thiazol-2-amine. A reaction mixture containing 2-bromo-l-(4-(2-methoxyethoxy)-2,6-dimethylphenyl)ethanone (322.9 mg, 1.1 mmol, 1.0 equiv) and thiourea (81.61 mg, 1.1 mmol, 1.0 equiv) in EtOH (3.0 mL) was heated at reflux for 16 h. The solution was concentrated under reduced pressure, and the residue was re-dissolved in EtOAc (20 mL). The solution was washed with saturated aqueous NaHC03 (30 mL), dried over MgS04, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (30% EtOAc in hexanes as eluant) to provide
4-(4-(2-methoxyethoxy)-2,6-dimethylphenyl)thiazol-2-amine (281.0 mg, 1.0 mmol) as yellow solids in 94% yield: 1HNMR (DMSO-d6, 500 MHz)□6.76 (s, 2 H), 5.31-5.33 (m, 1 H), 4.09-4.11 (m, 2 H), 3.64-3.65 (m, 2 H), 3.30 (s, 3 H), 2.12 (s, 6 H); ESI-MS: m/z 279.7 (M + H)+.
Figure imgf000043_0003
[00129] l-(4-(3-Methoxypropoxy)-2,6-dimethylphenyl)ethanone. A pressure glass vessel charged with l-(4-hydroxy-2,6-dimethylphenyl)ethanone (800 mg, 4.9 mmol, 1.0 equiv) and l-chloro-3-methoxypropane (528.97 mg, 4.9 mmol, 1.0 equiv) in 50% aqueous NaOH solution (10.0 mL) was stirred at 140 C for 16 h, The residue was diluted with H20 (20 rnL) and extracted with EtOAc (3□ 30 mL). The organic layer was separated, dried over MgS04(s), and concentrated under reduced pressure to give l-(4-(3-methoxypropoxy)-2,6-dimethylphenyl)ethanone (987.8 mg, 4.2 mmol) as yellow oil in 86% yield: 1H NMR (DIVISOR, 500 MHz)□6.56 (s, 2 H), 4.02-4.04 (m, 2 H), 3.53-3.55 (m, 2 H), 3.36 (s, 3 H), 2.45 (s, 3 H), 2.23 (s, 6 H), 2.02-2.04 (m, 3H); ESI-MS: m/z 237.7 (M + H)+.
Figure imgf000044_0001
[00130] 2-Bromo-l-(4-(3-methoxypropoxy)-2,6-dimethylphenyl)ethanone. To a CH3CN solution (15.0 mL) containing l-(4-(3-methoxypropoxy)-2,6-dimethylphenyl)ethanone (987.8 mg, 4.2 mmol, 1.0 equiv) was added TBABr3 (2.02 g, 4.2 mmol, 1.0 equiv). The reaction mixture was stirred at room temperature for 16 h. The solution was concentrated under reduced pressure, and the residue was re-dissolved in EtOAc (50 mL). The solution was washed with saturated aqueous NaHC03 (30 mL), dried over MgS04, and concentrated under reduced pressure.
2-Bromo-l-(4-(3-methoxypropoxy)-2,6-dimethylphenyl)ethanone (1.23 g, 3.9 mmol) was obtained as yellow oil in 93% yield: 1H NMR (CDCl3, 500 MHz)□6.58 (s, 2 H), 4.24-^.35 (m, 2 H), 4.03^1.05 (m, 2 H), 3.53-3.55 (m, 2 H), 3.35 (s, 3 H), 2.24 (s, 6 H), 2.01-2.06 (m, 2 H).
Figure imgf000044_0002
[00131] 4-(4-(3-Methoxypropoxy)-2,6-dimethylphenyl)thiazol-2-amine. A reaction mixture containing 2-bromo-l-(4-(3-methoxypropoxy)-2,6-dimethylphenyl)ethanone (500.0 mg, 1.6 mmol, 1.0 equiv) and thiourea (126.8 mg, 1.6 mmol, 1.0 equiv) in EtOH (10.0 mL) was heated at reflux for 16 h. The solution was concentrated under reduced pressure, and the residue was re-dissolved in EtOAc (50 mL). The solution was washed with saturated aqueous NaHC03 (30 mL), dried over MgS04, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (30% EtOAc in hexanes as eluant) to provide
4-(4-(3-methoxypropoxy)-2,6-dimethylphenyl)thiazol-2-amine (328.9 mg, 1.1 mmol) as yellow solids in 71% yield: 1H NMR (CDC¾, 500 MHz)□9.35 (brs, 1 H), 9.00 (brs, 1 H), 6.64 (s, 2 H), 6.22 (s, 1 H), 4.04-4.05 (m, 2 H), 3.54-3.56 (m, 2 H), 3.37 (s, 3 H), 2.19 (s, 6 H), 2.03-2.06 (m, 2 H); ESI-MS m/z 293.8 (M + H)+.
Figure imgf000045_0001
□MF-H20
[00132] l-(2,6-Dimethyl-4-(phenylthio)phenyl)ethanone. A mixture of
l-(4-iodo-2,6-dimethylphenyl)ethanone (1.5 g, 5.5 mmol, 1.0 equiv), benzenethiol (0.60 mL, 8.2 mmol, 1.5 equiv), copper(I) oxide (39.2 mg, 0.3 mmol, 0.05 equiv), and potassium hydroxide (614.1 mg, 11.0 mmol, 2.0 equiv) in DMF (4.4 mL) and H20 (1.1 mL) was heated at reflux for 20 h. The mixture was quenched with H.0 (10 mL) and extracted with ether (2□ 20 mL). The organic layer was collected, dried over MgSO^s), and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (3.0% EtOAc in hexanes as eluant) to provide l-(2,6-dimethyl-4-(phenylthio)phenyl)ethanone (931 mg, 3.6 mmol) as yellow oil in 66% yield: 1H NMR (CD3OD, 500 MHz)□7.34-7.35 (m, 5 H), 6.97 (s, 2 H), 2.46 (s, 3 H), 2.17 (s, 6 H); ESI-MS: m/z 257.0 (M + H)+.
Figure imgf000045_0002
[00133] 2-Bromo-l-(2,6-dimethyl-4-(phenylthio)phenyl)ethanone. To a CH3CN solution (15.0 mL) containing l-(2,6-dimethyl-4-(phenylthio)phenyl)ethanone (816.3 mg, 3.2 mmol, 1.0 equiv) was added TBABr3 (1.54 g, 3.2 mmol, 1.0 equiv). The reaction mixture was stirred at room temperature for 16 h. The solution was concentrated under reduced pressure, and the residue was re-dissolved in EtOAc (50 mL). The solution was washed with saturated aqueous NaHCC (30 mL), dried over MgS04, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (3.0% EtOAc in hexanes as the eluant) to provide
2-bromo-l-(2,6-dimethyl-4-(phenylthio)phenyl)ethanone (591.7 mg, 1.6 mmol) as yellow oil in 55% yield: 1H NMR (DMSO-d6, 500 MHz) D7.36-7.42 (m, 5 H), 7.01 (s, 2 H), 4.75 (s, 2 H), 2.13
(s, 6 H).
Figure imgf000045_0003
[00134] 4-(2,6-Dimethyl-4-(phenylthio)phenyl)thiazol-2-amine. A reaction mixture containing 2-bromo-l-(2,6-dimethyl-4-(phenylthio)phenyl)ethanone (591.7 mg, 1.8 mmol, 1.0 equiv) and thiourea (134.3 mg, 1.8 mmol, 1.0 equiv) in EtOH (l 5. O mL) was heated at reflux for 16 h. The solution was concentrated under reduced pressure, and the residue was re-dissolved in EtOAc (50 mL). The solution was washed with saturated aqueous NaHC03 (30 mL), dried over MgS04, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel ( .0% EtOAc in hexanes as eluant) to provide
4-(2,6-dimethyl-4-(phenylthio)phenyl)thiazol-2-amine (483.7 mg, 1.6 mmol) as yellow solids in 88% yield: 1H NMR (DMSO-d6, 500 MHz)□7.33-7.38 (m, 2 H), 7.29-7.33 (m, 3 H), 7.06 (brs, 2 H), 6.89 (s, 2 H), 6.38 (s, 1 H), 2.07 (s, 6 H); ESI-MS: m/z 313.8 (M + H)+.
Figure imgf000046_0001
[00135] l-(2,6-Dimethyl-4-(p-tolylthio)phenyl)ethanone. A mixture of
l-(4-iodo-2,6-dimethylphenyl)ethanone (1.5 g, 5.5 mmol, 1.0 equiv), 4-methylbenzenethiol (1.02 g, 8.2 mmol, 1.5 equiv), copper(I) oxide (39.2 mg, 0.3 mmol, 0.05 equiv), and potassium hydroxide (614.1 mg, 11.0 mmol, 2.0 equiv) in DMF (4.4 mL) and H2O (1.1 mL) was heated at reflux for 20 h. The mixture was quenched with H2O (10 mL) and extracted with ether (2□ 20 mL). The organic layer was collected, dried over MgS04(s), and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (3.0% EtOAc in hexanes as eluant) to provide 1 -(2,6-dimethyl-4-(p-tolylthio)phenyl)ethanone ( 1.16 g, 4.3 mmol) as yellow oil in 79% yield: 1H NMR (CD30D, 500 MHz)□7.29 (d, J= 8.0 Hz, 2 H), 7.20 (d, J= 8.0 Hz, 2 H), 6.88 (s, 2 H), 2.45 (s, 3 H), 2.35 (s, 3 H), 2.15 (s, 6 H); ESI-MS: m/z 271.8 (M + H)+.
Figure imgf000046_0002
[00136] 2-Bromo-l-(2,6-dimethyl-4-(p-tolylthio)phenyl)ethanone. To a CH3CN solution (20.0 mL) containing l-(2,6-dimethyl-4-(p-tolylthio)phenyl)ethanone (1.0 g, 3.7 mmol, 1.0 equiv) was added TBABr3 (1.79 g, 3.7 mmol, 1.0 equiv). The reaction mixture was stirred at room temperature for 16 h. The solution was concentrated under reduced pressure, and the residue was re-dissolved in EtOAc (50 mL). The solution was washed with saturated aqueous NaHCO3 (30 mL), dried over MgS04, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (3.0% EtOAc in hexanes as the eluant) to provide 2-bromo-l-(2,6-dimethyl-4-(p-tolylthio)phenyl)ethanone (394.8 mg, 1.1 mmol) as yellow oil in 31% yield: 1H NMR (DMSO-d6, 500 MHz)□7.33 (d, J= 8.0 Hz, 2 H), 7.25 (d, J= 8.0 Hz, 2 H), 6.92 (s, 2 H), 4.76 (s, 2 H), 2.32 (s, 3 H), 2.11 (s, 6 H).
Figure imgf000047_0001
[00137] 4-(2,6-Dimethyl-4-(p-tolylthio)phenyl)thiazol-2-amine. A reaction mixture containing 2-bromo-l-(2,6-dimethyl-4-(p-tolylthio)plienyl)ethanone (394.8 mg, 1.1 mmol, 1.0 equiv) and thiourea (86.04 mg, 1.1 mmol, 1. O equiv) in EtOH (10. O mL) was heated at reflux for 16 h. The solution was concentrated under reduced pressure, and the residue was re-dissolved in EtOAc (50 mL). The solution was washed with saturated aqueous NaHC03 (30 mL), dried over MgS04, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel ( .0% EtOAc in hexanes as eluant) to provide
4-(2,6-dimethyl-4-(p-tolylthio)phenyl)thiazol-2 -amine (371.9 mg, 1.1 mmol) as yellow solids in >99% yield: 1H NMR (DMSO-d6, 500 MHz)□7.27 (d, J= 8.0 Hz, 2 H), 7.21 (d, J= 8.0 Hz, 2 H), 6.97 (s, 2 H), 6.87 (s, 2 H), 6.36 (s, 1 H), 2.30 (s, 3 H), 2.05 (s, 6 H); ESI-MS: m/z 327.0 (M + H)+.
Figure imgf000047_0002
DMF-H20
[00138] l-(4-(4-Methoxyphenylthio)-2,6-dimethylphenyl)ethanone. A mixture of l-(4-iodo-2,6-dimethylphenyl)ethanone (1.5 g, 5.5 mmol, 1.0 equiv), 4-methoxybenzenethiol (1.01 mL, 8.2 mmol, 1.5 equiv), copper(I) oxide (39.2 mg, 0.3 mmol, 0.05 equiv), and potassium hydroxide (614.1 mg, 11.0 mmol, 2.0 equiv) in DMF (4.4 mL) and H20 (1.1 mL) was heated at reflux for 20 h. The mixture was quenched with H2O (10 mL) and extracted with ether (2□ 20 mL). The organic layer was collected, dried over MgSO4(s), and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (3.0% EtOAc in hexanes as eluant) to provide 1 -(4-(4-methoxyphenylthio)-2,6-dimethylphenyl)ethanone (1.41 g, 4.9 mmol) as yellow oil in 90% yield: :H NMR (DMSO-d6, 500 MHz)□7.39 (d, J= 8.5 Hz, 2 H), 6.96 (d, J= 8.5 Hz, 2 H), 6.79 (s, 2 H), 3.82 (s, 3 H), 2.43 (s, 3 H), 2.13 (s, 6 H); ESI-MS: m/z 287.6 (M 4- H)+.
Figure imgf000048_0001
[00139] 2-Bromo-l-(4-(4-methoxyphenylthio)-2,6-dimethylphenyl)ethanone. To a CH3CN solution (20.0 mL) containing l-(4-(4-methoxyphenylthio)-2,6-dimethylphenyl)ethanone (1.0 g, 3.5 mmol, 1.0 equiv) was added ΤΒΑΒr3 (1.684 g, 3.5 mmol, 1.0 equiv). The reaction mixture was stirred at room temperature for 16 h. The solution was concentrated under reduced pressure, and the residue was re-dissolved in EtOAc (50 mL). The solution was washed with saturated aqueous NaHC03 (30 mL), dried over MgS04, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (3.0% EtOAc in hexanes as eluant) to provide 2-bromo-l-(4-(4-methoxyphenylthio)-2,6-dimethylphenyl)ethanone (1.06 g, 2.9 mmol) as yellow oil in 83% yield: 1H NMR (DMSO- fi, 500 MHz)□7.44 (d, J= 8.7 Hz, 2 H), 7.03 (d, J= 8.7 Hz, 2 H), 6.83 (s, 2 H), 4.71 (s, 2 H), 3.80 (s, 3 H), 2.10 (s, 6 H).
Figure imgf000048_0002
[00140] 4-(4-(4-Methoxyphenylthio)-2,6-dimethylphenyl)thiazol-2-amine. A reaction mixture containing 2-bromo- 1 -(4-(4-methoxyphenylthio)-2,6-dimethylphenyl)ethanone ( 1.06 g, 2.9 mmol, 1.0 equiv) and thiourea (221.5 mg, 2.9 mmol, 1.0 equiv) in EtOH (20.0 mL) was heated at reflux for 16 h. The solution was concentrated under reduced pressure, and the residue was re-dissolved in EtOAc (50 mL). The solution was washed with saturated aqueous N HC03 (30 mL), dried over MgS04, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (5.0% EtOAc in hexanes as eluant) to provide
4-(4-(4-methoxyphenylthio)-2,6-dimethylphenyl)thiazol-2 -amine (890.9 mg, 2.6 mmol) as yellow solids in 90% yield: 1H NMR (DMSO-d6, 500 MHz)□77.40 (d, J= 8.7 Hz, 2 H), 7.00 (d, J= 8.7 Hz, 2 H), 6.86-6.87 (m, 4 H), 6.33 (s, 1 H), 3.78 (s, 3 H), 2.03 (s, 6 H); ESI-MS m/z 343.9 (M + H)+.
Figure imgf000048_0003
[00141] 2-Bromo-l-(4-(4-methoxyphenylsulfonyl)-2,6-dimethylphenyl)ethanone. A mixture of 2-bromo- l-(4-(4-methoxyphenylthio)-2,6-dimethylphenyl)ethanone (1.0 g, 2.7 mmol, 1.0 equiv) and m-chloroperoxybenzoic acid (1.69 g, 6.8 mmol, 2.5 equiv) in dichloromethane (10.0 mL) was stirred at room temperature for 16 h. The solution was concentrated under reduced pressure, and the residue was re-dissolved in EtOAc (50 mL). The solution was washed with saturated aqueous NaHC03 (30 mL), dried over MgS04, and concentrated under reduced pressure to give 2-bromo-l-(4-(4-methoxyphenylsulfonyl)-2,6-dimethylphenyl)ethanone (1.09 g, 2.7 mmol) as white solids in >99% yield: 1H NMR (CDCl3, 500 MHz)□7.85-7.90 (m, 2 H), 7.57-7.60 (m, 2 H), 6.97-6.90 (m, 2 H), 4.21 (s, 2 H), 3.85 (s, 3 H), 2.30 (s, 6 H).
Figure imgf000049_0001
[00142] 4-(4-(4-Methoxyphenylsulfonyl)-2,6-dimethylphenyl)thiazol-2-amine. A reaction mixture containing 2-bromo-l-(4-(4-methoxyphenylsulfonyl)-2,6-dimethylphenyl)ethanone (1.33 g, 3.4 mmol, 1.0 equiv) and thiourea (254.8 mg, 3.4 mmol, 1.0 equiv) in EtOH (5.0 mL) was heated at reflux for 1.0 h. The solution was concentrated under reduced pressure, and the residue was re-dissolved in EtOAc (50 mL). The solution was washed with saturated aqueous NaHC03 (30 mL), dried over MgS04, and concentrated under reduced pressure. The resultant solids were washed with hexanes to give
4-(4-(4-methoxyphenylsulfonyl)-2,6-dimethylphenyl)thiazol-2-amine (839.2 mg, 2.2 mmol) as yellow solids in 65% yield: 1H NMR (DMSO-d6, 500 MHz)□7.89 (d, J= 8.9 Hz, 2 H), 7.61 (s, 2 H), 7.13 (d,J= 8.9 Hz, 2 H), 6.95 (brs, 2 H), 6.43 (s, 1 H), 3.83 (s, 3 H), 2.16 (s, 6 H); ESI-MS: m/z 375.6 (M + H)+.
Figure imgf000049_0002
[00143] 2-Bromo-l-(4-(4-methoxyphenylsulfinyl)-2,6-dimethylphenyl)ethanone. A mixture of 2-bromo-l-(4-(4-methoxyphenylthio)-2,6-dimethylphenyl)ethanone (500.0 mg, 1.3 mmol, 1.0 equiv), acetic anhydride (0.14 mL, 1.5 mmol, 1.1 equiv), 30% hydrogen peroxide (55.86 mg, 1.6 mmol, 1.2 equiv) and silica gel (273.75 mg, 230-^-00 mesh) in dichloromethane (10.0 mL) was stirred at room temperature for 16 h. The solution was concentrated under reduced pressure, and the residue was re-dissolved in EtOAc (50 mL). The solution was washed with saturated aqueous NaHC03 (30 mL), dried over MgS04, and concentrated under reduced pressure to give 2-bromo-l-(4-(4-methoxyphenylsulfinyl)-2,6-dimethylphenyl)ethanone (235.4 mg, 0.6 mmol) as pale- yellow oil in 48% yield: 1H NMR (DMSO-d6, 500 MHz)□7.65 (d, J= 8.8 Hz, 2 H), 7.41 (s, 2 H), 7.09 (d, J= 8.8 Hz, 2 H), 4.78 (s, 2 H), 3.79 (s, 3 H), 2.21 (s, 6 H).
Figure imgf000050_0001
[00144] N-(4-(4-(4-Methoxyphenylsulfinyl)-2,6-dimethylphenyl)thiazol-2-yl)isonicotinami de. A reaction mixture containing
2-bromo-l-(4-(4-methoxyphenylsulfinyl)-2,6-dimethylphenyl)ethanone (235.4 mg, 0.6 mmol, 1.0 equiv) and thiourea (47.0 mg, 0.60 mmol, 1.0 equiv) in EtOH (5.0 mL) was heated at reflux for 1.0 h. The solution was concentrated under reduced pressure, and the residue was re-dissolved in EtOAc (50 mL). The solution was washed with saturated aqueous NaHC03 (30 mL), dried over MgS04, and concentrated under reduced pressure. The resultant solids were washed with hexanes to give N-(4-(4-(4-methoxyphenylsulfinyl)-2,6-dimethylphenyl)thiazol-2-yl)isonicotinamide (236.7 mg, 0.70 mmol) as yellow solids in >99% yield: 1H NMR (DMSO-d6, 500 MHz)□7.64 (d, J= 8.9 Hz, 2 H), 7.34 (s, 2 H), 7.09 (d, J= 8.9 Hz, 2 H), 6.90 (bra, 2 H), 6.39 (s, 1 H), 3.79 (s, 3 H), 2.13 (s, 6 H); ESI-MS m/z 359.0 (M + H)+.
Figure imgf000050_0002
[00145] 5-Methyl-4-phenylthiazol-2-amine. A mixture of 2-bromo- 1 -phenylpropan- 1 -one (3.00 g, 19.5 mmol) and thiourea (1.56 g, 20.5 mmol) in 95% EtOH (30 mL) was heated at reflux for 60 min. The solution was concentrated and mixed with water (100 mL) and saturated aqueous Na2C03 (5.0 mL). The resultant precipitate was filtered and recrystallized in toluene. The solids were filtered and dried under vacuum to give 5-methyl-4-phenylthiazol-2 -amine (4.07 g) as yellow solids in 77% yield: 1H NMR (500 MHz, DMSO-d6)□8.85 (s, 2 H), 7.54-7.49 (m, 5 H), 2.28 (s, 3 H).
Figure imgf000050_0003
[00146] 2-Bromo-l-(4-methoxyphenyl)propan-l-one. To a solution of
l-(4-methoxyphenyl)propan-l-one (5.01 g, 30.2 mol) in EtOAc (120 mL) was added copper(II) bromide (CuBr2, 13.6 g, 6.8 mmol). The reaction mixture was heated at reflux for 90 min. The solution was allowed to cool down, and the resultant solids were filtered off and washed with EtOAc. The filtrate was concentrated under reduced pressure to give crude
2-bromo-l-(4-methoxyphenyl)propan-l-one (10.4 g) as yellow oil: 1H NMR (500 MHz, CDCl3)□ 8.02 (2 H, m), 6.96 (2 H, m), 5.28-5.25 (m, 1 H), 3.89 (s, 3 H), 1.89 (d, 3 H).
Figure imgf000051_0001
[00147] 4-(4-Methoxyphenyl)-5-methylthiazol-2-amine. A mixture of
2-bromo-l-(4-methoxyphenyl)propan-l-one (10.4 g, 36.1 mmol) and thiourea (2.76 g, 36.2 mmol) in 95% EtOH (70 mL) was heated at reflux for 60 min. The solution was concentrated and mixed with water (100 mL) and saturated aqueous Na2CO3 (5.0 mL). The resultant precipitate was filtered and recrystallized in toluene. The solids were filtered and dried under vacuum to give
4-(4-methoxyphenyl)-5-methylthiazol-2 -amine (6.16 g) as yellow solids in 78% yield: 1H NMR (500 MHz, DMSO-d6)□8.90 (s, 2 H), 7.46-7.44 (m, 2 H), 7.09-7.07 (m, 2 H), 3.81 (s, 3 H), 2.47 (s, 3 H).
Figure imgf000051_0002
[00148] 2-Bromo-l-(2,4,6-trimethoxyphenyl)ethanone. To a solution of
1- (2,4,6-trimethoxyphenyl)ethanone (5.0 g, 23.3 mmol) in EtOAc (100 mL) was added copper(II) bromide (CuBr2, 10.4 g, 46.7 mmol). The reaction mixture was heated at reflux for 90 min. The solution was allowed to cool down, and the resultant solids were filtered off and washed with EtOAc. The filtrate was concentrated under reduced pressure to give crude
2- bromo-l-(2,4,6-trimethoxyphenyl)ethanone (2.70 g)
2-bromo-l-(2,4,6-trimethoxyphenyl)ethanone as yellow oil: 1H-NMR (500 MHz, CDCl3)□6.11 (m, 2 H), 4.36 (m, 2 H), 3.86 (s, 3 H), 3.82 (s, 6 H).
Figure imgf000051_0003
[00149] 4-(2,4,6-Trimethoxyphenyl)thiazol-2-amine. A mixture of
2-bromo-l-(2,4,6-trimethoxyphenyl)ethanone (2.49 g, 8.6 mmol) and thiourea (0.67 g, 8.7 mmol) in 95% EtOH (16 mL) was heated at reflux for 60 min. The solution was concentrated and mixed with water (100 mL) and saturated aqueous Na2C(¾ (5.0 niL). The resultant precipitate was filtered and recrystallized in toluene. The solids were filtered and dried under vacuum to give
4-(2,4,6-trimethoxyphenyl)thiazol-2 -amine (1.75 g) as yellow solids in >99% yield: 1H NMR (500 MHz, DMSO-d6) □9.00 (s, 2 H), 6.78 (s,l H), 6.36 (s, 2 H), 3.84 (s, 3 H), 3.79 (s, 6 H).
Figure imgf000052_0002
[00150] 2-Bromo-l-(4-methoxyphenyl)ethanone. To a solution of
1- (4-methoxyphenyl)ethanone (15.2 g, 0.10 mol) in EtOAc (250 mL) was added copper(II) bromide (CuBr2, 45.1 g, 0.20 mol). The reaction mixture was heated at reflux for 90 min. The solution was allowed to cool down, and the resultant solids were filtered off and washed with EtOAc. The filtrate was concentrated under reduced pressure to give crude
2- bromo-l-(4-methoxyphenyl)ethanone (15.8 g) as yellow oil: 1H NMR (500 MHz, CDCl3)□7.98 (m, 2 H), 6.97 (m, 2 H), 4.41 (s, 3 H), 3.89 (s, 6 H).
Figure imgf000052_0001
[00151] 4-(4-Methoxyphenyl)thiazol-2-amine. A mixture of
2-bromo-l-(4-methoxyphenyl)ethanone (5.00 g, 21.8 mmol) and thiourea (1.72 g, 22.6 mmol) in 95% EtOH (40 mL) was heated at reflux for 60 min. The solution was concentrated and mixed with water (100 mL) and saturated aqueous Na2C<¾ (5.0 mL). The resultant precipitate was filtered and recrystallized in toluene. The solids were filtered and dried under vacuum to give
4-(4-methoxyphenyl)thiazol-2 -amine (5.24 g) as yellow solids in >99% yield: 1H NMR (500 MHz, DMSO-d6)□7.72 (d, 2 H), 6.99 (s, 2 H), 6.92-6.91 (m, 2 H), 6.82 (s, 1 H), 3.76 (s, 3 H).
Figure imgf000052_0003
[00152] 2-Bromo-l-(2,4-dimethoxyphenyl)ethanone. To a solution of
l-(2,4-dimethoxyphenyl)ethanone (10.0 g, 54.4 mmol) in EtOAc (220 mL) was added copper(II) bromide (CuBr2, 24.3 g, 0.11 mol). The reaction mixture was heated at reflux for 90 min. The solution was allowed to cool down, and the resultant solids were filtered off and washed with EtOAc. The filtrate was concentrated under reduced pressure to give crude 2-bromo-l-(2,4-dimethoxyphenyl)ethanone (14.5 g) as yellow oil: 1H NMR (500 MHz, CDCl3)□ 7.91 (m, 2 H), 6.52 (m, 2 H), 4.57 (s, 3 H), 3.98 (s, 3 H), 3.85 (s, 3 H).
Figure imgf000053_0002
[00153] 4-(2,4-Dimethoxyphenyl)thiazol-2-amine. A mixture of
2-bromo-l-(2,4-dimethoxyphenyl)ethanone (14.5 g, 55.8 mmol) and thiourea (4.32 g, 56.7 mmol) in 95% EtOH (110 mL) was heated at reflux for 60 min. The solution was concentrated and mixed with water (100 mL) and saturated aqueous Na2CO3 (5.0 mL). The resultant precipitate was filtered and recrystallized in toluene. The solids were filtered and dried under vacuum to give
4-(2,4-dimethoxyphenyl)thiazol-2-amine (10.9 g) as yellow solids in 62% yield: *H NMR (500
MHz, DMSO-d6 □8.60 (s, 2 H), 7.53 (s, 1 H), 6.97 (s, 1 H), 6.69 (s, 1 H), 6.67-6.63 (m,l H), 3.86 (s, 3 H), 3.80 (s, 3 H).
Figure imgf000053_0003
[00154] 2-Chloro-l-(2,4,6-trifluorophenyl)ethanone. To a mechanically stirred solution of 1,3,5-trifluorobenzene (6.0 mL, 58 mmol) in dichloroethane (14.0 mL) was added gradually A1C¾ (15.5 g, 116 mmol) in a period of 15 min with caution. Violent bumping and HCl gas evolution was observed. The mixture was carefully heated to reflux, and chloroacetyl chloride (5.5 mL, 69 mmol) was added drop wisely in a period of 45 min. The reaction mixture was heated at reflux for additional 6.0 h. The solution was cooled, carefully poured onto an ice/water slush (200 mL) and the aqueous solution was extracted with ether (3□ 50 mL). The combined ethereal layers were washed with 10% aqueous HCl (2□ 30 mL), 1.0 N aqueous NaOH (3□ 30 mL), and brine (25 mL). The solution was dried over MgS04 and concentrated under reduced pressure to give
2-chloro-l-(2,4,6-trifluorophenyl)ethanone (5.28 g) as yellow solids in 51% yield: 1H NMR (500 MHz, CDCl3)□6.79-6.76 (m, 2 H), 4.50 (s, 2 H).
Figure imgf000053_0001
[00155] 4-(2,4,6-Trifluorophenyl)thiazol-2-amine. A mixture of
2-chloro-l-(2,4,6-trifluorophenyl)ethanone (9.04 g, 43.5 mmol) and thiourea (3.51 g, 46.1 mmol) in 95% EtOH (50 mL) was heated at reflux overnight. The solution was concentrated and mixed with water (100 mL) and saturated aqueous Na2CO3 (5.0 mL). The solids were filtered and dried under vacuum to give 4-(2,4,6-trifluorophenyl)thiazol-2 -amine (9.71 g) as pink-white solids in 97% yield: 1H NMR (500 MHz, DMSO-d6)□7.26-7.22 (m, 2 H), 7.09 (s, 2 H), 6.77 (s, 1 H).
Figure imgf000054_0001
[00156] l-(2,6-Dimethyl-4-(phenylamino)phenyl)ethanone. To a solution of
l-(4-amino-2,6-dimethylphenyl)ethanone (3.26 g, 20.0 mmol), K3P04 (9.2 g, 40 mmol), and 1-iodobenzene (4.08 g, 20.0 mmol) in DMF (35.0 mL) was added Cul (761.8 mg, 40 mmol). The reaction was heated at 110 C overnight under N2. The solution was cooled to room temperature and filtered through a small pad of Celite. The cake was washed with ethyl acetate (50 mL) and the combined filtrate was concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel to give 1 -(2,6-dimethyl-4-(phenylamino)phenyl)ethanone as red-brown syrup: 1H NMR (500 MHz, CDCl3)□7.30 (d, J= 8.2 Hz, 2 H), 7.10 (d, J= 7.7 Hz, 2 H), 6.99 (d, J= 4.2 Hz, 1 H), 6.71 (s, 1 H), 2.47 (s, 3 H) , 2.18 (s, 6 H); ESI-MS: m/z 239.5 (M + H)+.
Figure imgf000054_0002
[00157] l-(4-(4-Bromophenylamino)-2,6-dimethylphenyl)-2-bromoethanone. To a solution of 1 -(2,6-dimethyl-4-(phenylamino)phenyl)ethanone (2.10 g, 8.78 mmol) in acetonitrile (50 mL) was added tetrabutylammoniumtribromide (TBABr3, 4.24 g, 8.78 mmol). The reaction was stirred at room temperature for 60 min. The solution was concentrated under reduced pressure, added with water, and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous MgS04(s), and concentrated under reduced pressure to give
l-(4-(4-bromophenylamino)-2,6-dimethylphenyl)-2-bromoethanone (2.01 g), which was used directly for the next step without further purification.
Figure imgf000054_0003
[00158] 4-(4-(4-Bromophenylamino)-2,6-dimethylphenyl)thiazo]-2-amine. A solution of l-(4-(4-bromophenylamino)-2,6-dimethylphenyl)-2-bromoethanone (1.6 g, 4.0 mmol) and thiourea (0.79 g, 7.2 mmol) in acetonitrile (30 mL) was heated at reflux for 90 min. The solution was concentrated and added with water (50 mL) and saturated aqueous Na2CO3 (1.0 mL), and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous MgS04(s), and concentrated under reduced pressure to give product (1. lg), which was used directly for the next step without further purification.
Figure imgf000055_0001
[00159] 3-Chloro-5-methyl-phenylamine. An ethanol solution (75 mL) containing l-chloro-3-methyl-5-nitro-benzene (5.0 g, 29 mmol) are added with SnCl2-2H20 (32.8 g, 146 mmol). The reaction mixture was reflux for 3.0 h. The solution was concentrated under vacuum, and the residue was re-dissolved in aqueous NaOH, filtered, and extracted with EtOAc. The organic layer was collected, washed with brine, dried over MgS04, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel to give
3-chloro-5-methyl-phenylamine (4.0 g) as light yellow solids in 97% yield: 1H NMR (500 MHz, CDCl3) 06.56 (s, 1 H), 6.48 (s, 1 H), 6.36 (s, 1 H), 3.66 (bs, 2 H), 2.23 (s, 3 H); ESI-MS: m/z 141.7 (M + H)+.
Figure imgf000055_0002
[00160] N-(3-Chloro-5-methyl-phenyl)-acetamide. Acetic anhydride (6.7 mL) and
3-chloro-5-methyl-phenylamine (5.0 g, 35 mmol) was mixed and stand for 2.0 h. The reaction mixture was cooled to room temperature to give N-(3-chloro-5-methyl-phenyl)acetamide (5.1 g) as light yellow solids in 79% yield: 1H NMR (500 MHz, CDCl3)□7.38 (s, 1 H), 7.19 (s, 1 H), 7.12 (s, 1 H), 6.91 (s, 1 H), 2.31 (s, 3 H), 2.16 (s, 3 H).
Figure imgf000055_0003
[00161] iV-(4-Acetyl-3-chloro-5-methyl-phenyl)-acetamide. A dry CS2 solution (30 mL) containing N-(3-chloro-5-methyl-phenyl)acetamide (5.0 g, 27 mmol) and acetyl chloride (2.9 ml, 40.8 mmol) was slowly added with aluminum chloride (9.1 g, 68 mmol). The reaction mixture was heated at reflux for 30 min, cooled to room temperature, and stand for 4.0 h. The CS2 was decanted and the remaining syrup was poured into icy HCl. The resultant solids were collected, re-dissolved in EtOH, and decolorized by charcoal. The solution was filtered and the filtrate was concentrated under vacuum to give N-(4-acetyl-3-chloro-5-methylphenyl)acetamide (5.2 g) as light yellow solids in 85% yield: 1HNMR (500 MHz, CDCl3) 07.48 (s, 1 H), 7.26 (s, 1 H), 7.21 (s, 1 H), 2.52 (s, 3 H), 2.24 (s, 3 H), 2.18 (s, 3 H).
Figure imgf000056_0001
[00162] l-(4-Amino-2-chloro-6-methylphenyl)ethanone. An ethanol solution (4.0 mL) containing N-(4-acetyl-3-chloro-5-methylphenyl)acetamide (0.53 g, 2.3 mmol) and concentrated hydrochloric acid (1.6 mL) was heated at reflux for 15 h. The solution was added with 10% aqueous NaOH and the resultant solids were collected to give
l-(4-amino-2-chloro-6-methylphenyl)ethanone (0.37 g) as light yellow solids in 88% yield: 1H NMR (500 MHz, CDCl3)□6.46 (d, J= 1.77 Hz, 1 H), 6.34 (s, 1 H), 3.85 (bs, 2 H), 2.49 (s, 3 H), 2.14 (s, 3 H): ESI-MS: m/z 183.4 (M + H)+.
Figure imgf000056_0002
[00163] l-(2-Chloro-4-iodo-6-methyl-phenyl)-ethanone. A CH3CN solution (20 mL) containing KI (2.5 g, 15 mmol) and tert-butyl nitrite (2.00 mL, 16.9 mmol) was added with l-(4-amino-2-chloro-6-methyl-phenyl)ethanone (2.3 g, 12.5 mmol) in CH3CN (13 mL) at -10 C. The reaction mixture was warmed to room temperature and poured into aqueous HCl (20%, 23 mL). The solution was extracted with EtOAc (20 mL), and the organic layer was separated, washed with H20 (23 mL), dried over MgSO^s), and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel to give
l-(2-chloro-4-iodo-6-methylphenyl)ethanone (1.28 g) as yellow oil in 35% yield: 1HNMR (500 MHz, CDCl3) LT7.58 (s, 1 H), 7.49 (s, 1 H), 2.51 (s, 3 H), 2.21 (s, 3 H).
Figure imgf000057_0001
[00164] l-[2-Chloro-4-(4-methoxy-phenoxy)-6-methyl-phenyl]-ethanone. To a solution of l-(2-chloro-4-iodo-6-niethylphenyl)ethanone (1.1 g, 3.7 mmol), K3P04(1.6 g, 7.4 mmol), and 4-methoxyphenol (0.55 g, 4.44 mmol) in DMF (55 mL) was added tetrabutylammomium bromide (0.12 g, 0.37 mmol) and copper(I) iodide (70 mg, 0.37 mmol). The reaction was heated at reflux for 22 h. The solution was extracted with EtOAc ( 10 mL), and the organic layer was separated, washed with H20 (11 mL), dried over MgS04(s), and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel to give
1 -[2-chloro-4-(4-methoxyphenoxy)-6-methylphenyl]ethanone as yellow oil in 19% yield: 1H NMR (500 MHz, CDCI3)□6.97 (m, 2 H), 6.90 (m ,2 H), 6.73 (d, J = 2.19 Hz, 1 H), 6.67 (d, J = 1.99 Hz, 1 H), 3.81 (s, 3 H), 2.52 (s, 3 H) , 2.20 (s, 3 H).
Figure imgf000057_0002
[00165] 2-Bromo-l-[2-chloro-4-(4-methoxyphenoxy)-6-methylphenyl]ethanone. To a solution of l-[2-chloro-4-(4-methoxyphenoxy)-6-methylphenyl]ethanone (0.20 g, 0.69 mmol) in acetonitrile (6.0 mL) was added ΤΒΑΒr3 (0.33 g, 0.69 mmol). The reaction was stirred at room temperature for 30 min. The solution was concentrated under reduced pressure, added with water, and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous MgS04(s), and concentrated under reduced pressure to give
2-bromo- 1 -(2,6-dimethyl-4-phenoxyphenyl)ethanone, which was used directly for the next step without further purification.
Figure imgf000057_0003
[00166] 4-[2-Chloro-4-(4-methoxy-phenoxy)-6-methyl-phenyl]-thiazol-2-ylamine. A mixture of 2-bromo- l-(2,6-dimethyl-4-phenoxyphenyl)ethanone and thiourea (63 mg, 0.83 mmol) in 95% EtOH (3.0 mL) was heated at reflux for 60 min. The solution was concentrated and added with water (50 mL) and saturated aqueous NaHC03 (5.0 mL). The resultant precipitate was filtered and recrystallized in toluene (30 niL). The solids were filtered and dried under vacuum to give 4-[2-chloro-4-(4-methoxyphenoxy)-6-methylphenyl]thiazol-2-ylamine (0.10 g) as yellow solids in 42% yield: 1H NMR (500 MHz, CDCl3)□6.98 (m, 2 H), 6.90 (m, 2 H), 6.83 (d, J = 2.4 Hz, 1 H), 6.73 (d, J = 2.3 Hz, 1 H), 6.41 (s, 1 H), 4.97 (brs, 2 H) , 3.81 (s, 3 H), 2.16 (s, 3 H).
Figure imgf000058_0001
[00167] 2-Bromo-l-(2,6-dimethyl-4-(methylthio)phenyl)ethanone. To a solution of
1- (4-(cyclopentyloxy)-2,6-dimethylphenyl)ethanone (3.30 g, 17.0 mmol) in acetonitrile (34.0 mL) was added tetrabutylammoniumtribromide (TBABr3, 8.19 g, 17.0 mmol). The reaction was stirred at room temperature overnight. The solution was concentrated under reduced pressure, added with water, and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous MgS04(s), and concentrated under reduced pressure to give
2- bromo-l-(2,6-dimethyl-4-(methylthio)phenyl)ethanone (5.2 g), which was used directly for the next step without further purification.
Figure imgf000058_0002
[00168] 4-(2,6-Dimethyl-4-(methylthio)phenyl)thiazol-2-amine. A mixture of
2-bromo-l-(2,6-dimethyl-4-(methylthio)phenyl)ethanone (4.64 g, 17.0 mmol) and thiourea (1.29 g, 17.0 mmol) in 95% EtOH (24.3 mL) was heated at reflux for 120 min. The solution was concentrated and added with water (50 mL) and saturated aqueous Na2CO3 (4.0 mL). The resultant precipitate was filtered and recrystallized in toluene (30 mL). The solids were filtered and dried under vacuum to give 4-(2,6-dimethyl-4-(methylthio)phenyl)thiazol-2 -amine (1.9 g) as light yellow solids in 45% yield: 1H NMR (500 MHz, CDCl3)□6.97 (s, 2 H), 6.26 (s, 1 H), 2.47 (s, 3 H), 2.15 (s, 6 H).
Figure imgf000058_0003
[00169] 2-Bromo-l-(2,6-dimethyl-4-(methylsulfonyl)phenyl)ethanone. To a solution of 2-bromo-l-(2,6-dimethyl-4-(methylthio)phenyl)ethanone (4.92 g, 0.653 mol) in CH2Cl2 (36 mL) at 0 °C was added mCPBA (70%, 11.1 g, 1.63 mol). The mixture was stirred at room temperature for 7.0 h. The solution was filtered, and the filtrate was added with saturated aqueous NaHC03 (50 mL). The organic layer was dried over anhydrous MgSO^s) and concentrated under reduced pressure to give 2-bromo-l-(2,6-dimethyl-4-(methylsulfonyl)phenyl)ethanone (7.6 g), which was used directly for the next step without further purification.
Figure imgf000059_0001
[00170] 4-(2,6-Dimethyl-4-(methylsulfonyl)phenyl)thiazol-2-amine. A mixture of
2-bromo-l-(2,6-dimethyl-4-(methylsulfonyl)phenyl)ethanone (7.60 g, 24.9 mmol) and thiourea (1.90 g, 25.0 mmol) in 95% EtOH (35.6 mL) was heated at reflux for 90 min. The solution was concentrated and added with water (100 mL) and saturated aqueous Na2CO3 (5.0 mL). The resultant precipitate was filtered and recrystallized in toluene (20 mL). The solids were filtered and dried under vacuum to give 4-(2,6-dimethyl-4-(methylsulfonyl)phenyl)thiazol-2-amine (3.28 g) as yellow solids in 47% yield: 1H NMR (500 MHz, CDCl3)□7.64 (s, 2 H), 6.34 (s, 1 H), 5.1 (m, 1 H), 3.04 (s, 3 H), 2.26 (s, 6 H).
[00171]
Figure imgf000059_0002
[00172] 2-Amino-N-(4-(4-(4-methoxyphenoxy)-2,6-dimethylphenyl)thiazol-2-yl)isonicotin amide. A mixture of
N-(4-(4-(4-methoxyphenoxy)-2,6-dimethylphenyl)tMazol-2-yl)-2-mtroisonicotinamide (0.20 g, 0.40 mmol) and Pd/C (0.15 g, 10% w/w) in ethanol (10 mL) was stirred under H2 overnight. The reaction was filtered through diatomaceous earth and concentrated under reduced pressure to afford 2-amino-N-(4-(4-(4-methoxyphenoxy)-2,6-dimethylphenyl)thiazol-2-yl)isonicotinamide (0.11 g) as yellow solids in 59% yield: 1H-NMR (500 MHz, DMSO-d6)□7.88-7.89 (m, 1 H), 7.10-7.11 (m, 2 H), 6.95-6.97 (m, 2 H), 6.62 (s, 1 H), 5.76 (s, 1 H), 3.29 (s, 3 H), 2.03 (s, 6 H); ESI-MS: m/z 446.6 [M + H]+.
Figure imgf000060_0001
[00173] N-(4-Mesitylthiazol-2-yl)-2-morpholinoisonicotinamide. A mixture of
2-chloro-N-(4-mesitylthiazol-2-yl)isonicotinamide (500.0 mg, 1.4 mmol, 1.0 equiv) and morpholine (1.5 mL, 16.8 mmol, 12 equiv) in methylpyrrolidone (15.0 ruL) was stirred at 150 L for 16 h. The mixture was poured into icy H20 (20.0 mL), and the resultant solids were filtered to provide N-(4-mesitylthiazol-2-yl)-2-morpholmoisonicotmamide (358.6 mg, 0.90 mmol) as yellow solids in 63% yield: 1H NMR (DMSO-d6, 500 MHz)□8.30 (d, J = 5.1 Hz, 2 H), 7.50 (s, 1 H), 7.22 (d, J = 5.1 Hz, 2 H), 7.10 (s, 1 H), 6.92 (s, 2 H), 3.70-3.73 (m, 4 H), 3.53-3.55 (m, 4 H), 2.26 (s, 3 H), 2.05 (s, 6 H); ESI-MS: m/z 409.3 (M + H)+.
Figure imgf000060_0002
[00174] N-(4-Mesitylthiazol-2-yl)-2-(4-methylpiperazin-l-yl)isonicotinamide. A mixture of 2-chloro-N-(4-mesitylthiazol-2-yl)isonicotinamide (300.0 mg, 0.8 mmol, 1.0 equiv) and
1 -methylpiperazine (1.12 mL, 10.1 mmol, 12 equiv) in methylpyrrolidone (9.0 mL) was stirred at 150 CC for 16 h. The mixture was poured into icy H20 (15.0 mL) and the resultant solids were filtered to provide N-(4-mesitylthiazol-2-yl)-2-(4-methylpiperazin-l-yl)isonicotinamide (95.6 mg, 0.20 mmol) as yellow solids in 27% yield: 1H NMR (CDCl3, 500 MHz)□8.27 (d, J = 5.1 Hz, 1 H), 7.12 (s, 1 H), 6.83-6.86 (m, 3 H), 6.78 (s, 1 H), 3.63-3.65 (m, 4 H), 2.35 (s, 3 H), 2.27 (s, 3 H), 2.04 (s, 6 H); ESI-MS: m/z 422.1 (M + H)+.
Figure imgf000060_0003
[00175] N-(4-Mesitylthiazol-2-yl)-2-(piperidin-l-yl)isonicotinamide. A mixture of 2-chloro-N-(4-mesitylthiazol-2-yl)isonicotinamide (200 mg, 0.60 mmol, 1.0 equiv) and piperidine (0.70 mL, 6.7 mmol, 12 equiv) in methylpyrrolidone (6.0 mL) was stirred at 150□C for 16 h. The mixture was poured into icy H2O (10.0 mL) and the resultant solids were filtered. The solids were purified by column chromatography on silica gel (15% EtOAc in hexanes as elunant) to provide N-(4-mesitylthiazol-2-yl)-2-(piperidin-l-yl)isonicotinamide (87.2 mg, 0.20 mmol) as yellow solids in 38% yield: 1H NMR (CDCl3, 500 MHz)□8.29 (d, J = 5.1 Hz, 1 H), 7.15 (s, 1 H), 6.83-6.90 (m, 3 H), 6.79 (s, 1 H), 3.61-3.63 (m, 4 H), 2.31 (s, 3 H), 2.08 (s, 6 H), 1.57-1.67 (m, 6 H); ESI-MS: m/z 407.2 (M + H)+.
Figure imgf000061_0001
[00176] 2-(Dimethylamino)-N-(4-mesitylthiazol-2-yl)isonicotinamide. A mixture of 2-chloro-N-(4-mesitylthiazol-2-yl)isonicotinamide (200 mg, 0.60 mmol, 1.0 equiv), caesium carbonate (2.73 g, 0.6 mmol, 15 equiv) and 2.0 M dimethylamine in THF (3.4 mL, 6.7 mmol, 12 equiv) in DMF (6.0 mL) was heated at reflux for 16 h. The mixture was poured into icy H2O (10.0 mL) and extracted with EtOAc. The organic layer was collected, dried over MgS04(s), and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (15% EtOAc in hexanes as eluant) to provide
2-(dimethylamino)-N-(4-mesityl-thiazol-2-yl)isonicotinamide (5.5 mg, 0.10 mmol) as yellow solids in 3.0% yield: 1HNMR (CDCl3, 500 MHz)□8.32 (d, J= 5.1 Hz, 1 H), 7.02 (s, 1 H), 6.92 (s, 2 H), 6.85 (d, J = 5.1 Hz, 1 H), 6.80 (s, 1 H), 3.16 (s, 6 H), 2.31 (s, 3 H), 2.09 (s, 6 H); ESI-MS: m/z 367.1 (M + H)+.
Figure imgf000061_0002
[00177] N-(4-(4-Benzyl-2,6-dimethylphenyl)thiazol-2-yl)isonicotinamide. A THF solution of benzylzinc(II) bromide (4.0 mL, 2.0 mmol) was added to a degassed solution of
N-(4-(4-iodo-2,6-dimethylphenyl)thiazol-2-yl)isonicotinamide (435 mg, 1.0 mmol) and tetrakistriphenylphosphine palladium (57.8 mg, 0.10 mmol) in THF (5.0 mL). The reaction mixture was heated at reflux for 16 h under N2 and then poured into saturated aqueous NaHC03. The mixture was extracted with ethyl acetate, washed with brine, dried MgS04, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel to give N-(4-(4-benzyl-2,6-dimethylphenyl)miazol-2-yl)isonicotinamide: 1H NMR (500 MHz, CDCl3)□ 8.70 (d, J = 4.9 Hz, 2 H), 7.67 (d, J = 4.9 Hz, 2 H), 7.33 (d, J = 8.6 Hz, 2 H), 7.10-7.26 (m, 3 H), 6.80 (s, 1 H), 6.24 (s, 1 H), 3.86 (s, 2 H), 2.04 (s, 6 H); ESI-MS: m/z 399.9 (M + H)+.
Figure imgf000062_0001
[00178] N-(4-(4-(4-Methoxybenzyl)-2,6-dimethylphenyl)thiazol-2-yl)isonicotinamide. A THF solution of 4-methoxylbenzylzinc(II) bromide (4.0 mL, 2.0 mmol) was added to a degassed solution of N-(4-(4-iodo-2,6-dimethylphenyl)thiazol-2-yl)isonicotinamide (435 mg, 1.0 mmol) and tetrakistriphenylphosphine palladium (57.8 mg, 0.10 mmol) in THF (5.0 mL). The reaction mixture was heated at reflux for 16 h under N2 then poured into saturated aqueous NaHC03. The mixture was extracted with ethyl acetate, washed with brine, dried MgS04, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel to give
N-(4-(4-(4-methoxybenzyl)-2,6-dimethylphenyl)thiazol-2-yl)isonicotinamide: 1H NMR (500 MHz, CDCl3)□8.69 (d, J = 5.2 Hz, 2 H), 7.66 (d, J = 4.9 Hz, 2 H), 7.11 (d, J = 8.4 Hz, 2 H), 6.86 (d, 2 H), 6.80 (s, 1 H), 6.75 (s, 2 H), 3.80 (s, 2 H), 3.78 (s, 2 H), 1.98(s, 6 H); ESI-MS: m/z 399.9 (M + H)+.
Exemplary Compounds and Physicochemical Data
Figure imgf000062_0002
[00179] Yield: 67%; 1H NMR (500 MHz, DMSO-d6)□8.23 (d, 2 H), 8.02 (d, 2 H), 7.09 (s, 1 H), 6.92 (s, 2 H), 2.26 (s, 3 H), 2.05 (s, 6 H); ESI-MS: m/z 348.0 (M + H)+.
Figure imgf000062_0003
[00180] Yield: 62%; 1HNMR (500 MHz, DMSO-d6)□9.41 (s, 1 H), 9.15 (d, 1 H), 8.14 (d, 1 H), 7.17 (s, 1 H), 6.89 (s, 2 H), 2.25 (s, 3 H), 2.03 (s, 6 H); ESI-MS: m/z 325.1 (M + H)+.
Figure imgf000063_0001
[00181] Yield: 8.6%; 1H NMR (500 MHz, CDCl3)□8.70 (d, J = 5.5 Hz, 2 H), 7.65-7.63 (m, 2 H), 7.60 (d, J = 8.0 Hz, 2 H), 7.17 (s, 1 H), 7.14 (d, J = 7.5 Hz, 2 H), 2.34 (s, 6 H); ESI-MS: m/z 295.9 (M + H)+.
Figure imgf000063_0002
[00182] Yield: 63%; 1HNMR (500 MHz, CDCl3)□7.89 (d, J = 8.5 Hz, 2 H), 7.62 (d, J = 8.5 Hz, 2 H), 7.55 (d, J = 8.5 Hz, 2 H), 7.17 (s, 1 H), 7.12 (d, J = 8.0 Hz, 2 H), 2.34 (s, 6 H); ESI-MS: m/z 317.9 (M - H)-.
Figure imgf000063_0003
[00183] Yield: 62%; 1H NMR (500 MHz, DMSO-d6)□9.72 (s, 1 H), 9.50 (d, 1 H), 8.21 (m, 1 H), 7.13 (s, 1 H), 6.94 (s, 2 H), 2.27 (s, 3 H), 2.06 (s, 6 H); ESI-MS: m/z 324.5 (M + H)-h
Figure imgf000063_0004
[00184] Yield: 40%; 1H NMR (500 MHz, DMSO-d6)□9.36 (s, 1 H), 8.82 (brs, 1 H), 7.06 (s, 1 H), 6.93 (s, 2 H), 2.26 (s, 3 H), 2.05 (s, 6 H); ESI-MS: m/z 329.3 (M + H)+.
Figure imgf000064_0001
[00185] Yield: 74%; 1H NMR (500 MHz, CDCl3)□9.09 (d, 1 H), 8.73-8.72 (m, 1 H), 8.15-8.14 (m, 1 H), 7.42-7.41 (m, 2 H), 7.35 (m, 1 H), 6.87-6.85 (m, 2 H), 3.82 (s, 3 H), 2.51 (s, 6 H); ESI-MS: m/z 325.3 [M + H]+.
Figure imgf000064_0003
[00186] Yield: 87%; 1H NMR (500 MHz, CDCl3)□9.30 (s, 1 H), 8.82-8.81 (m, 1 H), 8.39-8.36 (m, 1 H), 7.80-7.79 (m, 1 H), 7.48-7.46 (m, 1 H),7.43-7.39 (m, 1 H), 6.58-6.55 (m, 2 H), 3.92 (s, 3 H), 3.86 (s, 3 H); ESI-MS: m/z 341.4 [M + H]+.
Figure imgf000064_0004
[00187] Yield: >99%; 1H NMR (500 MHz, CDCl3)□ 10.55 (s, 1 H), 8.65-8.64 (m, 1 H), 8.30-8.29 (m, 1 H), 7.93 (m, 1 H), 7.60-7.58 (m, 2 H), 7.54-7.53 (m, 1 H), 6.99-6.98 (m, 2 H), 3.86 (s, 3 H), 2.54 (s, 3 H); ESI-MS: m/z 325.6 [M + H]+.
Figure imgf000064_0002
[00188] Yield: >99%; 1H NMR (500 MHz, DMSO-d6)□l 1.98 (s, 1 H), 8.78-8.77 (m, 1 H), 8.19-8.17 (m, 1 H), 8.11-8.09 (m, 1 H), 7.89-7.87 (m, 2 H), 7.74-7.71 (m, 1 H), 7.58 (m, 1 H), 7.00-6.99 (m, 2 H), 3.79 (s, 3 H), 2.54 (s, 3 H); ESI-MS: m/z 310.0 [M- H]-.
Figure imgf000065_0004
[00189] Yield: 89%; 1H NMR (500 MHz, DMSO-d6) Dl 1.9 (s, 1 H), 8.79-8.78 (m, 1 H), 8.20-8.19 (m, 1 H), 8.12-8.07 (m, 1 H), 7.75-7.74 (m, 2 H), 7.61 (s, 1 H), 6.68-6.63 (m, 2 H), 3.92 (s, 3 H), 3.82 (s, 3 H); ESI MS: m/z 340.3 [M - H]-.
Figure imgf000065_0001
[00190] Yield 90%: 1H NMR (500 MHz, DMSO-c¾□ 11.9 (s, 1 H), 8.76-8.77 (m, 1 H), 8.18-8.19 (m, 1 H), 8.10 (m, 1 H), 7.69-7.73 (m, 3 H), 7.45-7.48 (m, 1 H), 7.36-7.38 (m, 1 H), 2.50 (s, 3 H); ESI-MS: m/z 295.4 [M + H]+.
Figure imgf000065_0002
[00191] Yield 78%: 1H NMR (500 MHz, DMSO-</tf)□9.24 (d, 1 H), 8.79 (t, 1 H), 8.44 (d, 1 H), 7.75 (s, 1 H), 7.58-7.60 (m, 1 H), 7.26 (s, 2 H), 3.85 (s, 6 H), 3.69 (s, 3 H); ESI-MS: m/z 372.5 [M + H]+.
Figure imgf000065_0003
[00192] Yield 81%: 1H NMR (500 MHz, DMSO-d6)□9.23 (d, 1 H), 8.80 (t, 1 H), 8.44 (d, 1 H), 8.00-8.03 (m, 1 H), 7.58-7.60 (m, 1 H), 7.46 (d, 1 H), 6.90-6.98 (m, 2 H), 3.82 (s, 3 H); ESI-MS: m/z 330.0 [M + H]+.
Figure imgf000066_0001
[00193] Yield 53%: 1H NMR (500 MHz, CDCl3)□l 1.01 (s, 1 H), 7.82-7.86 (m, 1 H), 7.27 (d, 1 H), 6.63-6.84 (m, 6 H), 3.80 (s, 3 H), 3.76 (s, 3 H), 2.77 (t, 2 H), 2.29 (t, 3 H); ESI-MS: m/z 387.0 [M + H]+.
Figure imgf000066_0002
[00194] Yield 45%: 1H NMR (500 MHz, CDCl3)□10.87 (s, 1 H), 7.83-7.87 (m, 1 H), 7.15-7.27 (m, 5 H), 7.95 (d, 2 H), 6.62-6.73 (m, 2 H), 3.80 (s, 3 H), 2.86 (t, 2 H), 2.36 (t, 2 H); ESI-MS: m/z 356.0 [M + H]+.
Figure imgf000066_0003
[00195] Yield 77%: 1H NMR (500 MHz, DMSO-c¾□12.04 (s, 1 H), 8.79 (d, 2 H), 8.02-8.21 (m, 3 H), 7.74 (t, 1 H), 7.49 (d, 2 H), 6.90-6.97 (m, 2 H), 3.82 (s, 3 H); ESI-MS: m/z 330.0 [M + H]+.
Figure imgf000066_0004
[00196] Yield 75%: 1H NMR (500 MHz, DMSO-d6) □12.04 (s, 1 H), 8.78 (s, 1 H), 8.18 (d, 1 H), 8.11 (t, 1 H), 7.78-7.82 (m, 2 H), 7.28 (s, 2 H), 3.86 (s, 6 H), 3.69 (s, 3 H); ESI-MS: m/z 372.0 [M + H]+.
Figure imgf000067_0004
[00197] Yield 84%: 1H NMR (500 MHz, DMSO-d6) □8.82 (d, 2 H), 7.99-8.03 (m, 3 H), 7.48 (d, 1 H), 6.91-6.98 (m, 2 H), 3.83 (s, 3 H); ESI-MS: m/z 330.0 [M + H]+.
Figure imgf000067_0001
[00198] Yield 82%: 1H NMR (500 MHz, DMSO-d6)□8.79 (d, 2 H), 8.00-8.01 (m, 2 H), 7.71 (s, 1 H), 7.26 (s, 2 H), 3.85 (s, 6 H), 3.70 (s, 3 H); ESI-MS: m/z 372.0 [M + H]+.
Figure imgf000067_0002
[00199] Yield: 6.7%; 1H NMR (500 MHz, CDCl3)□ 10.96 (bs, 1 H), 9.11 (bs, 1 H), 8.75 (bs, 1 H), 8.14 (d, J = 8.0 Hz, 1 H), 7.60 (d, J = 7.5 Hz, 2 H), 7.34 (s, 1 H), 7.15 (s, 1 H), 7.12 (d, J = 7.5 Hz, 2 H), 2.33 (s, 6 H); ESI-MS: m/z 293.7 (M - H)-.
Figure imgf000067_0005
[00200] Yield: 83%; 1H NMR (500 MHz, CDCl3)□ 11.24 (s, 1 H), 8.68 (d, J = 4.5 Hz, 1 H), 8.31 (d, J = 8.0 Hz, 1 H), 7.95 (m, 1 H), 7.78 (d, J= 8.0 Hz, 2 H), 7.54 (m, 1 H), 7.24 (m, 2 H), 7.17 (s, 1 H), 2.39 (s, 6 H); ESI-MS: m/z 295.6 (M + H)+.
Figure imgf000067_0003
Figure imgf000068_0005
[00201] Yield: 36%; 1HNMR (500 MHz, CDCl3)□7.72 (d, J = 8.5 Hz, 2 H), 7.49 (d, J = 8.5 Hz, 2 H), 7.20 (d, J = 8.0 Hz, 2 H), 6.99 (d, J = 8.0 Hz, 2 H), 2.51 (s, 3 H), 2.27 (s, 3 H); ESI-MS: m/z 332.0 (M - H)-.
Figure imgf000068_0001
[00202] Yield: 56%; 1HNMR (500 MHz, CDCl3)□8.99 (s, 1 H), 8.63 (d, J = 5.0 Hz, 1 H), 8.01 (d, J = 7.9 Hz, 1 H), 7.29-7.21 (m, 3 H), 7.03 (d, J = 7.8 Hz, 2 H), 2.49 (s, 3 H), 2.29 (s, 3 H); ESI-MS: m/z 310.3 (M + H)+.
Figure imgf000068_0002
[00203] Yield: 79%; 1H NMR (500 MHz, CDCl3)□ 11.11 (s, 1 H), 8.64 (d, J = 4.5 Hz, 1 H), 8.29 (d, J = 7.5 Hz,l H), 7.93 (t, J = 8.0 Hz, 1 H), 7.55-7. 1 (m, 3 H), 7.25 (d, J = 7.5 Hz,l H), 2.54 (s, 3 H), 2.40 (s, 3 H); ESI-MS: m z 309.0 (M - H)-.
Figure imgf000068_0003
compound 33
[00204] Yield: 37%; 1H NMR (500 MHz, DMSO-d6)□ 12.59 (s, 1 H), 8.60 (s, 1 H), 7.69-7.76 (m, 2 H), 7.04 (s, 1 H), 6.93 (s, 2 H), 2.27 (s, 3 H), 2.06 (s, 6 H); ESI-MS: m/z 327.1 (M - H)-.
Figure imgf000068_0004
[00205] Yield: 54%; 1H NMR (500 MHz, DMSO-d6)□8.89 (d, 2 H), 8.00 (d, 2 H), 7.57 (d, 1 H), 7.44-7.46 (m, 1 H), 7.26 (d, 1 H), 7.11 (s, 3 H), 3.81 (s, 3 H); ESI-MS: m/z 327.9 (M + H)+.
Figure imgf000069_0001
[00206] Yield: 44%; 1H NMR (500 MHz, DMSO-d6)□9.25 (s, 1 H), 8.91 (s, 1 H), 8.45-8.48 (m, 1 H), 7.65-7.67 (m, 1 H), 7.57 (d, 1 H), 7.44-7.46 (m, 1 H), 7.26 (d, 1 H), 7.10 (s, 2 H), 3.81 (s, 3 H); ESI-MS: m/z 328.0 (M + H)+.
Figure imgf000069_0002
[00207] Yield: 37%; 1H NMR (500 MHz, DMSCWs)□8.82 (d, 1 H), 8.23 (d, 1 H), 8.08 (d, 1 H), 7.74-7.75 (m, 1 H), 7.57 (d, 1 H), 7.44-7.46 (m, 1 H), 7.23 (d, 1 H), 7.10 (s, 2 H), 3.81 (s, 3 H); ESI-MS: m/z 328.1 (M + H)+.
Figure imgf000069_0003
[00208] Yield: 94%; 1H NMR (500 MHz, DMSO-d6)□12.98 (s, 1 H), 9.23 (m, 1 H), 8.80 (m, 1 H), 8.46-8.43 (m, 1 H), 7.90-7.88 (m, 2 H), 7.61-7.56 (m, 1 H), 7.02-7.00 (m, 2 H), 3.80 (s, 3 H); ESI-MS: m/z 310.0 [M - H]-.
Figure imgf000069_0004
[00209] Yield: 99%; 1HNMR (500 MHz, DMSO-d6)□7.82-7.80 (m, 2 H), 7.60-7.58 (m, 2 H), 7.41-7.40 (m, 2 H), 7.30-7.29 (m, 2 H), 7.22-7.19 (m, 1 H), 2.54 (s, 3 H); ESI-MS: m/z 320.0 [M + H]+.
Figure imgf000070_0001
[00210] Yield: 66%; 1H NMR (500 MHz, CD3OD)□8.18-8.17 (m, 2 H), 7.92-7.90 (m, 2 H), 7.60-7.58 (m, 2 H), 7.01-7.00 (m, 2 H), 3.84 (s, 3 H), 2.50 (s, 2 H); ESI-MS m/z 349.5 [M + H]+.
Figure imgf000070_0002
[00211] Yield: 85%; 1H NMR (500 MHz, DMSO-d6) D12.3 (s, 1 H), 7.99-7.97 (m, 1 H), 7.64 (s, 1 H), 7.24 (m, 1 H), 6.91 (m, 2 H), 6.90 (m, 1 H), 6.66-6.61 (m, 2 H), 3.89 (s, 3 H), 3.80 (s, 3 H), 3.75-3.74(m, 5 H); ESI-MS: m/z 385.1 [M + H]+.
Figure imgf000070_0003
[00212] Yield: 76%; 1HNMR (500 MHz, CDCl3)□8.90 (s, 1 H), 7.56-7.55 (m, 2 H), 7.43-7.40 (m, 2 H), 7.34-7.33 (m, 1 H), 7.26-7.22 (m, 1 H), 3.77 (s, 3 H), 3.47 (s, 2 H), 2.49 (s, 3 H);
ESI-MS: m/z 339.2 [M + H]+.
Figure imgf000070_0004
[00213] Yield: 69%; 1HNMR (500 MHz, CDCl3)□8.67 (d, J = 5.5 Hz, 2 H), 7.55 (d, J = 6.0 2 H), 6.77 (s, 1 H), 6.32 (s, 2 H), 3.73 (s, 3 H), 1.91 (s, 6 H); ESI-MS: m/z 340.0 (M + H)+.
Figure imgf000070_0005
Figure imgf000071_0004
[00214] Yield: 54%; 1HNMR (500 MHz, CDCl3)□8.57 (d, J = 5.0 Hz, 2 H), 7.46 (d, J = 5.5 Hz, 2 H), 7.25 (d, J = 4.5 Hz, 2 H), 7.02 (d, J = 7.5 Hz, 2 H), 2.51 (s, 3 H), 2.28 (s, 3 H); ESI-MS: m/z 309.9 (M + H)+.
Figure imgf000071_0001
[00215] Yield: 51%; 1HNMR (500 MHz, CDCl3)□8.79 (d, J = 5.5 Hz, 2 H), 7.70 (d, J = 5.5 Hz, 2 H), 6.86 (s, 1 H), 6.77 (s, 1 H), 2.45 (s, 3 H), 2.23 (s, 3 H), 2.03 (s, 3 H); ESI-MS: m/z 324.5 (M + H)+.
Figure imgf000071_0002
[00216] Yield: 18%; 1H NMR (500 MHz, CDCl3)□ 11.22 (s, 1 H), 8.65 (d, J = 4.5 Hz, 1 H), 8.31 (d, J = 7.5 Hz, 1 H), 7.96 (t, J = 7.5 Hz, 1 H), 7.54 (m, 1 H), 6.92 (s, 1 H), 6.85 (s, 1 H), 2.52 (s, 3 H), 2.37 (s, 3 H), 2.133 (s, 3 H); ESI-MS: m/z 325.0 (M + H)+.
Figure imgf000071_0003
[00217] Yield: 18%; 1H NMR (500 MHz, CDCl3)□9.11 (s, 1 H), 8.77 (s, 1 H), 8.17 (d, J = 7.5 Hz, 1 H), 7.42 (m, 1 H), 6.85 (s, 1 H), 6.78 (s, 1 H), 2.45 (s, 3 H), 2.27 (s, 3 H), 2.02 (s, 3 H); ESI-MS: m/z 325.1 (M + H)+.
Figure imgf000071_0005
[00218] Yield: 54%; 1H NMR (500 MHz, DMSO-d6)□9.75 (s, 1 H), 9.61 (s, 1 H), 8.28-8.30 (m, 1 H), 7.58 (d, 1 H), 7.46-7.48 (m, 1 H), 7.29 (d, 1 H), 7.12 (s, 3 H), 3.82 (s, 3 H); ESI-MS: m/z 329.4 (M + H)+.
Figure imgf000072_0001
[00219] Yield: 44%; 1H NMR (500 MHz, DMSO-d6)□9.49 (d, 1 H), 9.19 (d, 1 H), 8.22-8.23 (m, 1 H), 7.58 (d, 1 H), 7.45-7.47 (m, 1 H), 7.27 (d, 1 H), 7.12 (s, 3 H), 3.82 (s, 3 H); ESI-MS: m/z 328.9 (M + H)+.
Figure imgf000072_0002
[00220] Yield: 37%; 1H NMR (500 MHz, DMSO-d6)□8.58 (d, 1 H), 7.73-7.75 (m, 1 H), 7.60 (d, 1 H), 7.55 (d, 1 H), 7.42-7.44 (m, 1 H), 7.18 (d, 1 H), 7.09 (m, 3 H); ESI-MS: m/z 333.0 (M + H)+.
Figure imgf000072_0003
[00221] Yield: 37%; 1HNMR (500 MHz, DMSO-d6)□9.49 (s, 1 H), 8.75 (s, 1 H), 7.56 (s, 1 H), 7.43-7.45 (m 1 H), 7.24 (d, 1 H), 7.11 (m, 3 H), 3.81 (s, 3 H); ESI-MS: m/z 333.9 (M + H)+.
Figure imgf000072_0004
[00222] Yield: 32%; 1HNMR (500 MHz, DMSO-d6)□8.63 (s, 1 H), 7.91 (s, 1 H), 7.54 (s, 1 H), 7.41-7.43 (m, 1 H), 7.08-7.18 (m, 4 H), 6.93 (s, 1 H), 3.80 (s, 3 H); ESI-MS: m/z 316.9 (M + H)+.
Figure imgf000073_0001
[00223] Yield: 88%; 1H NMR (500 MHz, CDCl3)□8.70 (d, J = 6.0 Hz, 2 H), 7.58(d, J = 6.0 Hz, 2 H), 6.78 (s, 1 H), 6.37 (s, 2 H), 3.95 (q, J = 7.0 Hz, 2 H), 1.94 (s, 6 H), 1.41(t, J = 7.0 Hz, 3 H); ESI-MS: m/z 353.6 (M + H)+.
Figure imgf000073_0002
[00224] Yield: 78%; 1H NMR (500 MHz, CDCl3)□8.58 (m, 2 H), 7.53-7.44 (m, 5 H), 7.37 (i 1 H), 7.03 (s, 2 H), 6.86 (s, 1 H), 2.02 (s, 6 H); ESI-MS: m/z 385.7 (M + H)+.
Figure imgf000073_0003
[00225] Yield: 89%; 1H NMR (500 MHz, CDCl3)□8.76 (d, J = 6.0 Hz, 2 H), 7.57 (m, 2 H), 6.81 (m, 3 H), 1.92 (s, 6 H); ESI-MS: m/z 343.8 (M + H)+.
Figure imgf000073_0004
[00226] Yield: 38%; 1H NMR (500 MHz, DMSO-d6)□8.28 (d, 2 H), 8.09 (d, 2 H), 7.88 (d, 2 H), 7.31 (d, 2 H), 7.04-7.08 (m, 3 H); ESI-MS: m/z 322.0 (M + H)+.
Figure imgf000073_0005
Figure imgf000074_0005
[00227] Yield: 75%; 1H NMR (500 MHz, DMSO-d6) 08.89 (d, 2 H), 8.01-8.06 (m, 2 H), 7.89 (d, 2 H), 7.32 (d, 2 H), 7.05-7.09 (m, 3 H); ESI-MS: m/z 297.6 (M + H)+.
Figure imgf000074_0001
[00228] Yield: 48%; 1H NMR (500 MHz, DMSO-d6)□9.49 (s, 1 H), 9.18 (d, 1 H), 8.23 (d, 1 H), 7.86-7.91 (m, 2 H), 7.33 (d, 2 H), 7.06-7.09 (m, 3 H); ESI-MS: m/z 192.5 (M - 106, aminothiazole).
Figure imgf000074_0002
[00229] Yield: 49%; 1H NMR (500 MHz, DMSO-i¾)□8.82 (d, 1 H), 8.24 (d, 1 H), 8.07-8.10 (m, 1 H), 7.88 (d, 2 H), 7.73-7.75 (m, 1 H), 7.30 (d, 2 H), 7.05-7.08 (m, 3 H); ESI-MS: m/z 297.7 (M + H)+.
Figure imgf000074_0003
[00230] Yield: 49%; 1H NMR (500 MHz, DMSO-d6)□9.26 (d, 1 H), 8.91 (d, 1 H), 8.47 (d, 1 H), 7.89 (d, 2 H), 7.65-7.67 (m, 1 H), 7.32 (d, 2 H), 7.05-7.08 (m, 3 H); ESI-MS: m/z 297.6 (M + H)+.
Figure imgf000074_0004
[00231] Yield: 48%; 1H NMR (500 MHz, DMSO-d6)□8.24-8.30 (m, 2 H), 8.04-8.11 (m, 2 H), 7.63 (d, 1 H), 7.00-7.20 (m, 4 H), 6.67 (s, 1 H); ESI-MS: m/z 335.7 (M + H)+.
Figure imgf000075_0001
[00232] Yield: 67%; 1HNMR (DMSO-d6 500 MHz)□13.10 (s, 1 H), 8.82 (d, J = 5.6 Hz, 2 H), 8.00 (d, J = 5.6 Hz, 2 H), 7.88 (s, 1 H), 7.70-7.72 (m, 2 H), 3.96 (s, 3 H); ESI-MS m/z 348.0 (M + H)+.
Figure imgf000075_0002
[00233] Yield: 40%; 1HNMR (500 MHz, DMSO-d6)□10.49 (bs, 1 H), 8.54 (d, J = 6.5 Hz, 2 H), 7.94 (s, 2 H), 6.88 (s, 1 H), 6.74 (s, 2 H), 3.76 (s, 3 H), 2.10 (s, 6 H); ESI-MS: m/z 354.8 (M + H)+.
Figure imgf000075_0003
[00234] Yield: 73%; 1H NMR (500 MHz, DMSO-d6)□9.87 (s, 1 H), 9.40 (s, 1 H), 8.39 (d, J = 6.0 Hz, 2 H), 7.49 (d, J = 6.5 Hz, 2 H), 7.32 (s, 2 H), 6.92 (s, 1 H), 2.06 (s, 6 H), 2.04 (s, 3 H); ESI-MS: m/z 381.8 (M + H)+.
Figure imgf000075_0004
[00235] Yield: 62%; 1HNMR (500 MHz, CDCl3)□8.83 (d, J = 5.5 Hz, 2 H), 7.83 (d, J = 6.0 Hz, 2 H), 7.06 (s, 2 H), 6.82 (s, 1 H), 2.94 (m, 1 H), 2.64 (m, 2 H), 1.29 (d, J = 7.0 Hz, 6 H), 1.13 (d, J = 7.0 Hz, 12 H); ESI-MS: m/z 407.9 (M + H)+.
Figure imgf000076_0001
[00236] Yield: 39%; 1H NMR (500 MHz, DMSO-d6)□13.03 (bs, 1 H), 9.86 (s, 1 H), 8.80 (d, J = 5.5 Hz, 2 H), 7.99 (d, J = 5.5 Hz, 2 H), 7.34 (s, 2 H), 7.13 (s, 1 H), 2.06 (s, 6H); ESI-MS: m/z 385.7 (M + H)+.
Figure imgf000076_0002
[00237] Yield: 23%; 1H NMR (500 MHz, CDCl3)□l 1.32 (bs, 1 H), 8.57 (m, 2 H), 7.80 (t, J = 5.5 Hz, 1 H), 6.80 (s, 1 H), 6.71 (s, 2 H), 2.23 (s, 3 H), 1.96 (s, 6 H); ESI-MS: m/z 341.9 (M + H)+.
Figure imgf000076_0003
[00238] Yield: 49%; 1H NMR (DMS0-d6, 500 MHz)□ 13.13 (s, 1 H), 8.81 (d, J = 5.9 Hz, 2 H), 8.00 (d, J = 5.9 Hz, 2 H), 7.46 (s, 1 H), 6.86-6.88 (m, 2 H), 3.83 (s, 3 H); ESI-MS: m/z 348.7 (M + H)+.
Figure imgf000076_0004
[00239] Yield: 30%; 1H NMR (500 MHz, CDCl3)□8.81 (d, J = 5.5 Hz, 2 H), 7.99 (d, J = 5.5 Hz, 2 H), 7.41 (t, J = 8.0 Hz, 2 H), 7.19 (s, 1 H), 7.15 (t, J = 7.5 Hz, 1 H), 7.04 (d, J = 8.2 Hz, 2 H), 6.78 (s, 2 H), 2.07 (s, 6 H); ESI-MS: m/z 401.8 (M + H)+.
Figure imgf000077_0001
[00240] Yield: 80%; 1H NMR (500 MHz, CDCl3)□8.67 (d, J = 6.0 Hz, 2 H), 7.55 (d, J = 6.0 Hz, 2 H), 6.77 (s, 1 H), 6.30 (s, 2 H), 4.43 (m, 1 H), 1.89 (s, 6 H), 1.3 l(d, J = 6.0 Hz, 6 H); ESI-MS: m/z 368.1 (M + H)+.
Figure imgf000077_0002
[00241] Yield: 62%; 1H NMR (500 MHz, CDCl3)□8.71 (d, J = 6.0 Hz, 2 H), 7.60 (d, J = 6.0 Hz, 2 H), 6.78 (s, 1 H), 6.37 (s, 2 H), 4.68 (m, 1 H), 1.95 (s, 6 H), 1.80-1.92 (m, 6 H), 0.85 (m, 2 H); ESI-MS: m/z 394.1 (M + H)+.
Figure imgf000077_0003
[00242] Yield: 4.0%; 1H NMR (CDCl3, 500 MHz)□8.80 (d, J = 5.9 Hz, 2 H), 7.69 (d, J = 5.9 Hz, 2 H), 6.81 (s, 1 H), 6.55 (s, 2 H), 4.19-4.25 (brs, 1 H), 4.10-4.15 (m, 1 H), 3.91-3.98 (m, 1 H), 3.78-3.82 (m, 1 H), 2.05 (s, 6 H), 1.28 (s, 3 H); ESI-MS: m/z 384.7 (M + H)+.
Figure imgf000077_0004
[00243] Yield: 95%; 1H NMR (500 MHz, CDCl3) 08.73 (m, 2 H), 7.62 (m, 2 H), 6.90-6.96 (m, 4 H), 6.80 (s, 1 H), 6.45 (s, 2 H), 3.83 (s, 3 H), 1.92 (s, 6 H); ESI-MS: m/z 431.7 (M + H)+.
Figure imgf000077_0005
Figure imgf000078_0005
[00244] Yield: 17%; 1H NMR (500 MHz, CDCl3)□8.72 (d, J = 5.5 Hz, 2 H), 7.60 (d, J = 5.5 Hz, 2 H), 7.04 (m, 2 H), 6.94 (m, 2 H), 6.81 (s, 1 H), 6.43 (s, 2 H), 1.92 (s, 6 H); ESI-MS: m/z 420.2 (M + H)+.
Figure imgf000078_0001
[00245] Yield: 12%; 1H NMR (DMSO-d6, 500 MHz)□8.78 (d, J = 4.5 Hz, 2 H), 7.98 (d, J = 4.5 Hz, 2 H), 7.15 (s, 1 H), 6.69 (s, 2 H), 4.95^1.96 (m, 1 H), 4.68^1.69 (m, 1 H), 3.97-3.98 (m, 1 H), 3.84-3.85 (m, 1 H), 3.78-3.79 (m, 1 H), 2.06 (s, 6 H); ESI-MS: m/z 400.7 (M + H)+.
Figure imgf000078_0002
[00246] Yield: 99%; 1H NMR (500 MHz, CDCl3)□8.68 (d, J = 6.0 Hz, 2 H), 7.56 (d, J = 6.0 Hz, 2 H), 6.77 (s, 1 H), 6.33 (s, 2 H), 3.62 (d, J = 6.5 Hz, 2 H), 2.08 (m, 1 H), 1.91 (s, 6 H), 1.05 (d, J = 6.7 Hz, 6 H); ESI-MS: m/z 381.1 (M + H)+.
Figure imgf000078_0003
[00247] Yield: 92%; 1H NMR (500 MHz, CDCl3)□8.73 (m, 2 H), 7.62 (m, 2 H), 6.81 (s, 1 H), 6.78 (d, J = 8.5 Hz, 1 H), 6.43-6.52 (m, 4 H), 6.00 (s, 2 H), 1.93 (s, 6 H); ESI-MS: m/z 445.9 (M + H)+.
Figure imgf000078_0004
[00248] Yield: 94%; 1H NMR (500 MHz, CDCl3)□8.81 (d, J = 5.1 Hz, 2 H), 7.78 (d, J = 5.6 Hz, 2 H), 6.84 (s, 1 H), 6.78 (s, 1 H), 6.64 (s, 2 H), 6.61 (s, 2 H), 2.31 (s, 6 H), 2.02 (s, 6 H); ESI-MS: m/z 429.8 (M + H)+.
Figure imgf000079_0001
[00249] Yield: 51%; 1H NMR (500 MHz, CDCl3)□8.75 (m, 2 H), 7.62 (m, 2 H), 7.25 (m, 1 H), 6.82 (s, 1 H), 6.69 (m, 1 H), 6.56 (d, 1 H), 6.51 (m, 2 H), 6.47 (s, 2 H), 3.81 (s, 3 H), 1.94 (s, 6 H); ESI-MS: m/z 431.6 (M + H)+.
Figure imgf000079_0004
[00250] Yield: 87%; 1H NMR (500 MHz, CDCl3)□8.76 (m, 2 H), 7.64 (m, 2 H), 7.58 (d, J = 8.5 Hz, 2 H), 7.01 (d, J = 8.5 Hz, 2 H), 6.86 (s, 1 H), 6.57 (s, 2 H), 1.98 (s, 6 H); ESI-MS: m/z 469.7 (M + H)+.
Figure imgf000079_0002
[00251] Yield: 85%; 1HNMR (500 MHz, DMSO-d6)□8.80-8.81 (m, 2 H), 7.98-7.99 (m, 2 H), 7.16-7.21 (m, 3 H), 6.99-7.06 (m, 2 H), 6.59 (s, 2 H), 3.76 (s, 3 H), 2.03 (s, 6 H); ESI-MS: m z 431.5 [M + H]+.
Figure imgf000079_0003
[00252] Yield: 89%; 1H NMR (500 MHz, DMSO-d6)□8.80-8.81 (m, 2 H), 7.98-7.99 (m, 2 H), 7.18-7.22 (m, 3 H), 6.94-6.95 (m, 2 H), 6.73 (s, 2 H), 2.30 (s, 3 H), 2.06 (s, 6 H); ESI-MS: m/z 414.9 [M - H]-.
Figure imgf000080_0002
[00253] Yield: 91%; 1HNMR (500 MHz, CDCl3)□8.78 (d, J = 6.0 Hz, 2 H), 8.67 (m, 2 H), 7.18 (d, J = 8.0 Hz, 2 H), 6.93 (d, J = 8.5 Hz, 2 H), 6.83 (s, 1 H), 6.56 (s, 2 H), 2.65 (m, 2 H), 1.98 (s, 6 H), 1.26 (t, J = 7.5 Hz, 3 H); ESI-MS: m/z 429.6 (M + H)+.
Figure imgf000080_0001
[00254] Yield: 61%; 1H NMR (500 MHz, CDCl3)□8.76 (m, 2 H), 7.52 (m, 2 H), 7.11 (s, 2 H), 6.80 (s, 1 H), 1.84 (s, 6 H); ESI-MS: m/z 435.6 (M + H)+.
Figure imgf000080_0003
[00255] Yield: 63%; 1H NMR (DMSO-d6, 500 MHz)□8.77 (d, J = 5.4 Hz, 2 H), 7.98 (d, J = 5.4 Hz, 2 H), 7.38-7.40 (m, 2 H), 7.31-7.35 (m, 3 H), 7.11 (s, 3 H), 2.07 (s, 6 H); ESI-MS: m/z 418.8 (M + H)+.
Figure imgf000080_0004
[00256] Yield: 84%; 1H NMR (DMSO-d6, 500 MHz)□8.78 (d, J = 5.2 Hz, 2 H), 7.98 (d, J = 5.2 Hz, 2 H), 7.30 (d, J = 8.0 Hz, 2 H), 7.23 (d, J = 8.0 Hz, 2 H), 7.10 (s, 1 H), 7.02 (s, 2 H), 2.36 (s, 3 H), 2.04 (s, 6 H); ESI-MS: m/z 432.5 (M + H)+.
Figure imgf000080_0005
[00257] Yield: 64%; 1H NMR (DMSO-d6, 500 MHz)□8.79 (d, J = 5.0 Hz, 2 H), 7.98 (d, J = 5.0 Hz, 2 H), 7.43 (d, J = 8.4 Hz, 2 H), 7.12 (s, 1 H), 7.02 (d, J = 8.4 Hz, 2 H), 6.92 (s, 2 H), 3.79 (s, 3 H), 2.02 (s, 6 H); ESI-MS: m/z 448.1 (M + H)+.
Figure imgf000081_0001
[00258] Yield: 62%; 1H NMR (500 MHz, DMSO-d6)□12.8 (s, 1 H), 8.54-8.58 (m, 2 H), 7.55-7.56 (m, 1 H), 7.14 (s, 1 H), 6.96-7.03 (m, 4 H), 6.67 (s, 2 H), 3.76 (s, 3 H), 2.40 (s, 3 H), 2.05 (s, 6 H); ESI-MS: m/z 445.7 [M + H]+.
Figure imgf000081_0002
[00259] Yield: 60%; 1HNMR (500 MHz, CDCl3)□8.79 (d, J = 4.5 Hz, 2 H), 7.85 (d, J = 4.5 Hz, 2 H), 7.39 (d, J = 8.6 Hz, 2 H), 6.97 (d, J = 8.6 Hz, 2 H), 6.83 (s, 1 H), 2.05 (s, 6 H); ESI-MS: m/z 479.2 (M + H)+.
Figure imgf000081_0003
[00260] Yield: 58%; 1HNMR (500 MHz, CDCl3)□8.87 (d, J = 4.5 Hz, 2 H), 8.02 (d, J = 4.5 Hz, 2 H), 7.47 (d, J = 8.6 Hz, 2 H), 7.08 (d, J = 8.6 Hz, 2 H), 6.89 (s, 1 H), 6.85 (s, 1 H), 6.24 (s, 1 H), 2.04 (s, 6 H); ESI-MS: m/z 479.3 (M + H)+.
Figure imgf000081_0004
[00261] Yield: 94%; 1H NMR (500 MHz, DMSO-d6)□8.82 (s, 1 H), 8.71-8.72 (m, 1 H), 8.39-8.40 (m, 1 H), 7.01-7.03 (m, 2 H), 6.96-6.99 (m, 2 H), 6.64-6.67 (m, 3 H), 3.75 (s, 3 H), 2.03 (s, 6 H); ESI-MS: m/z 476.8 [M + H]+.
Figure imgf000082_0001
[00262] Yield: 94%; 1H NMR (500 MHz, CDCl3)□8.66-8.68 (m, 2 H), 7.49-7.50 (m, 2 H), 6.77 (s, 1 H), 6.57 (s, 2 H), 2.42 (s, 3 H), 1.87 (s, 6 H); ESI-MS: m/z 355.6 (M + H)+.
Figure imgf000082_0002
[00263] Yield: 39%; 1H NMR (500 MHz, CDCl3)□8.80-8.81 (m, 2 H), 7.98-8.00 (m, 2 H), 7.70 (s, 2 H), 7.30 (s, 1 H), 3.30 (s, 1 H), 2.20 (s, 6 H); ESI-MS: m/z 387.6 (M + H)+.
Figure imgf000082_0003
[00264] Yield: 61%; 1H NMR (DMSO-d6, 500 MHz)□8.79 (s, 2 H), 7.97 (d, J = 6.0 Hz, 2 H), 7.91 (d, J = 8.9 Hz, 2 H), 7.69 (s, 2 H), 7.27 (s, 1 H), 7.15 (d, J = 8.9 Hz, 2 H), 3.84 (s, 3 H), 2.16 (s, 6H); ESI-MS: m/z 480.6 (M + H)+.
Figure imgf000082_0004
[00265] Yield: 43%; 1HNMR (DMSO-d6, 500 MHz)□13.1 (brs, 1 H), 8.80 (d, J = 6.0 Hz, 2 H), 7.97 (d, J = 6.0 Hz, 2 H), 7.66 (d, J = 8.8 Hz, 2 H), 7.42 (s, 2 H), 7.23 (s, 1 H), 7.10 (d, J = 8.8 Hz, 2 H), 3.80 (s, 3 H), 2.13 (s, 6H); ESI-MS: m/z 464.7 (M + H)+.
Figure imgf000083_0001
[00266] Yield: 24%; 1H NMR (500 MHz, CDCl3)□8.80 (s, 2H), 7.70 (d, J = 5.1 Hz, 2 H), 6.97 (m, 2 H), 6.92 (m, 3 H), 6.70 (d, J = 2.4 Hz, 1 H), 6.61 (d, J = 2.3, 1 H), 3.83 (s, 3 H), 2.02 (s, 3 H); ESI-MS: m/z 452.4 (M + H)+.
Figure imgf000083_0002
[00267] General Procedure II for the Synthesis of 4-Aryl-2-amidothiazoles. To a suspension of arylcarboxylic acid (1.5 equiv) in dichloromethane was added Ι,Γ-carbonyldiimidazole (CDI, 3.0 equiv). After being stirred at room temperature for 2.0 h, the solution was added with
4-arylthiazol-2 -amine (q.O equiv). The reaction mixture was stirred at room temperature overnight. The solution was concentrated and the residue was re-dissolved in dichloromethane. The solution was washed with brine, dried over MgSO4, and concentrated under reduced pressure to give the corresponding 4-aryl-2-amidothiazoles.
Figure imgf000083_0003
[00268] Yield: 77%; 1H NMR (500 MHz, CD3OD)□ 8.75-8.76 (m, 2 H), 7.96-7.99 (m, 2 H), 6.90-6.92 (m, 3 H), 2.29 (s, 3 H), 2.08 (s, 6 H); ESI-MS: m/z 324.0 [M + H]+.
Figure imgf000083_0004
100269] Yield: 77%; 1HNMR (500 MHz, CDCl3)□l 1.7 (s, 1 H), 8.61-8.62 (m, 2 H), 7.51-7.53 (m, 2 H), 7.41-7.43 (m, 2 H), 7.26-7.30 (m, 2 H), 7.20-7.22 (m, 1 H), 2.54 (s, 3 H); ESI-MS: m/z 295.3 [M + H]+.
Figure imgf000084_0001
[00270] Yield: 15%; 1HNMR (500 MHz, CDCl3)□l 1.7 (s, 1 H), 9.03 (s, 1 H), 8.68-8.69 (m, 1 H), 8.06-8.08 (m, 1 H), 7.45-7.47 (m, 2 H), 7.22-7.31 (m, 4 H), 2.54 (s, 3 H); ESI-MS: m/z 295.9 [M + H]+.
Figure imgf000084_0002
[00271] Yield: 12%; 1H NMR (500 MHz, DMSO-d6)□12.9 (s, 1 H), 8.80-8.81 (m, 2 H), 7.99-8.00 (m, 2 H), 7.61-7.63 (m, 2 H), 7.02-7.04 (m, 2 H), 3.80 (s, 3 H), 2.49 (s, 3 H); ESI-MS: m/z 326.0 [M + H]+.
Figure imgf000084_0003
[00272] Yield: 12%; 1H NMR (500 MHz, DMSO-d6)□13.0 (s, 1 H), 8.78 (s, 2 H), 7.98-8.00 (m, 3 H), 6.98 (s, 1 H), 6.29 (s, 2 H), 3.82 (s, 3 H), 3.68 (s, 3 H); ESI-MS: m/z 369.9 [M - H]-.
Figure imgf000084_0004
[00273] Yield: 50%; HNMR (500 MHz, CDCl3)□l 1.7 (s, 1 H), 8.61-8.62 (m, 2 H), 7.51-7.53 (m, 2 H), 7.41-7.43 (m, 2 H), 7.26-7.30 (m, 2 H), 7.20-7.22 (m, 1 H), 2.54 (s, 3 H); ESI-MS: m/z 310.1 [M - H]-.
Figure imgf000085_0001
[00274] Yield: 10%; 1H NMR (500 MHz, DMSO-d6)□12.97 (s, 1H), 8.81-8.82 (m, 2 H), 8.00-8.07 (m, 3 H), 7.59 (s, 1 H), 6.64-6.68 (m, 2 H), 3.92 (s, 3 H), 3.81 (s, 3 H); ESI-MS: m/z 340.3 [M - H]-.
Figure imgf000085_0002
[00275] Yield: 95%; 1H NMR (500 MHz, CDCl3)□8.33-8.34 (m, 1 H), 7.47-7.54 (m, 4 H), 7.11 (s, 1 H), 6.79-6.80 (m, 2 H), 3.81 (s, 3 H); ESI-MS: m/z 345.7 [M + H]+.
Figure imgf000085_0003
[00276] Yield: 83%; 1H NMR (500 MHz, CDCl3)□8.52-8.53 (m, 1 H), 7.69-7.70 (m, 1 H), 7.59-7.60 (m, 1 H), 7.28-7.47 (m, 2 H), 7.16 (s, 1 H), 6.93-6.97 (m, 1 H), 3.93 (s, 3 H); ESI-MS: m/z 363.7 [M + H]+.
Figure imgf000085_0004
[00277] Yield: 87%; 1H NMR (500 MHz, CDCl3)□8.49-8.50 (m, 1 H), 7.74 (m, 1 H), 7.62 (m, 1 H), 6.83 (s, 1 H), 6.72 (m, 2 H), 2.26 (s, 3 H), 1.97(s, 6 H); ESI-MS: m/z 357.7 [M + H]+.
Figure imgf000086_0001
[00278] Yield: 63%; 1H NMR (500 MHz, CDCl3)□8.60-8.61 (m, 1 H), 7.91-7.96 (m, 2 H), 6.87 (s, 1 H), 6.58 (m, 2 H), 3.81 (s, 3 H), 2.1 l(s, 6 H); ESI-MS: m/z 373.9 [M + H]+.
Figure imgf000086_0002
[00279] Yield: 95%; 1H NMR (500 MHz, CDCl3)□8.53-8.54 (m, 1 H), 7.74-7.84 (m, 2 H), 6.83 (s, 1 H), 6.48 (m, 2 H), 3.98-4.02 (m, 2 H), 2.01(s, 6 H), 1.41-1.44 (m, 3 H); ESI-MS: m/z 387.9 [M + H]+.
Figure imgf000086_0003
[00280] Yield: 68%; 1H NMR (500 MHz, CDCl3)□8.36-8.38 (m, 1 H), 7.72 (s, 1 H), 7.42 (s, 1 H), 6.84 (s, 1 H), 6.48 (s, 2 H), 3.78 (s, 3 H), 2.03 (s, 6 H); ESI-MS: m/z 357.5 [M + H]+.
Figure imgf000086_0004
[00281] Yield: 94%; 1H NMR (500 MHz, CDCl3)□8.39-8.40 (m, 1 H), 7.78 (s, 1 H), 7.48 (s, 1 H), 6.85 (s, 1 H), 6.50 (s, 2 H), 3.98-4.01 (q, 2 H), 2.05(s, 6 H), 1.42-1.44 (t, 3 H); ESI-MS: m/z 371.8 [M + H]+.
Figure imgf000086_0005
compound 71
[00282] Yield: 75%; 1HNMR (500 MHz, CDCl3)□8.15-8.16 (d, 2 H), 7.78-7.79 (d, 2 H), 6.83 (s, 1 H), 6.80 (s, 2 H), 2.23 (s, 3 H), 2.01 (s, 6 H); ESI-MS: m/z 340.1 [M + H]+.
Figure imgf000087_0001
[00283] Yield: 43%; 1H NMR (500 MHz, CDCl3) G8.23 (s, 2 H), 8.04 (s, 2 H), 6.85 (s, 1 H), 6.60 (s, 2 H), 3.80 (s, 3 H), 2.12 (s, 6 H); ESI-MS: m/z 355.8 [M + H]+.
Figure imgf000087_0002
[00284] Yield: 18%; 1H NMR (500 MHz, CDCl3)□9.01 (s, 1 H), 8.66 (s, 1 H), 6.82 (s, 1 H), 6.59 (s, 2 H), 3.81 (s, 3 H), 2.13 (s, 6 H); ESI-MS: m/z 345.6 [M + H]+.
Figure imgf000087_0003
[00285] Yield: 46%; 1H NMR (500 MHz, CDCl3)□8.78-8.79 (m, 2 H), 7.73-7.74 (m, 2 H), 7.26-7.28 (m, 1 H), 6.76-6.79 (m, 1 H), 6.67-6.70 (m, 2 H); ESI-MS: m z 335.5 [M + H]+.
Figure imgf000087_0004
[00286] Yield: 21%; 1HNMR (500 MHz, CDCl3)□8.68 (s, 1 H), 8.59-8.60 (m, 1 H), 7.54-7.55 (m, 1 H), 6.81-6.83 (m, 2 H), 2.30 (s, 3 H), 2.01 (s, 6 H); ESI-MS: m z 357.8 [M + H]+.
Figure imgf000088_0001
[00287] Yield: 42%; 1H NMR (500 MHz, DMSO-d6)□8.63-8.64 (m, 1 H), 8.11 (s, 1 H), 7.98-7.99 (m, 1 H), 7.12 (s, 1 H), 6.93 (m, 2 H), 2.50 (s, 3 H), 2.05 (s, 6 H); ESI-MS: m/z 357.9 [M + H]+.
Figure imgf000088_0002
[00288] Yield: 40%; 1H NMR (500 MHz, CDCl3)□8.38-8.39 (m, 1 H), 7.55-7.56 (m, 1 H), 7.41 (s, 1 H), 6.91-6.93 (m, 2 H), 6.86 (s, 1 H), 5.30 (s, 1 H), 4.00 (s, 3 H), 2.32 (s, 3 H), 2.12 (s, 6 H); ESI-MS: m/z 355.0 [M + H]+.
Figure imgf000088_0003
[00289] Yield: 63%; 1H NMR (500 MHz, CDCl3)□7.31 (s, 1 H), 7.06 (s, 1 H), 6.81 (s, 1 H), 6.76 (s, 2 H), 4.00 (s, 3 H), 2.32 (s, 3 H), 1.98 (s, 6 H); ESI-MS: m/z 387.9 [M + H]+.
Figure imgf000088_0004
[00290] Yield: 70%; 1H NMR (500 MHz, CDCl3)□7.61 (s, 2 H), 6.80 (s, 1 H), 6.73 (s, 2 H), 2.29 (s, 3 H), 1.94 (s, 6 H); ESI-MS: m/z 392.0 [M + H]+.
Figure imgf000088_0005
compound 89
[00291] Yield: 61%; 1H-NMR (500 MHz, CDCl3)□8.81 (s, 1 H), 8.37 (s, 1 H), 7.80-7.77 (m, 1 H), 6.91 (s, 2 H), 6.80 (s, 1 H), 2.30 (s, 3 H), 2.26 (s, 3 H), 2.11 (s, 6 H); ESI-MS: m/z 381.2 [M + H]+.
Figure imgf000089_0001
[00292] Yield: 67%; 1H-NMR (500 MHz, CDCl3)□7.11 (s, 2 H), 6.81 (s, 1 H), 6.68 (s, 1 H), 2.30 (s, 3 H), 1.91 (s, 6 H); ESI-MS: m/z 360.0 [M + H]+.
Figure imgf000089_0002
[00293] Yield: 65%; 1H-NMR (500 MHz, DMSO-cfc)□8.52-8.53 (m, 2 H), 7.35-7.36 (m, 2 H), 6.99 (s, 1 H), 6.91 (s, 1 H), 3.84 (s, 1 H), 2.25 (s, 3 H), 2.02 (s, 6 H); ESI-MS: m/z 338.1 [M + H]+.
Figure imgf000089_0003
[00294] Yield: 70%; 1H-NMR (500 MHz, CDCl3)□8.38-8.40 (m, 1 H), 7.66-7.67 (m, 2 H), 7.43 (s, 1 H), 6.98-7.00 (m, 2 H), 6.91-6.93 (m, 2 H), 6.84 (s, 1 H), 6.54 (s, 1 H), 3.83 (s, 3 H), 2.0 (s, 6 H); ESI-MS: m/z 450.0 [M + H]+.
Figure imgf000089_0004
[00295] Yield: 83%; 1H-NMR (500 MHz, CDCl3)□8.40 (m, 1 H), 7.78 (s, 1 H), 7.50 (s, 1 H), 6.84 (s, 1 H), 6.53 (s, 2 H), 4.52-4.56 (m, 1 H), 2.06 (s, 6 H), 1.33 (s, 6 H); ESI-MS: m/z 385.8 [M + H]+.
Figure imgf000090_0001
[00296] Yield: 34% yield; 1H NMR (DMSO-d6, 500 MHz)□ 12.48 (brs, 1 H), 8.82-8.83 (m, 1 H), 8.60-8.61 (m, 1 H), 8.04-8.05 (m, 1 H), 7.76-7.79 (m, 1 H), 7.49-7. 1 (m, 1 H), 7.00-7.03 (m, 2 H), 6.92 (s, 2 H), 2.26 (s, 3 H), 2.05 (s, 6 H); ESI-MS: m/z 350.7 (M + H)+.
Figure imgf000090_0002
[00297] Yield: 25%; 1HNMR (DMS0-d6, 500 MHz)□13.20 (brs, 1 H), 8.36 (s, 1 H), 8.19 (s, 1 H), 7.87-7.88 (m, 1 H), 7.72-7.83 (m, 1 H), 7.00 (s, 1 H), 6.93 (s, 2 H), 2.27 (s, 3 H), 2.07 (s, 6 H); ESI-MS: m/z 363.9 (M + H)+.
Figure imgf000090_0003
[00298] Yield: 38% yield; 1H NMR (DMSO-d6 500 MHz)□13.20 (brs, 1 H), 8.66 (s, 1 H), 8.26 (s, 1 H), 8.08 (d, J = 8.4 Hz, 1 H), 7.65 (d, J = 8.4 Hz, 1 H), 7.02 (s, 1 H), 6.93 (s, 2 H), 2.36 (s, 3 H), 2.07 (s, 6 H); ESI-MS: m/z 363.9 (M + H)+.
Figure imgf000090_0004
[00299] Yield: 41%; 1H NMR (DMSO-d6, 500 MHz)□8.78 (s, 1 H), 8.11 (d, J = 8.4 Hz, 1 H), 7.96 (d, J = 8.4 Hz, 1 H), 7.07 (s, 1 H), 6.93 (s, 2 H), 2.27 (s, 3 H), 2.07 (s, 6 H); ESI-MS: m/z 364.9 (M + H)+.
Figure imgf000091_0001
[00300] Yield: 19%; 1H NMR (DMSO-d6, 500 MHz)□8.79-8.80 (m, 12H), 7.98-7.99 (m, 2 H), 7.08 (s, 1 H), 6.70 (s, 2 H), 4.08^4.10 (m, 2 H), 3.65-3.66 (m, 2 H), 3.31 (s, 3 H), 2.06 (s, 6 H); ESI-MS: m/z 384.6 (M + H)+.
Figure imgf000091_0002
[00301] Yield: 58%; 1H NMR (DMSO-d6, 500 MHz)□8.78-8.79 (m, 2 H), 7.98-7.99 (m, 2 H), 7.05 (s, 1 H), 6.69 (s, 2 H), 4.00-4.02 (m, 2 H), 3.46-3.48 (m, 2 H), 3.25 (s, 3 H), 2.06 (s, 6 H), 1.93-1.95 (m, 2 H); ESI-MS: m/z 398.8 (M + H)+.
Figure imgf000091_0003
[00302] Yield: 69%; 1H NMR (500 MHz, CDCl3)□8.46-8.48 (m, 1 H), 8.39-8.43 (m, 2 H), 8.32-8.33 (m, 1 H), 7.02-7.05 (m, 2 H), 6.93-6.95 (m, 3 H), 6.70 (s, 2 H), 3.84 (s, 3 H), 2.19 (s, 3 H), 2.16 (s, 3 H); ESI-MS: m/z 447.8 [M + H]+.
Figure imgf000091_0004
[00303] Yield: 65%; 1H-NMR (500 MHz, DMSO-c1H□ 13.1 (s, 1 H), 8.46-8.47 (m, 1H), 7.93-7.94 (m, 1 H), 7.78 (s, 1 H), 7.42-7.44 (m, 2 H), 7.19 (s, 1 H), 7.01-7.03 (m, 2 H), 6.91 (s, 2 H), 3.79 (s, 3 H), 2.02 (s, 6 H); ESI-MS: m/z 465.4 [M + H]+. Exemplary Compounds and Inhibitory Activity [00304] The following table lists exemplary results for selected compounds illustrating the antiproliferative activity on selected cancer cells using exposure of the cells in growth medium with the compounds as indicated. Antiproliferative effect is expressed as IC50 values in microMolar final concentration.
Figure imgf000092_0001
MeO
O
Figure imgf000093_0001
Figure imgf000094_0001
Figure imgf000095_0001
Figure imgf000096_0001
Figure imgf000097_0001
Figure imgf000098_0001
Figure imgf000099_0001
Figure imgf000100_0001
98 0.04 0.02 0.04 0.02
Figure imgf000101_0001
OMe O
Figure imgf000102_0001
Figure imgf000103_0001
Exemplary Biological Activities of Selected Compounds
[00305] The following data provide exemplary guidance with respect to the biological activity of certain compounds in vitro and in vivo. Where compounds are referenced by number, the number is with regard to the compounds listed in the table above. [00306] Cytotoxicity and Antiproliferative Activity: Cells from established cell lines {e.g. from cell lines like MDA-MB-231 , MDA-MB-468, Hela, and K562) were cultured in 10% FBS (Hylcone) in DMEM medium (Sigma, D5523). Cells were grown at 37°C in a humidified atmosphere with 5% C02 and 95% air. Cells were seeded in 96 well tissue culture plates.
[00307] Compound treatment started after overnight incubation of cells (TO). Compound was prepared in an eight point 3x dilution from 10, M to 4.6 nM. Compound was added to the plate in triplicate wells, and the plates were then incubated for 96 hours. DMSO (compounds diluents) was also included and added to the plate in control wells. Cell viability was then determined by MTS assay using CellTiter 96® AQueous non-radioactive cell proliferation assay system (Promega). A plate reader (Molecular Devices, Vmax) was used to read the optical densities, and the results were used to deduce concentration-response curves. All data represent the results of triplicate experiments, and are the mean of three separate determinations with variations of less than ±20%. The results were analyzed using linear regression software (GraphPad Prism 5; GraphPad Software Inc.). [00308] The IC50 values refer to the concentration that causes 50% growth inhibition. The GI50 values (growth inhibitory activity) were determined to emphasize on the correction for the cell count at time zero; thus, the % inhibition of test drug were: [1- (T - T0)/(C - T0)] x 100; and these value were used to plot the concentration-response curves, and then analyzed with linear regression software (GraphPad Prism 5). [00309] As can be seen from Figure1A, selected compounds had significant cytotoxic and antiproliferative effect on multiple solid tumor cells as well as leukemia cells. In contrast, as can be taken from Figure 1B, the same compounds at exhibited no significant cytotoxic and
antiproliferative effect on several normal cell lines. Here, WI-38 is human normal lung fibroblast cell line, RPTEC is renal proximal tubule epithelial cells, HuVec is human umbilical vein endothelial cells, and HAoSMC is Human aortic smooth muscle cells. [00310] Selected compounds disrupt Hec1/Nek2 Interaction, trigger Nek2 degradation, and increase Nek2 protein instability: Cells were resuspended in ice-cold Lysis buffer 250 (50 mM Tris-HCl, pH 7.4, 250 mM NaCl, 0.3% Nonidet P-40, 10 mM NaF, supplemented with protease inhibitors) were subjected to three freeze/thaw cycles and centrifuged at 14,000 rpm for 2 min at room temperature. The supernatants were used for lysate analysis or immunoprecipitation. For immunoprecipitation, supernatants were incubated with anti-Hec1 antibody mAb1 9G3or mouse polyclonal anti-Nek2 for 1-h, then with protein A-Sepharose beads for another hour. Beads were collected and washed five times with lysis buffer containing hypertonic NaCl, and boiled in SDS-loading buffer for immunoblot analysis. After immunoblotting to Immobilon-P membrane (Millipore Corp., Bedford, MA), blots were probed with anti-Hec1 antibodies or anti-Nek2 antibodies (Genetex, Irvine, CA). Blots were developed using an ECL chemiluminescence kit (Amersham Biosciences). Additional details can be found elsewhere (Phosphorylation of the mitotic regulator protein Hec1 by Nek2 kinase is essential for faithful chromosome segregation. J Biol Chem. 2002 Dec 20;277(51):49408-16. Epub 2002 Oct 16). [00311] Figures 2A and 2B depicts an exemplary result of such experiment where it is readily apparent that selected compounds tested significantly disrupted Hec1/Nek2 interaction. Figure 2C shows typical results of the Nek2 reduction upon incubation of K562 cells for 24 hrs with 1mcM of tested compounds, and Figure 2D depicts results demonstrating protein instability of Nek2 over time after treatment of K562 cells exposed to selected compounds at 1 mcM final concentration. [00312] Selected compounds induce aberrant mitosis: Cells were grown on cover slips and gently washed with PEMG buffer [80 mM piperazine-N,N -bis(2-ethanesulfonic acid) (PIPES), pH 6.8, 5 mM EGTA, 1 mM MgCl2, and 4 M glycerol] or phosphate-buffered saline(PBS). Cells were then fixed with 100% methanol at–20°C or 4% paraformaldehyde in PEMG or PBS buffer and permeabilized with 0.4% Triton-X 100. Cells were blocked with 5% normal goat serum (NGS) in PBS and incubated with primary antibodies in PBS with 5% NGS (1-2 h at room temperature). Secondary antibodies were conjugated with Alexa 488 or 594 (Invitrogen, Carlsbad, CA). After incubation with secondary antibody, 4 ,6-Diamidino-2-phenylindole (DAPI) staining was applied and cells were mounted on cover slides with Prolong gold anti-fade reagent (Invitrogen). Images were captured with a Nikon H550L microscope equipped with digital cameras and SPOT digital imaging software (version 4, Diagnostic Instruments, Inc). Further image analysis or quantification was performed with Image-Pro Plus (MediaCybernetics, Bethesda, MD) or Adobe Photoshop software (Adobe Systems, Mountain View, CA). Further details are described elsewhere (Hec1 contributes to mitotic centrosomal microtubule growth for proper spindle assembly through interaction with Hice1. Mol Biol Cell. 2009 Nov;20(22):4686-95. Epub 2009 Sep 23). [00313] Figure 3 is a table depicting the effect of selected compounds on mitosis. More specifically, the results are expressed as percentages of chromosome misalignment in mitotic cells over 48 hrs. As can be taken, the tested compounds substantially affected mitosis in a large number of cells. [00314] Selected compounds are highly selective kinase inhibitors: Inhibition of kinase activity by test compound was measured by quantifying the amount of [33P] incorporation of substrate in the present of test compound. The standard kinase assays were initiated with MgATP, in the presence of test compound (diluted in final concentration of 4% DMSO) or DMSO control, stopped by the addition of 3 % phosphoric acid and harvested onto a filter plate using a unifilter harvester (PerkinElmer, Boston, MA, U.S.A.) and counted using TopCount. For primary screening of kinase activitylnhibition, each test compound was evaluated at two concentrations (10mM and 1mM) in duplication. The results were the average of duplicate measurements and expressed as percentage inhibition (compound treatment versus DMSO control). The available kinase assays are as followed: VEGFR2, PDGFR- , FGFR1, Flt3, c-Met, CHK1, CHK2, Cdk1/Cyclin B, Aurora A, Aurora B, B-Raf, B-Raf (V600E), C-Raf, and mTOR. The ATP concentration used in most of the kinase assay is at or below the Km for ATP for each enzyme. [00315] Despite the significant effects of contemplated compounds at very low IC50, the inhibitory profile was highly selective as can be seen from the table of Figure 4. [00316] Bioavailability: Selected compounds were administered to rats per os or via injection following well known procedures. For example, compound 82 was injected i.v. at a concentration of 2 mg/kg in a formulation containing 5 % DMSO, 10 % Cremophor, and 85% WFI. The table below lists exemplary pharmacokinetic data
[
Figure imgf000106_0001
formulation containing 1 % methyl-cellulose. The table below lists exemplary pharmacokinetic data
l
Figure imgf000106_0002
formulations and routes of administration. The following tables exemplarily illustrate the results. [00319] Compound 42 i.v. and oral are shown in the respective tables below:
Figure imgf000106_0003
Mean 1.52 11488 10959 11108 397 180 1.26
Figure imgf000107_0001
[00320] Compound 95 i.v. and oral are shown in the respective tables below:
SD rat T1/2 C0 AUC0-t AUC0-inf Vz CL MRT Number (hr) (ng/ml) (ng/ml hr) (ng/ml hr) (ml/kg) (ml/hr/kg) (hrs)
Figure imgf000107_0002
[00321] Selected compounds are effective in mouse xenograft model: The procedure was adapted from a previous published protocol (Small molecule targeting the Hec1Nek2 mitotic pathway suppresses tumor cell growth in culture and in animal. Cancer Res. 2008 Oct 15;68(20):8393-9). More specifically, female BALB/c nude (nu/nu) mice (5–8 weeks) were purchased from Lasco (Taiwan). The animals were maintained under specific pathogen-free conditions, and food and water were supplied ad libitum. Housing and all procedures involving animals were performed according to protocols approved by the IACUC in DCB. For subcutaneous implantation of MDA-MB-468 and MDA-MB-231 cells, cells (1 x107 in matrix gel/animal, and 0.5 x107 /animal, respectively) were injected subcutaneously into the right subaxillary region. After 10 days of tumor implantation, mice were treated (i.v., QD/21 cycles or p.o., QD/28 cycles in total) with vehicle A (5% DMSO, 10% Cremophor, 85% H2O), or candidate compounds formulated in vehicle A (7.5-150 mg/kg body weight). Perpendicular diameter measurement of each tumor were made with digital calipers and the volume of the tumor calculated using formula (Lx W x W)/2, in which L and W represent the length and the width, respectively. Body weights were measured three times weekly. Mean tumor growth inhibition of each treated group was compared with vehicle control and a Tumor growth inhibition value calculated using the formula: [1-(T/C) x100%]. [00322] The in vivo effect of contemplated compounds on the tumor volume in nude mice is readily apparent from the graphs in Figures 5A and 5B. Despite the tumor reduction, body weight remained constant in all cases (data not shown). [00323] It should be apparent to those skilled in the art that many more modifications besides those already described are possible without departing from the inventive concepts herein. The inventive subject matter, therefore, is not to be restricted except in the spirit of the appended claims. Moreover, in interpreting both the specification and the claims, all terms should be interpreted in the broadest possible manner consistent with the context. In particular, the terms“comprises” and “comprising” should be interpreted as referring to elements, components, or steps in a non-exclusive manner, indicating that the referenced elements, components, or steps may be present, or utilized, or combined with other elements, components, or steps that are not expressly referenced. Where the specification claims refers to at least one of something selected from the group consisting of A, B, C…. and N, the text should be interpreted as requiring only one element from the group, not A plus N, or B plus N, etc.

Claims

What is claimed is: 1. A compound having a structure according to Formula I
Figure imgf000109_0001
ormu a
R1 is hydrogen, alkyl, alkenyl, alkynyl, alkoxy, aryl, halogen, nitro, cyano, cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, ORa, SRa, NRaRb, –S(O)2Ra,–S(O)2NRaRb,–C(O)Ra,–C(O)NRaRb,–NRaC(O)Rb,–NRaS(O)2Rb, –N=CRaRb, or–NRaC(O)NHRb;
Ra and Rb are independently hydrogen, alkyl, alkenyl, alkynyl, aryl, aryloxy, alkoxy, hydroxy, heteroaryl, cycloalkyl, heterocycloalkyl, cycloalkenyl, or heterocycloalkenyl, or Ra and Rb, together with a nitrogen atom to which they are bonded, are heteroaryl, heterocycloalkyl, or heterocycloalkenyl;
R2, R3, and R4 are independently hydrogen C1–C6 alkyl, halogen, or ORa; and
R5 is alkyl, phenylalkyl, heteroarylalkyl, phenyalkenyl, heteroarylalkenyl, phenyl, heteroaryl, heterocycloalkyl, or heterocycloalkenyl;
wherein each of R1, R2, R3, R4, R5, Ra, and Rb is independently optionally substituted; and
with the proviso that
(I) where R1 and R2 are methyl and where R3 is hydrogen, R5 is not thiazolyl,
N-methylimidazolyl, pyrazinyl, pyridinyl, morpholinyl, phenyl, or dimethoxyphenyl;
(II) where R1, R2, and R3 are methyl, R5 is not thiazolyl, N-methylimidazolyl,
pyrazinyl, pyridinyl, morpholinyl, phenyl, methoxyphenyl, dihydroxyphenyl, hydroxymethoxyphenyl, trifluoromethylphenyl, or dimethoxyphenyl;
(III) where R1 and R2 are methyl and where R3 is hydroxyl or methoxy, R5 is not phenyl.
2. The compound of claim 1 wherein R1 is alkoxy, SRa, ORa, or ,–S(O)2Ra, wherein Ra is alkyl or optionally substituted aryl, R2, R3, and R4 are independently hydrogen or C1–C6 alkyl, and wherein R5 is optionally substituted heteroaryl.
3. The compound of claim 2 wherein R1 is alkoxy, SRa, ORa, or ,–S(O)2Ra, wherein Ra is alkyl or optionally substituted aryl, R2 and R3 are C1–C6 alkyl, and wherein R5 is optionally substituted pyridinyl.
4. The compound of claim 3 wherein R1 is ORa, wherein Ra is optionally substituted aryl, R2 and R3 are C1–C6 alkyl, and wherein R5 is optionally substituted pyridinyl.
5. The compound of claim 1 having a structure according to Formula II
Figure imgf000110_0001
ormu a
wherein X1 and X2 are independently H, alkyl, alkenyl, alkynyl, halogen, nitro, cyano, cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, ORa, NRaRb, –S(O)2Ra,–S(O)2NRaRb,–C(O)Ra,–C(O)NRaRb,–NRaC(O)Rb,–NRaS(O)2Rb, –N=CRaRb, or–NRaC(O)NHRb;
Y is CH2, CHRa, CRaRb, O, NH, NRa, S, SO, or SO2;
R1, R2, and R3 are independently H, alkyl, alkoxy, or halogen;
n is 0, 1, or 2;
wherein each of X1 and X2 is independently optionally substituted;
and
wherein Rc and Rd is independently Ra
Figure imgf000110_0002
6. The compound of claim 5 wherein Y is O, S, or SO2.
7. The compound of claim 5 wherei is .
Figure imgf000111_0001
8. The compound of claim 5 wherein Y is O, S, or SO2 , wherei is
Figure imgf000111_0002
, and wherein R 1 , R 2 , and R 3 are independently H or alkyl.
Figure imgf000111_0003
9. The compound of claim 8 wherein X1 and X2 are independently H, alkyl, and alkoxy, and wherein n is 0 or 1.
10. The compound of claim 5 wherein n is 0.
11. The compound of claim 1 having a structure according to Formula III
Figure imgf000111_0004
wherein X1, X2, and X3 are independently H, alkyl, alkenyl, alkynyl, halogen, nitro, cyano, cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, ORa, NRaRb,–S(O)2Ra,–S(O)2NRaRb,–C(O)Ra,–C(O)NRaRb,–NRaC(O)Rb, –NRaS(O)2Rb,–N=CRaRb, or–NRaC(O)NHRb;
Y is CH2, CHRa, CRaRb, O, NH, NRa, S, SO, or SO2;
R1, R2, and R3 are independently H, alkyl, alkoxy, or halogen;
n is 0, 1, or 2;
wherein each of X1 and X2 is independently optionally substituted;
wherein Rc and Rd is independently Ra;
; and
Figure imgf000112_0001
.
Figure imgf000112_0002
12. The compound of claim 11 wherein is .
Figure imgf000112_0004
Figure imgf000112_0003
13. The compound of claim 11 wherein Y is O, S, or S02, wherein
Ra
Figure imgf000113_0001
and wherein R1, R2, and R3 are independently H or alkyl.
14. The compound of claim 1 having a structure selected from the group consisting of
Figure imgf000113_0002
Figure imgf000113_0003
15. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to claim 1 in a concentration effective to disrupt Hecl Nek2 binding in a patient when the composition is administered to the patient.
The pharmaceutical composition of claim 15, further comprising a drug that interferes with microtubule formation or degradation.
17. The pharmaceutical composition of claim 15 wherein the compound is a compound according to claim 14.
18. A method of disrupting Nek2/Hec1 interaction, comprising contacting a Nek2/Hec1 complex with a compound according to claim 1 in an amount effective to disrupt Nek2/Hec1 binding.
19. The method of claim 18 wherein the step of contacting the Nek2/Hec1 complex is performed in vivo in a mammal, and wherein the compound is administered orally, topically, or parenterally.
20. The method of claim 18 further comprising a step of co-administering an agent that interferes with microtubule formation or degradation.
PCT/US2011/028532 2010-03-17 2011-03-15 Modulators of hec1 activity and methods therefor WO2011115998A2 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
BR112012023355A BR112012023355A2 (en) 2010-03-17 2011-03-15 compound, pharmaceutical composition and method of disruption of nek2 / hec1 interaction
ES11756862.6T ES2557465T3 (en) 2010-03-17 2011-03-15 Modulators of HEC 1 activity and procedures for it
MX2012010664A MX2012010664A (en) 2010-03-17 2011-03-15 Modulators of hec1 activity and methods therefor.
SG2012064762A SG183853A1 (en) 2010-03-17 2011-03-15 Modulators of hec1 activity and methods therefor
RU2012144022/04A RU2576036C2 (en) 2010-03-17 2011-03-15 Modulators of hec1 activity and methods therefor
JP2013500159A JP5825535B2 (en) 2010-03-17 2011-03-15 Modulators of HEC1 activity and methods therefor
MX2015015934A MX346395B (en) 2010-03-17 2011-03-15 Modulators of hec1 activity and methods therefor.
NZ602121A NZ602121A (en) 2010-03-17 2011-03-15 Modulators of hec1 activity and methods therefor
KR1020127027026A KR101609856B1 (en) 2010-03-17 2011-03-15 Modulators of hec1 activity and methods therefor
CN201180024772.3A CN103038231B (en) 2010-03-17 2011-03-15 HEC1 active regulator and method thereof
MYPI2012003984A MY192693A (en) 2010-03-17 2011-03-15 Modulators of hec1 activity and methods therefor
EP11756862.6A EP2547676B1 (en) 2010-03-17 2011-03-15 Modulators of hec1 activity and methods therefor
AU2011227398A AU2011227398C1 (en) 2010-03-17 2011-03-15 Modulators of Hec1 activity and methods therefor
CA2793311A CA2793311C (en) 2010-03-17 2011-03-15 Modulators of hec1 activity and methods therefor
HK13103078.4A HK1176055A1 (en) 2010-03-17 2013-03-12 Modulators of hec1 activity and methods therefor hec1

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31479810P 2010-03-17 2010-03-17
US61/314,798 2010-03-17

Publications (2)

Publication Number Publication Date
WO2011115998A2 true WO2011115998A2 (en) 2011-09-22
WO2011115998A3 WO2011115998A3 (en) 2012-01-05

Family

ID=44647719

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/028532 WO2011115998A2 (en) 2010-03-17 2011-03-15 Modulators of hec1 activity and methods therefor

Country Status (16)

Country Link
US (2) US8946268B2 (en)
EP (1) EP2547676B1 (en)
JP (2) JP5825535B2 (en)
KR (1) KR101609856B1 (en)
CN (2) CN103038231B (en)
AU (2) AU2011227398C1 (en)
BR (1) BR112012023355A2 (en)
CA (1) CA2793311C (en)
ES (1) ES2557465T3 (en)
HK (1) HK1176055A1 (en)
MX (2) MX2012010664A (en)
MY (1) MY192693A (en)
NZ (1) NZ602121A (en)
RU (1) RU2576036C2 (en)
SG (1) SG183853A1 (en)
WO (1) WO2011115998A2 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013041535A1 (en) * 2011-09-23 2013-03-28 Beiersdorf Ag Aromatic amidothiazoles, cosmetic or dermatological preparations containing said aromatic amidothiazoles, and use thereof to combat or prevent undesired pigmentation of the skin
WO2013078145A1 (en) 2011-11-21 2013-05-30 Taivex Therapeutics Corporation Biomarkers for cancers responsive to modulators of hec1 activity
WO2013082324A1 (en) 2011-11-29 2013-06-06 Taivex Therapeutics Corporation Improved modulators of hec1 activity and methods therefor
JP2014506897A (en) * 2011-03-02 2014-03-20 ▲華▼中科技大学 2-Aminothiazole derivatives, formulation methods and uses thereof
CN103998434A (en) * 2011-10-18 2014-08-20 华东理工大学 Thiazole derivative as DHODH inhibitor and use thereof
JP2015505566A (en) * 2012-02-01 2015-02-23 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ Ribonucleotide reductase inhibitors and methods of use
US20150105391A1 (en) * 2013-07-20 2015-04-16 Wen-Hwa Lee Small molecule modifiers of the hec1-nek2 interaction in g2/m
US11071736B2 (en) 2011-11-21 2021-07-27 Taivex Therapeutics Corporation Modulators of HEC1 activity and methods therefor

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103038231B (en) 2010-03-17 2016-04-20 泰纬生命科技股份有限公司 HEC1 active regulator and method thereof
US11028061B2 (en) * 2015-07-27 2021-06-08 Sanford Burnham Prebys Medical Discovery Institute Modulators of myocyte lipid accumulation and insulin resistance and methods of use thereof
CN112153984A (en) * 2018-01-30 2020-12-29 福宏治疗公司 Compound and use thereof
KR20220133258A (en) 2020-01-29 2022-10-04 포그혼 쎄라퓨틱스 인크. Compounds and uses thereof
WO2021255011A1 (en) * 2020-06-15 2021-12-23 Dsm Ip Assets B.V. Process for the manufacture of alkylamidothiazoles
CN111925377B (en) * 2020-08-31 2022-05-31 上海应用技术大学 Para-substituted dihydrofurocoumarin neuraminidase inhibitor and preparation method and application thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6014A (en) * 1849-01-09 Stop-motion for drawing-frames
US5011A (en) * 1847-03-13 V boring-machine
FR2677356B1 (en) * 1991-06-05 1995-03-17 Sanofi Sa HETEROCYCLIC DERIVATIVES OF SUBSTITUTED ACYLAMINO-2 THIAZOLES-5, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME.
FR2701708B1 (en) * 1993-02-19 1995-05-19 Sanofi Elf Polysubstituted 2-amido-4-phenylthiazole derivatives, process for their preparation, pharmaceutical composition and use of these derivatives for the preparation of a medicament.
CN100357283C (en) * 2002-04-02 2007-12-26 中国科学院上海药物研究所 Methionyl aminopeptidase inhibitor
EP1519736A2 (en) 2002-06-12 2005-04-06 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. Use of hec1 antagonists in the treatment of proliferative disorders and cancer
US8252520B2 (en) * 2002-10-11 2012-08-28 Taivex Therapeutics Corporation Methods and compounds for inhibiting Hec1 activity for the treatment of proliferative diseases
FR2854158B1 (en) * 2003-04-25 2006-11-17 Sanofi Synthelabo 2-ACYLAMINO-4-PHENYLETHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
RU2006111093A (en) * 2003-09-06 2007-10-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) MODULATORS OF ATR-BINDING CASSETTE TRANSPORTERS
FR2872813B1 (en) 2004-07-09 2007-01-19 Sanofi Synthelabo 2-CARBAMID-4-PHENYLTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
CN101048158A (en) * 2004-08-13 2007-10-03 健泰科生物技术公司 Thiazole based inhibitors of ATP-utilizing enyzmes
KR20080019213A (en) * 2005-05-09 2008-03-03 아칠리온 파르마세우티칼스 인코포레이티드 Thiazole compounds and methods of use
JP4612487B2 (en) * 2005-06-30 2011-01-12 キョーラク株式会社 Container cap
WO2007004038A1 (en) * 2005-07-05 2007-01-11 Pfizer Products Inc. Aminothiazole derivatives as agonists of the thrombopoietin receptor
WO2007008541A2 (en) * 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
WO2007019251A2 (en) 2005-08-04 2007-02-15 Apogee Biotechnology Corporation Sphingosine kinase inhibitors and methods of their use
WO2007131071A2 (en) 2006-05-02 2007-11-15 Washington State University Mig-7 as a specific anticancer target
WO2008124000A2 (en) * 2007-04-02 2008-10-16 Ligand Pharmaceuticals Incorporated Thiazole derivatives as androgen receptor modulator compounds
JP4986749B2 (en) * 2007-07-09 2012-07-25 富士フイルム株式会社 Material for pressure measurement
WO2009014674A1 (en) * 2007-07-23 2009-01-29 Sirtris Pharmaceuticals, Inc. Heterocyclylamides as gut microsomal triglyceride transport protein inhibitors
CN102088973A (en) * 2008-05-15 2011-06-08 杜克大学 Compositions and methods relating to heat shock transcription factor activating compounds and targets thereof
US8324385B2 (en) * 2008-10-30 2012-12-04 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
EP2309273B1 (en) 2009-09-16 2016-05-18 ZEILLINGER, Robert Novel tumor marker determination
CN103038231B (en) 2010-03-17 2016-04-20 泰纬生命科技股份有限公司 HEC1 active regulator and method thereof
CN104395752B (en) 2011-11-21 2017-09-15 泰纬生命科技股份有限公司 There is the biomarker of the cancer of reaction to HEC1 active regulators

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CANCER RES., vol. 68, no. 20, 15 October 2008 (2008-10-15), pages 8393 - 9
J. MED. CHERN., vol. 52, no. 6, 2009, pages 1757 - 1767
See also references of EP2547676A4

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014506897A (en) * 2011-03-02 2014-03-20 ▲華▼中科技大学 2-Aminothiazole derivatives, formulation methods and uses thereof
JP2014526536A (en) * 2011-09-23 2014-10-06 バイヤースドルフ・アクチエンゲゼルシヤフト Aromatic amidothiazole, cosmetic or dermatological formulations containing it, and its use for treating and preventing unwanted skin pigmentation
JP2017141242A (en) * 2011-09-23 2017-08-17 バイエルスドルフ・アクチエンゲゼルシヤフトＢｅｉｅｒｓｄｏｒｆ ＡＧ Aromatic amide thiazole, cosmetic or dermatological preparation containing the same and use thereof for treating and preventing undesired skin pigmentation
WO2013041535A1 (en) * 2011-09-23 2013-03-28 Beiersdorf Ag Aromatic amidothiazoles, cosmetic or dermatological preparations containing said aromatic amidothiazoles, and use thereof to combat or prevent undesired pigmentation of the skin
CN103930409A (en) * 2011-09-23 2014-07-16 拜尔斯道夫股份公司 Aromatic amidothiazoles, cosmetic or dermatological preparations containing said aromatic amidothiazoles, and use thereof to combat or prevent undesired pigmentation of the skin
CN103930409B (en) * 2011-09-23 2016-08-24 拜尔斯道夫股份公司 Armaticity amide thiazole, containing its cosmetic or dermatological preparations and their purposes overcoming and preventing less desirable cutaneous pigmentation
CN103998434B (en) * 2011-10-18 2016-10-12 华东理工大学 Thiazole and application thereof as DHODH inhibitor
CN103998434A (en) * 2011-10-18 2014-08-20 华东理工大学 Thiazole derivative as DHODH inhibitor and use thereof
US11071736B2 (en) 2011-11-21 2021-07-27 Taivex Therapeutics Corporation Modulators of HEC1 activity and methods therefor
US9976183B2 (en) 2011-11-21 2018-05-22 Taivex Therapeutics Corporation Biomarkers for cancers responsive to modulators of HEC1 activity
JP2015500008A (en) * 2011-11-21 2015-01-05 タイヴェックス・セラピューティクス・コーポレイションＴａｉｖｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｏｒｐｏｒａｔｉｏｎ Cancer biomarkers responsive to modulators of HEC1 activity
WO2013078145A1 (en) 2011-11-21 2013-05-30 Taivex Therapeutics Corporation Biomarkers for cancers responsive to modulators of hec1 activity
WO2013082324A1 (en) 2011-11-29 2013-06-06 Taivex Therapeutics Corporation Improved modulators of hec1 activity and methods therefor
KR20140138596A (en) * 2011-11-29 2014-12-04 타이벡스 세라피틱스 코포레이션 Improved modulators of hec1 activity and methods therefor
CN104254534B (en) * 2011-11-29 2017-07-14 泰纬生命科技股份有限公司 The improved adjusting control agent and its method of HEC1 activity
AU2012345843B2 (en) * 2011-11-29 2017-11-23 Taivex Therapeutics Corporation Improved modulators of Hec1 activity and methods therefor
CN104254534A (en) * 2011-11-29 2014-12-31 泰纬生命科技股份有限公司 Improved modulators of hec1 activity and methods therefor
TWI640519B (en) * 2011-11-29 2018-11-11 泰緯生命科技股份有限公司 Modulators of hec1 activity and methods therefor
KR101983585B1 (en) * 2011-11-29 2019-05-29 타이벡스 세라피틱스 코포레이션 Improved modulators of hec1 activity and methods therefor
JP2014534271A (en) * 2011-11-29 2014-12-18 タイヴェックス・セラピューティクス・コーポレイションＴａｉｖｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｏｒｐｏｒａｔｉｏｎ Improved modulators for HEC1 activity and methods thereof
JP2015505566A (en) * 2012-02-01 2015-02-23 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ Ribonucleotide reductase inhibitors and methods of use
US9422275B2 (en) * 2013-07-20 2016-08-23 The Regents Of The University Of California Small molecule modifiers of the HEC1-NEK2 interaction in G2/M
US20150105391A1 (en) * 2013-07-20 2015-04-16 Wen-Hwa Lee Small molecule modifiers of the hec1-nek2 interaction in g2/m

Also Published As

Publication number Publication date
CN105906617B (en) 2018-09-04
JP2016040288A (en) 2016-03-24
JP6294277B2 (en) 2018-03-14
US9409902B2 (en) 2016-08-09
AU2011227398A1 (en) 2012-09-20
MX346395B (en) 2017-03-17
CA2793311A1 (en) 2011-09-22
ES2557465T3 (en) 2016-01-26
WO2011115998A3 (en) 2012-01-05
CA2793311C (en) 2019-01-15
AU2011227398C1 (en) 2014-11-27
MX2012010664A (en) 2013-02-07
US8946268B2 (en) 2015-02-03
US20150057281A1 (en) 2015-02-26
JP2013522310A (en) 2013-06-13
CN103038231A (en) 2013-04-10
AU2011227398B2 (en) 2014-06-12
AU2014210678B2 (en) 2015-08-20
CN105906617A (en) 2016-08-31
KR101609856B1 (en) 2016-04-07
HK1176055A1 (en) 2013-07-19
EP2547676A2 (en) 2013-01-23
AU2014210678A1 (en) 2014-08-28
KR20130076800A (en) 2013-07-08
US20110230486A1 (en) 2011-09-22
SG183853A1 (en) 2012-10-30
CN103038231B (en) 2016-04-20
RU2576036C2 (en) 2016-02-27
NZ602121A (en) 2014-05-30
EP2547676B1 (en) 2015-07-29
RU2012144022A (en) 2014-04-27
MY192693A (en) 2022-09-01
JP5825535B2 (en) 2015-12-02
BR112012023355A2 (en) 2016-05-31
EP2547676A4 (en) 2013-08-14

Similar Documents

Publication Publication Date Title
EP2547676B1 (en) Modulators of hec1 activity and methods therefor
US7767665B2 (en) 1,3-benzothiazinone derivatives and use thereof
RU2721844C2 (en) Urat1 inhibitors
TW201026676A (en) A method of inhibiting hepatitis C virus by combination of a 5,6-dihydro-1H-pyridin-2-one and one or more additional antiviral compounds
TW201910329A (en) Substituted five-membered and six-membered heterocyclic compound, preparation method thereof, pharmaceutical combination and use thereof
KR100915287B1 (en) Thiadiazoline derivative
AU2012345843B2 (en) Improved modulators of Hec1 activity and methods therefor
US20240092770A1 (en) Heterocycle RMB39 Modulators
SK2722002A3 (en) Use of bis-sulfonamides for producing medicaments used for preventing or treating hyperlipidaemia
EP3129102A1 (en) Iodonium analogs as inhibitors of nadph oxidases and other flavin dehydrogenases; formulations thereof; and uses thereof
US20200325156A1 (en) Heteroaryl amide compounds, preparation method therefor, pharmaceutical compositions thereof, and applications thereof
US8669248B1 (en) Adenine inhibitors of HSP90
JPS6132287B2 (en)

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201180024772.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11756862

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2011227398

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 7568/DELNP/2012

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2011756862

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2793311

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2013500159

Country of ref document: JP

Ref document number: MX/A/2012/010664

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2011227398

Country of ref document: AU

Date of ref document: 20110315

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20127027026

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2012144022

Country of ref document: RU

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012023355

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112012023355

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20120917